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Abstract 
 
 Toxoplasma gondii, an obligate intracellular protozoan parasite, is one of the most 
successful eukaryotic pathogens. It can infect virtually any warm-blooded animal, including 
humans, in whom it can cause serious disease. Its success is likely due to its ability to modulate 
host immune responses and host innate immune signaling pathways allowing it to establish a 
chronic infection with few symptoms in its hosts, which favors transmission to new hosts. Here, 
we report that Toxoplasma activates NF-κB and inhibits STAT1 signaling pathways to promote 
both its own survival and the survival of its host. We identified GRA15, a novel Toxoplasma 
secreted factor that activates the host cell NF-κB pathway. GRA15 is polymorphic between 
Toxoplasma strains and only active in the type II clonal lineage. GRA15 expression increases 
host pro-inflammatory cytokine production in vivo, thereby helping the host to control parasite 
growth. Conversely, Toxoplasma infection dampens the activation of other immune responses by 
inhibiting IFN-γ and STAT1 signaling. All of the Toxoplasma strains that we have tested directly 
inhibit the activity of STAT1, the transcription factor through which IFN-γ signals. We found 
that infection does not inhibit STAT1 phosphorylation, dimerization, nuclear translocation, or 
DNA binding. Instead, Toxoplasma must act even farther downstream, perhaps by inhibiting the 
recruitment of co-activators or RNA polymerase. Infection actually increased the association of 
STAT1 with DNA, which has been shown previously to be associated with decreased STAT1 
transcriptional activity. The Toxoplasma effector that inhibits STAT1 remains unknown, but our 
results suggest that it is not secreted into the host cell upon invasion but must interface with its 
cellular target after the parasitophorous vacuole is formed. A deeper knowledge of how and why 
Toxoplasma modulates these processes will help us to understand more about the basic signaling 
pathways themselves and to discover clues on how to better treat Toxoplasma infections in 
humans. 
 
Thesis Supervisor: Jeroen Saeij 
Title: Associate Professor of Biology 
 
 
 
4 
 
 
 
  
5 
 
Acknowledgements 
 The person to whom I owe the most for the ability to complete this thesis is my advisor, 
Jeroen. At the beginning of my graduate career, you gave me an abundance of guidance on my 
projects, while also encouraging me to think independently. Later, you gave me so much 
freedom to explore the research and questions in which I was most interested. I think that 
creating a community atmosphere in a lab where the lab members are put in a good position to 
succeed and at the same time be friends is very difficult, but you have really accomplished that, 
whether the lab had five people or fifteen people. So thank you for creating such a great place to 
work. 
 Thank you to my thesis committee members, Graham Walker and Aviv Regev, for advice 
and encouragement on my research projects and on my future career. 
 Every member of the Saeij lab has contributed in small or large part to this work. The 
only lab member who has been around for the entirety of my time here is Lindsay—the lab 
would not be what it is without her. Special thanks to Kirk for rambling philosophical 
immunological conversations and Dan for rambling biochemistry (usually requested) and life 
(usually unasked for) advice. Mariane, Ana, Wendy, Ninghan, Kim, and Musa, thanks for 
lightening up the lab, listening to my science problems, and making me laugh. Chapter 2 of this 
thesis was a joint effort and could not have been done without Diana, Kirk, Rogier, Lindsay, and 
Lauren. 
 We’ve been lucky to share the second floor with great neighbors, especially Laurie 
Boyer’s lab. Besides lending countless supplies, you have all given great feedback and advice on 
my project even though our scientific interests are quite different. 
 Many of my classmates have become my good friends; all of the time spent hanging out 
with you guys has kept me sane and all of our biological discussions have broadened my 
interests and perspective. 
 Lastly I want to thank my family. To my parents, who instilled in me a strong work ethic 
and the belief that everything I do should be done to the best of my ability. For encouragement 
during the past six years, but also for supporting all of my interests throughout childhood. To my 
sister, Katie, for always being there to talk to, even if it is only once a month. 
 
  
6 
 
  
7 
 
Table of contents 
Abstract............................................................................................................................................3 
Acknowledgements..........................................................................................................................5 
Chapter 1. Introduction....................................................................................................................9
 Intracellular pathogens.......................................................................................................10 
 Toxoplasma gondii as a model intracellular pathogen.......................................................11 
 The innate immune response to Toxoplasma infection in mice.........................................14 
 Strain differences in how Toxoplasma evades and modulates the immune response.......18 
 Summary............................................................................................................................19 
 References..........................................................................................................................20 
Chapter 2. Strain-specific activation of the NF-κB pathway by GRA15, a novel Toxoplasma 
gondii dense granule protein..........................................................................................................25 
 Abstract..............................................................................................................................26 
 Introduction........................................................................................................................26 
 Results................................................................................................................................29 
 Discussion..........................................................................................................................51 
 Materials and Methods.......................................................................................................56 
 Acknowledgements............................................................................................................65 
 References..........................................................................................................................66 
 Supplementary Figures......................................................................................................71 
Chapter 3. Toxoplasma gondii Clonal Strains All Inhibit STAT1 Transcriptional Activity but 
Polymorphic Effectors Differentially Modulate IFN-γ Induced Gene Expression and STAT1 
Phosphorylation.............................................................................................................................81 
 Abstract..............................................................................................................................82 
 Introduction........................................................................................................................82 
 Results................................................................................................................................85 
 Discussion..........................................................................................................................99 
 Materials and Methods.....................................................................................................101 
 Acknowledgements..........................................................................................................104 
 References........................................................................................................................104 
8 
 
 
Chapter 4. Toxoplasma gondii inhibits IFN-γ- and IFN-β-induced host cell STAT1 
transcriptional activity by increasing the association of STAT1 with DNA...............................109 
 Abstract............................................................................................................................110 
 Introduction......................................................................................................................110 
 Results..............................................................................................................................112 
 Discussion........................................................................................................................129 
 Materials and Methods.....................................................................................................135 
 Acknowledgements..........................................................................................................139 
 References........................................................................................................................140 
 Supplementary Figures....................................................................................................146 
Chapter 5. Discussion and Future Directions..............................................................................151 
 The interplay between Toxoplasma and its host is a balancing act, not a battle.............152 
 Elucidating the role of GRA15 in vivo............................................................................153 
 What role does Toxoplasma’s inhibition of STAT1 signaling play in vivo?...................157 
 What happens after STAT1 DNA binding?.....................................................................159 
 Does eospora caninum modulate the IFN-γ response?.................................................163 
 What is the Toxoplasma STAT1 inhibitor?.....................................................................164 
 Unbiased methods to determine the mechanism of inhibition and/or the Toxoplasma 
 effector.............................................................................................................................168 
 How does Toxoplasma continuously secrete dense granule proteins across the PVM into 
 the host cell post-invasion?..............................................................................................174 
 References........................................................................................................................174 
Appendix 1. Construction of additional STAT1 reporter cell lines.............................................181 
Appendix 2. FACS analysis of IFN-γ-induced protein expression in RAW264.7 murine 
macrophages................................................................................................................................187 
Appendix 3. Effect of eospora caninum on host IFN-γ/STAT1 and NF-κB pathways............191 
Appendix 4. Toxoplasma genes that are dispensable for inhibition of IFN-γ induced IRF1 
expression....................................................................................................................................195 
 
9 
 
 
 
 
 
 
 
Chapter 1. Introduction 
 
  
10 
 
Intracellular pathogens 
 According to the World Health Organization, infectious disease is responsible for more 
than 15% of all world-wide deaths. This number is even higher in developing regions of the 
world such as Africa (> 43%) and Southeast Asia (> 17%) (Mathers et al., 2008). Of all of the 
causative agents of infectious diseases, the three that account for the most mortality—
HIV/AIDS, Tuberculosis, and Malaria—are all intracellular pathogens.  
 Intracellular pathogens live within a specialized niche that allows them to evade certain 
mechanisms of the host immune system such as the complement system and antibodies, but this 
niche also presents its own set of problems with which the pathogens must deal. Every 
intracellular pathogen must get itself into a host cell, either by active invasion or by subverting 
host processes such as phagocytosis, and then get itself out of the host cell in order to 
disseminate to new cells and new hosts. Intracellular pathogens also must acquire nutrients and 
dispose of waste through the host cell. Hosts also possess immune mechanisms specifically 
designed to detect intracellular pathogens such as intracellular pattern recognition receptors that 
recognize pathogen-associated molecular patterns (PAMPs), and to destroy such pathogens, such 
as T cell and NK cell mediated killing of infected cells, oxygen and nitrogen radicals, limitation 
of nutrients such as iron and tryptophan, and GTPases that can destroy the vacuoles within which 
these pathogens live and the membranes of the pathogens themselves. 
 Pathogens have in turn evolved virulence factors and mechanisms to evade multiple 
aspects of host-mediated killing. However, obligate intracellular pathogens also rely on their 
hosts for survival and it is not advantageous for the pathogen to kill its host before it is 
transmitted to a new one. Therefore, this interplay between the pathogen and the host is more of 
a balance than a battle, and successful pathogens might need to evade some host immune 
responses while actually inducing other immune responses. It is also likely that different 
pathogens and strains of pathogens are specifically adapted to different hosts and also that 
different hosts have adapted immune mechanisms against their own natural pathogens. 
 A major question that then arises is, why do different hosts have different responses to 
different intracellular infections and what host and pathogen factors account for these 
differences? 
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Toxoplasma gondii as a model intracellular eukaryotic pathogen 
 Much is known about how viruses and bacteria evade host immune responses and cause 
disease, but how eukaryotic pathogens modulate these responses, and what genetic factors lead 
to differences in how different strains of eukaryotic pathogens cause disease, is less well-studied. 
 Toxoplasma gondii is an obligate intracellular protozoan parasite that belongs to the same 
phylum Apicomplexa, Plasmodium, the causative agent of malaria, and it serves as an excellent 
model intracellular pathogen. The Apicomplexa are named for a complex at their apical end 
which is involved in the invasion of these parasites into host cells. Within its hosts, the parasite 
can infect any nucleated cell, and it can be grown easily in the lab within tissue culture cells and 
is therefore amenable to a variety of assays to study how it interact with host cells. With respect 
to questions regarding discovering host and pathogen factors that account for differences in the 
outcome of infection, it is an especially useful model. Mice are a natural host and mouse 
infection models have been widely studied, utilizing different infection routes (intraperitoneal 
injection or oral ingestion) as well as different mouse strains and mouse gene knockouts. The 
Toxoplasma genome has been sequenced and is ~65 Mb, consisting of 14 chromosomes and 
~8000 genes (Gajria et al., 2008; Khan et al., 2005). Great genetic methods have been developed 
for Toxoplasma and it is relatively easy to ectopically express genes, knockout genes, and 
chemically mutagenize the parasite genome.  
 The natural life cycle of Toxoplasma is composed of a definitive host (the felines) and 
intermediate hosts (all warm-blooded animals, including mammals and birds) (Dubey, 2008; 
Wendte et al., 2011) (Fig. 1). After a cat eats an infectious stage of the parasite, within the gut of 
the cat haploid Toxoplasma parasites differentiate into micro- and macro-gametes and mate to 
form diploid oocysts. These oocysts are then shed into the environment where they undergo 
meiosis to form haploid sporozoites. Oocysts are orally infectious and lie dormant in the 
environment until they are consumed by an intermediate host or another cat. If ingested by an 
intermediate host, these sporozoites differentiate to a fast-growing life stage of the parasite, the 
tachyzoite, which can disseminate throughout the host. Intermediate hosts can pass this acute 
infection onto their progeny by congenital transmission. After the host mounts an immune 
response to combat this acute infection, these tachyzoites convert into slow-growing bradyzoites 
which are present during the chronic stage in tissue cysts. This encysted stage mainly forms in 
 the muscle and brain tissue of the host, and is crucial for its life cycle, as it is the other orally 
infectious stage of the parasite besides the oocyst. 
infected by consumption of an intermediate host carrying these infectious tissue cy
form this chronic stage, Toxoplasma
balance between the pathogen and the host is especially important for this pathogen.
 
Figure 1. Life cycle of Toxoplasma gondii
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 Many different Toxoplasma strains exist and the genomes and transcriptomes of many of 
these strains have been sequenced (Gajria et al., 2008; Minot et al., 2012). The population 
structure of Toxoplasma has been an area of active research. Originally, three major clonal 
lineages (types I, II, and III) were identified in North America and Europe on the basis of six 
restriction fragment length polymorphisms (RFLPs) (Howe and Sibley, 1995), and a fourth 
clonal lineage, haplogroup 12, was also later identified in North American wild animals (Khan et 
al., 2011). More recently, however, whole genome sequencing has shown that while clonal 
lineages do predominate in North America and Europe, large genetic diversity is the norm 
among strains in South America (Minot et al., 2012). These strains differ in many different 
phenotypes, for example, type I strains are categorically lethal in mice, with an LD100 = 1, while 
type II and type III infections are much less virulent (LD50 ~ 10
2 and ~105, respectively) (Saeij et 
al., 2006; Sibley and Boothroyd, 1992). Type II strains are also more commonly isolated from 
humans and associated with inflammatory disease while type III strains are more commonly 
isolated from wild animals (Boothroyd and Grigg, 2002; Dardé, 2004). These three types also 
differ in their ability to migrate in vivo, their attraction of different host cell types, and their 
induction of cytokine expression (Saeij et al., 2005a). Many of these strain differences are likely 
due to the adaptation of these different strains to different hosts with different immune systems, 
and parasite-induced pathology is likely caused by the infection of a host with a strain not 
adapted to that host’s particular immune system. 
 Upon invasion of a host cell, Toxoplasma secretes an array of proteins into the cell from 
specialized secretory organelles: the micronemes, rhoptries, and dense granules (Fig. 2). Proteins 
from the micronemes and rhoptry neck are primarily involved in the formation of a moving 
junction through which Toxoplasma invades (Carruthers and Boothroyd, 2007). The parasite 
creates an invagination in the host plasma membrane, pulling it around itself to form a 
parasitophorous vacuole (PV) surrounded by a parasitophorous vacuole membrane (PVM) (Fig. 
2) (Carruthers and Boothroyd, 2007). This vacuole does not enter endocytic or lysosomal 
pathways, as host proteins are excluded from the PVM during the invasion process (Mordue et 
al., 1999a, 1999b). During this process, rhoptry bulb contents are directly injected into the host 
cell, where they can traffic to cellular locations in the host cell such as the nucleus or back to the 
outside of the PVM (Boothroyd and Dubremetz, 2008), and some dense granule proteins are also 
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injected into the host cell at this time (Rosowski et al., 2011). However, there is evidence that 
dense granule proteins are also continually released into the PV (Dubremetz et al., 1993). Some 
of these dense granule proteins are then secreted into the host cell post-invasion through an 
unknown mechanism (Bougdour et al., 2013), likely involving protein export machinery similar 
to that used by malaria parasites upon infection of red blood cells (Haase and De Koning-Ward, 
2010; Hsiao et al., 2013). Toxoplasma secreted rhoptry proteins affect a wide array of host cell 
processes, including JAK/STAT signaling (Denkers et al., 2012), MAPK signaling (Peixoto et 
al., 2010), and interfering with GTPase oligomerization and activity (Fleckenstein et al., 2012; 
Niedelman et al., 2012). Dense granule proteins can also be involved in remodeling the host cell, 
including recruiting endo-lysosomes to the vacuole (Coppens et al., 2006). 
 
 
Figure 2. Toxoplasma invasion and protein secretion into the host cell. 
 
The innate immune response to Toxoplasma infection in mice 
 The innate immune response to Toxoplasma infection in mice is comprised of two main 
phases (reviewed in (Denkers, 2003))(Fig. 3). First, the transcription factor nuclear factor-kappa 
B (NF-κB) is activated in cells such as macrophages and dendritic cells. Commonly, this 
activation is through the recognition of pathogen-associated molecular patterns (PAMPs) that 
activate Toll-like receptors (TLRs). The major TLR ligand in Toxoplasma is the protein profilin, 
which is recognized by both TLR11 and TLR 12 (Andrade et al., 2013; Koblansky et al., 2013; 
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Yarovinsky et al., 2005). Toxoplasma RNA and DNA can also activate TLR7 and TLR9 
(Andrade et al., 2013) and glycosylphosphatidylinositols (GPIs) activate TLR2 and TLR4 
(Debierre-Grockiego et al., 2007). The NF-κB family of transcription factors is comprised of five 
members which form hetero- and homo- dimers in the cell cytosol (Fig. 4). These factors are 
bound by inhibitor of kappa B (IκB) proteins, such as IκBα, which block nuclear localization 
signals of the NF-κB subunits. TLR activation, or activation of other receptors, leads to the 
phosphorylation of the inhibitor of kappa kinase (IKK) complex, which phosphorylates IκB 
proteins, marking them for ubiquitination and degradation. This frees NF-κB dimers to 
translocate to the nucleus and stimulate transcription of target genes (Fig. 4) (reviewed in 
(Vallabhapurapu and Karin, 2009)). The NF-κB dimer most commonly associated with 
transcriptional activation is the p65/p50 heterodimer (reviewed in (Vallabhapurapu and Karin, 
2009)). 
 A major target gene of NF-κB p65/p50 dimers is the cytokine interleukin (IL)-12. This 
cytokine is produced in and secreted by macrophages and dendritic cells and it stimulates T cells 
and NK cells to produce the cytokine interferon-gamma (IFN-γ), beginning the second phase of 
the response (Fig. 3). IFN-γ receptors are expressed on the surface of many different cell types, 
and binding of IFN-γ leads to the phosphorylation of the transcription factor signal transducer 
and activator of transcription (STAT) 1 at tyrosine residue 701 (Fig. 5) (reviewed in (Platanias, 
2005)). The tyrosine phosphorylated form of STAT1 can then dimerize and translocate to the 
nucleus, where STAT1 dimers bind gamma activated sequence (GAS) sites, and stimulate 
transcription of target genes. Initially STAT1 induces the expression of interferon regulatory 
factor (IRF) 1, another transcription factor. STAT1 and IRF1 together then induce both negative 
regulatory proteins, such as suppressor of cytokine signaling (SOCS) proteins, to downregulate 
the pathway and prevent excessive inflammation, and a gene expression program which restricts 
the growth of many pathogens, including Toxoplasma (reviewed in (Saha et al., 2010)). One set 
of genes upregulated by IFN-γ are genes encoding MHC molecules, which allow cells to present 
more antigen to and activate T cells. IFN-γ-inducible GTPases are also expressed, including the 
immunity-related p47 GTPases (IRGs) and p65 guanylate binding proteins (GBPs). The IRGs 
can coat Toxoplasma PVs and function as dynamins to strip both PV and parasite membranes 
(Ling et al., 2006; Martens et al., 2005), and the GBPs are required for the proper recruitment of 
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IRGs to the Toxoplasma PV (Yamamoto et al., 2012). Both the IFN-γ-induced production of 
nitric oxide (NO), through the upregulation of inducible nitric oxide synthase (iNOS/Nos2) 
(Khan et al., 1997), and degradation of tryptophan, through indoleamine 2,3-dioxygenase (IDO1) 
(Dai et al., 1994; Habara-Ohkubo et al., 1993; Pfefferkorn, 1984), also inhibit the 
growth/survival of intracellular pathogens such as Toxoplasma. 
 This innate response is crucial for mouse survival upon Toxoplasma infection. Mice 
lacking certain single NF-κB subunits are more susceptible to both the acute and chronic phase 
of Toxoplasma infection (Mason et al., 2004), and mice deficient in TLR11/12, IL-12, IFN-γ, 
STAT1, and IRF1 are all acutely susceptible to Toxoplasma infection (Gazzinelli et al., 1994; 
Koblansky et al., 2013; Lieberman et al., 2004; Silva et al., 2002; Suzuki et al., 1988). 
 
Figure 3. Innate immune response to Toxoplasma 
 
17 
 
 
Figure 4. +F-κB signaling. 
 
 
 
 
Figure 5. IF+-γ/STAT1 signaling 
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Strain differences in how Toxoplasma evades and modulates the immune response 
 The major hypothesis driving my thesis work is that the ability of Toxoplasma (and 
intracellular pathogens in general) to modulate host cell innate immune signaling pathways 
determines its ability to evade the host innate immune response and thus its success as a 
pathogen and its ability to live within and disseminate between hosts. A corollary of this 
hypothesis is that some differences between Toxoplasma strains in their ability to cause disease 
are due to differences in how these strains modulate host cell innate immune responses. At the 
beginning of this work this hypothesis had begun to be tested in experiments using an array of F1 
progeny from crosses between the type I, II, and III clonal strains of Toxoplasma.  
 In two different studies, mice were infected with F1 progeny from either a I x III or a II x 
III cross, and mouse survival, among other phenotypes, was measured (Saeij et al., 2006; Taylor 
et al., 2006). Quantitative trait locus (QTL) mapping was then used to find regions of the 
Toxoplasma genome that were polymorphic between the strains and significantly associated with 
infection outcome. Both of these studies identified the polymorphic rhoptry kinase ROP18 as a 
significant predictor for the ability of a Toxoplasma strain to kill a mouse. Later, the rhoptry 
pseudokinase ROP5 was also identified from this same data (Reese et al., 2011). ROP18 and 
ROP5 cooperatively inhibit the activity of the IFN-γ induced IRGs (Behnke et al., 2012; 
Fleckenstein et al., 2012; Niedelman et al., 2012), demonstrating that the modulation of host cell 
processes and immune mechanisms by Toxoplasma does affect infection outcome and that these 
strains vary in how they modulate these processes. 
 However, these Toxoplasma virulence factors directly interact with specific host cell 
effector mechanisms, and it was still unclear whether strain-specific modulation of host cell 
transcription and transcription factors by Toxoplasma occurs and whether this modulation could 
affect disease outcome. Therefore, in another study, host gene expression was analyzed by 
microarrays upon infection of human fibroblasts with type I, II, or III strains in vitro, and indeed, 
subsets of host genes were found to be strain-specifically induced or inhibited by infection (Saeij 
et al., 2007). When these infections and microarray analyses were done with F1 progeny from a 
II x III cross, QTL mapping revealed that much of this strain-specific host cell gene expression is 
due to modulation of STAT3 and STAT6 transcription factor activity by another Toxoplasma 
rhoptry kinase, ROP16 (Saeij et al., 2007). ROP16 affects cytokine secretion and mouse survival 
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(Saeij et al., 2006, 2007), demonstrating that the modulation of signaling pathways by 
Toxoplasma can affect infection and disease outcome. 
 
Summary 
 In the first third of my thesis work, I further analyzed these previously performed 
microarray analyses, focusing on host genes that were strain-specifically modulated by 
Toxoplasma infection, but whose expression was not dependent on the ROP16 effector. In the 
initial infection of HFFs with type I, II, and III parasites, we noticed that a subset of host genes 
was specifically induced by type II infection, and analysis of transcription factor binding sites in 
the promoters of these genes revealed that they were controlled by the NF-κB transcription 
factor. Therefore, we used F1 progeny from II x III crosses and QTL mapping to locate a 
genomic region responsible for NF-κB activation in type II strains. We then used a candidate 
gene approach to discover a novel dense granule protein, GRA15, responsible for this phenotype. 
A type II copy of GRA15 activates NF-κB p65 nuclear translocation, NF-κB-mediated 
transcription, and IL-12 secretion. While GRA15 affects parasite growth in vivo early after 
infection it does not affect overall mouse survival, probably because NF-κB also can be activated 
via many other pathways in vivo, including by the TLRs. 
 I then became interested in the second phase of the murine innate immune response to 
Toxoplasma, the IFN-γ response. Some strains of Toxoplasma can directly evade specific IFN-γ 
induced effector killing mechanisms such as the IRGs (Zhao et al., 2009), however, it has been 
known since 1998 that Toxoplasma infection can block the expression of IFN-γ induced MHC 
class II gene expression (Lüder et al., 1998), and this has been extended to the expression of 
other IFN-γ induced genes such as IRF1 and class II transactivator (CIITA) (Lüder et al., 2001). 
In fact, infection can dysregulate IFN-γ induced gene expression globally (Kim et al., 2007a). In 
studying the inhibition of this response, we had two major questions: 1) are there any differences 
in how type I, II, and III Toxoplasma strains modulate this response and 2) what is the 
mechanism of this inhibition? In my research I have found that while type I, II, and III strains do 
differentially modulate specific aspects of this pathway such as STAT1 phosphorylation and 
IRF1 expression through the polymorphic effectors ROP16 and GRA15, globally all of these 
strains equally inhibit STAT1 transcriptional activity and IFN-γ induced gene expression. I then 
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focused on the mechanism of this inhibition, measuring each phase of STAT1 activation to 
narrow down the exact step at which Toxoplasma acts. I found that this inhibition happens 
downstream of STAT1 binding to DNA and that it is not dependent on histone deacetylases. 
Additionally, this inhibition affects STAT1 in IFN-β induced interferon stimulated gene factor 
(ISGF) 3 complexes. The Toxoplasma effector responsible for this inhibition is still unknown, 
but I determined that it is not secreted into the host cell upon invasion. 
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Abstract 
 NF-κB is an integral component of the immune response to Toxoplasma. While evidence 
exists that Toxoplasma can directly modulate the NF-κB pathway, the parasite-derived 
effector(s) involved are unknown. We determined that type II strains of Toxoplasma activate 
more NF-κB than type I or type III strains, and using forward genetics we found that this 
difference is due to the polymorphic protein GRA15, a novel dense granule protein that 
Toxoplasma secretes into the host cell upon invasion. A GRA15-deficient type II strain has a 
severe defect in both NF-κB nuclear translocation and NF-κB-mediated transcription. Further, 
human cells expressing type II GRA15 also activate NF-κB, demonstrating that GRA15 alone is 
sufficient for NF-κB activation. Along with the rhoptry protein ROP16, GRA15 is responsible 
for a large part of the strain differences in the induction of IL-12 secretion by infected mouse 
macrophages. In vivo bioluminescent imaging showed that a GRA15-deficient type II strain 
grows faster compared to wild-type, most likely through its reduced induction of interferon-
gamma (IFN-γ). These results show for the first time that a dense granule protein can modulate 
host signaling pathways, and dense granule proteins can therefore join rhoptry proteins in 
Toxoplasma’s host cell-modifying arsenal. 
 
Introduction 
 Toxoplasma gondii is an obligate intracellular parasite capable of infecting a wide range 
of warm-blooded hosts, including humans. Toxoplasma establishes a life-long chronic infection 
in the host by evading and subverting the immune system. Toxoplasma infection is usually 
asymptomatic in healthy humans, but can lead to flu-like and neurological symptoms in 
immunosuppressed patients and the fetuses of pregnant women infected for the first time. The 
vast majority of Toxoplasma strains isolated from Europe and North America belong to three 
clonal lineages, types I, II, and III, which differ in many phenotypes, including virulence (Saeij 
et al., 2005a). In mice, type I strains are categorically lethal, with an LD100 = 1, while type II or 
type III infections are not (LD50 ~ 10
2 and ~105, respectively) (Saeij et al., 2006; Sibley and 
Boothroyd, 1992). Strain differences in the modulation of host immune signaling pathways are 
one way by which this diversity arises. For example, the strain-specific modulation of the 
STAT3/6 signaling pathway by the secreted kinase ROP16 accounts for some of the strain 
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differences in virulence (Saeij et al., 2006). Evidence also exists for the strain-specific 
modulation of NF-κB (Robben et al., 2004), an important host signaling pathway in the 
regulation of inflammatory, immune, and anti-apoptotic responses. 
 The NF-κB family of transcription factors is composed of five members: p50 (NF-κB1), 
p52 (NF-κB2), p65 (RelA), RelB and c-Rel (Chap. 1 Fig. 4) (reviewed in (Vallabhapurapu and 
Karin, 2009)). In unstimulated cells, homo- or hetero-dimers of NF-κB are sequestered in the 
cytoplasm by members of the IκB (inhibitor of κB) family. Activation of NF-κB is initiated by 
the degradation of IκB proteins. This occurs via the activation of kinases called IκB kinases 
(IKKs), which phosphorylate two serine residues located in IκB regulatory domains, leading to 
their ubiquitination and subsequent proteasomal degradation. The NF-κB complex is then free to 
enter the nucleus where it can induce expression of specific genes that have NF-κB-binding sites 
in their promoters. 
 Many pathogens have developed strategies to modulate the host NF-κB pathway 
(reviewed in (Tato and Hunter, 2002)). Several bacteria and viruses inhibit NF-κB activation and 
its resultant recruitment and activation of immune cells, resulting in enhanced survival of the 
pathogen. Others pathogens induce NF-κB activation, which inhibits apoptosis, an important 
defense against intracellular pathogens, and increases cell migration, thereby recruiting new cells 
to infect.  Further, NF-κB-mediated inflammation leads to tissue damage, allowing pathogens to 
cross tissue barriers. Thus, depending on the host, pathogen, and site of infection, an active NF-
κB pathway can benefit either the host or the pathogen. 
 Mice deficient in some NF-κB family members have increased susceptibility to 
Toxoplasma, indicating the importance of this pathway in pathogen resistance (Mason et al., 
2004). C-Rel-/- mice are highly susceptible to the acute stage of Toxoplasma intraperitoneal (i.p.) 
infection which can be rescued solely by treatment with IL-12, indicating that a major role of 
NF-κB in resistance to Toxoplasma is the induction of IL-12 secretion (Mason et al., 2004). IL-
12 is a major mediator of the pro-inflammatory Th1 response development, and the major cause 
of chronic phase death in mice lacking RelB, p52, or the IκB protein Bcl-3 is also a deficient T 
cell response (Mason et al., 2004). While it is clear that the NF-κB pathway is important for an 
adequate response to Toxoplasma infection, the mice used in these studies all lack a particular 
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NF-κB subunit in every cell of their bodies, and it is currently unknown what the role of NF-κB 
is in specific cell types, such as those directly infected with Toxoplasma. 
 Evidence currently exists for both inhibition and activation of the NF-κB pathway in host 
cells by Toxoplasma. Less than six hours after infection, a type I strain was shown to block the 
nuclear translocation of p65 and the in vitro binding of NF-κB subunits to DNA (Butcher et al., 
2001; Kim et al., 2004; Shapira et al., 2002). Induction of IL-12 in response to tumor necrosis 
factor-alpha (TNF-α) or lipopolysaccharide (LPS) stimulation was also reduced (Butcher et al., 
2001; Kim et al., 2004). This inhibition of the NF-κB pathway was dependent on active invasion 
by live parasites (Butcher and Denkers, 2002). After more than six hours of infection, inhibition 
of p65 nuclear translocation and in vitro DNA binding was no longer observed (Kim et al., 2004; 
Leng et al., 2009). However, chromatin immunoprecipitation experiments showed that the in 
vivo binding of p65 to the TNF-α promoter was blocked even at late time points (Leng et al., 
2009). Other groups, however, have shown that NF-κB is activated by a type I strain of 
Toxoplasma, and that this activation is necessary for the inhibition of apoptosis (Molestina and 
Sinai, 2005a; Molestina et al., 2003; Payne et al., 2003). A consistent observation has been the 
phosphorylation and ubiquitination of IκBα upon Toxoplasma infection, though it is unclear what 
effect this has on the nuclear translocation of NF-κB and transcription of downstream genes 
(Butcher et al., 2001; Molestina et al., 2003; Shapira et al., 2005). All of these studies used a type 
I strain of Toxoplasma, suggesting that different observations might be due to different cell types 
and/or host species. Strain differences have been observed in the manipulation of the host NF-κB 
pathway by Toxoplasma. Type II strains were shown to cause the translocation of NF-κB to the 
nucleus of mouse splenocytes and mouse bone marrow-derived macrophages (BMDM), while 
type I strains did not (Dobbin et al., 2002; Robben et al., 2004). This strain difference was also 
shown to have downstream effects, as infection of BMDM with type II parasites resulted in high 
levels of IL-12 secretion compared to infection with type I parasites (Robben et al., 2004). At 
present, the Toxoplasma factor(s) involved in the modulation of the NF-κB pathway is not 
known. 
 In our experiments, infection with type II strains induces a high level of NF-κB 
activation, while infection with type I or III strains does not. Using F1 progeny from a type II x 
type III cross we identify a type II gene responsible for NF-κB activation, GRA15. The protein 
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product of GRA15 is a novel dense granule protein that is necessary and sufficient for p65 
nuclear translocation and NF-κB mediated host cell transcription. We show that GRA15 
activates the NF-κB pathway independent of MyD88 and TRIF but dependent on TRAF6 and the 
IKK complex. While GRA15 does not affect overall virulence of parasites, it does have more 
subtle phenotypes in vivo, affecting both parasite growth and cytokine levels.  
 
Results 
Host gene expression analysis shows strain-specific activation of the F-κB pathway 
 We previously generated a large gene expression dataset from human foreskin fibroblasts 
(HFFs) infected with type I, II or III Toxoplasma strains (Saeij et al., 2007). In our dataset 
analysis, we focused on the human genes that were differentially regulated by type II strain 
infection because published data indicated that type II strains might induce more NF-κB nuclear 
translocation compared to type I strains (Dobbin et al., 2002; Robben et al., 2004). If 
Toxoplasma strains differ in the activation of the NF-κB pathway, this should lead to differences 
in expression of genes with NF-κB transcription factor binding sites (TFBS) in their promoters. 
105 genes were found to be more than 2-fold upregulated in type II infections compared to type I 
and type III infections (Fig. S1A). Analysis of TFBS in the regulatory elements of these genes 
revealed enrichment of NF-κB TFBS in their promoters, and a network analysis of molecular 
relationships between the products of these 105 genes resulted in high scores for two networks 
whose central factors were the transcription factor NF-κB (network 1) and IL1β/PTGS2(COX-2) 
(network 2) (Fig. S1B).  IL1β and COX-2 are also regulated by NF-κB (Newton et al., 1997; 
Vallabhapurapu and Karin, 2009). These data suggest that there is at least one polymorphic locus 
between type II and type I/III strains that modulates the NF-κB pathway. 
 We also looked for polymorphic loci between type II and type III strains that modulate 
host gene expression using quantitative trait locus (QTL) analysis of human gene expression 
levels of cells infected with 19 different F1 progeny from II x III crosses. We identified 3,188 
human cDNAs that were regulated by a specific Toxoplasma genomic locus (Saeij et al., 2007). 
1,176 of these human cDNAs were regulated by a locus on chromosome VIIb. The Toxoplasma 
polymorphic ROP16 kinase resides on this chromosome and, via its strain-specific activation of 
STAT3/6, is responsible for the differential expression of many of the genes that are regulated by 
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a chromosome VIIb locus (Saeij et al., 2007). Loci on chromosome X also influenced the 
expression of 563 human cDNAs. To discover if these cDNAs are regulated by a common 
transcription factor, we determined if any TFBS were enriched in the promoters of genes that are 
differentially modulated by F1 progeny with a type II allele versus a type III allele at each 
chromosome X marker. At many markers, the expression of genes with NF-κB TFBS in their 
promoters was enriched in F1 progeny with a type II genotype, suggesting that a Toxoplasma 
factor responsible for strain differences in NF-κB activation resides on chromosome X (Fig. 
S1C).  Additionally, network analysis of molecular relationships between the 563 genes that 
were significantly influenced by a chromosome X locus and their gene products resulted in high 
scores for two networks, one of which had the transcription factor NF-κB as its central factor 
(Fig. S1C). We therefore hypothesized that a polymorphic Toxoplasma locus on chromosome X 
contributes to differential regulation of the host NF-κB pathway by type II and type I/III strains. 
 
Toxoplasma type II parasites activate F-κB 
 To investigate modulation of the NF-κB pathway by Toxoplasma gondii, we infected 
human foreskin fibroblasts (HFFs) with type I, II or III Toxoplasma strains for 1-24 hours, and 
measured nuclear translocation of the NF-κB p65 subunit by immunofluorescence (IF). Starting 
after four hours of infection and continuing until at least 24 hours of infection, many cells 
infected with a type II strain contained high levels of p65 in their nucleus, while a type I or a 
type III strain did not induce translocation of high levels of p65 to the nucleus (Fig. 1A and B, 
data not shown). We have observed the translocation of p65 by infection with various type II 
strains, including ME49, Pru, DAG, or Beverley, and the absence of high levels of p65 
translocation after infection with both RH or GT1 type I strains and CEP or VEG type III strains. 
Uninfected HFFs surrounding infected HFFs did not contain increased p65 in the nucleus, 
indicating that activation is not caused by a secreted host factor or a contaminant in the medium. 
Activation of p65 translocation after infection with type II strains was not inhibited by previous 
infection with type I or type III strains, demonstrating that this translocation is due to specific 
activation by type II parasites rather than inhibition by type I/III parasites (Fig. 1C and D, data 
not shown). We have observed the activation of NF-κB p65 nuclear translocation by type II 
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parasites in 293T cells, HeLa cells, mouse BMDM, RAW264.7 murine macrophages, mouse 
embryonic fibroblasts (MEFs), and rat embryonic fibroblasts (REFs) (Fig. 3, data not shown). 
 
Figure 1. Toxoplasma strains differ in the activation of +F-κB. HFFs were infected with Toxoplasma strains for 
18-24 hours, fixed, and stained with α-NF-κB p65 (red) and Hoechst dye (blue). Infection with A. a type II (GFP) 
strain; or B. a type III (GFP) strain; C, D. HFFs co-infected with a type I (non-GFP, arrow) and a type II (GFP) 
strain of Toxoplasma (C, brightfield; D, immunofluorescence). Cells infected with only type I parasites (arrowhead) 
do not contain nuclear NF-κB. This experiment has been repeated more than 10 times with similar results. Scale bar 
represents 5 µm. 
 
Type I parasites do not inhibit F-κB activation 
 While we observed that a type I strain does not inhibit p65 nuclear translocation in a co-
infection with a type II strain, previous reports have shown that in mouse macrophages infection 
with type I parasites can inhibit the activation of NF-κB in response to LPS or TNF-α (Butcher et 
al., 2001; Kim et al., 2004; Shapira et al., 2002). To further investigate if type I parasites can 
inhibit NF-κB translocation, we infected BMDM with type I parasites for 1 or 18 hours, 
stimulated the cells with LPS or TNF-α, and measured the translocation of p65 to the nucleus by 
IF (Fig. 2A). In uninfected cells, both LPS and TNF-α stimulation induced the translocation of 
p65 subunits to the nucleus. Pre-stimulation with LPS inhibited later LPS-induced translocation, 
as the activation of Toll-like receptor pathways induces negative feedback mechanisms to inhibit 
further signaling (Lang and Mansell, 2007; Wang et al., 2009). However, pre-infection with type 
I parasites did not inhibit LPS or TNF-α stimulated translocation, at early or late time points after 
infection. In fact, pre-infection with Toxoplasma led to higher levels of p65 translocation after 
LPS stimulation, perhaps due to increased TLR4 expression (Kim et al., 2004). 
 To test whether TNF-α stimulated NF-κB-mediated transcription can be inhibited by type 
I parasites, we used a HEK293 NF-κB reporter cell line which expresses GFP upon NF-κB 
activation. Infection of this reporter cell line with type II parasites results in high levels of GFP 
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in infected cells (data not shown). We added type I parasites to these cells for 45 minutes, 
stimulated the cells with TNF-α, and measured GFP levels of infected and uninfected cells by 
microscopy (Fig. 2B). After four hours of stimulation, both infected and uninfected cells had 
varying levels of GFP, with some cells containing almost no GFP and < 50% of cells having a 
high level of GFP. However, the distribution of GFP intensity in the populations of infected and 
uninfected cells was not significantly different. Unstimulated cells, either infected or uninfected, 
had negligible levels of GFP (data not shown). Type I parasites also did not inhibit NF-κB-
mediated transcription of luciferase in a HEK293 NF-κB luciferase reporter cell line (data not 
shown). 
 To investigate if type I pre-infection might inhibit transcription of specific subsets of NF-
κB regulated genes, we infected HFFs with a type I strain for 18 hours or left cells uninfected 
and subsequently stimulated the cells with TNF-α for six hours. We then performed gene 
expression analysis using Affymetrix microarrays. Comparing the expression data to uninfected 
HFF expression data, the genes regulated by TNF-α stimulation alone and type I pre-infection 
followed by TNF-α stimulation were not identical, however, genes with NF-κB TFBS in their 
promoters or belonging to an NF-κB related pathway were equally enriched in those two samples 
(Fig. 2C). We therefore conclude that type I parasites do not inhibit TNF-α or LPS stimulated 
NF-κB p65 translocation or TNF-α stimulated NF-κB-mediated transcription, but they may be 
able to modulate other pathways or host cell transcription factors which are important for 
expression of a small subset of TNF-α stimulated genes. 
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Figure 2. Type I parasites do not inhibit +F-κB activation. A. C57BL/6 BMDM were untreated, stimulated with 
100 ng/ml LPS or 20 ng/ml mouse TNF-α, or infected with type I parasites (MOI = 2) for one hour (top) or 18 hours 
(bottom). Cells were then re-stimulated for 30 min with LPS or 45 min with TNF-α, fixed, and stained with α-NF-
κB p65 and Hoechst dye. The intensity of nuclear NF-κB p65 was quantitated in at least ten cells per treatment. 
Values represent the fold induction of nuclear p65 levels over uninfected, unstimulated cells. This experiment was 
done once in BMDM. A second experiment of HFFs infected with type I parasites and subsequently stimulated with 
TNF-α yielded similar results. B. A HEK293 NF-κB GFP reporter cell line was plated on coverslips and infected 
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with type I parasites (MOI = 1-2) for 45 min, then stimulated with 100 ng/ml human TNF-α for 4 hours, fixed, and 
stained with α-SAG1 (red). The GFP intensity was quantitated for at least 30 infected cells and 30 uninfected cells 
(bottom) (n.s. = not significant, two sample t-test). Scale bar represents 10 µm. This experiment was performed 
twice, with the same qualitative results. Similar results were also obtained with a HEK293 NF-κB luciferase reporter 
cell line.  C. Microarray analysis was done on HFFs pre-infected with a type I strain (MOI = 7.5) for 18 hours, or 
left uninfected, and subsequently stimulated with 20 ng/ml human TNF-α for 6 hours. Genes were pre-ranked for 
both samples by the difference in expression as compared to uninfected, untreated HFFs, and gene set enrichment 
analysis (GSEA) was used to determine whether genes with NF-κB TFBS in their promoters or belonging to NF-κB 
related canonical pathways were enriched in either or both samples. FDR q-values less than 0.25 were considered 
significant. One array per strain and treatment was done. 
 
A Toxoplasma genomic locus on chromosome X mediates strain-specific activation of F-κB 
 To find the Toxoplasma genomic region(s) mediating the type II versus type I/III strain-
specific difference in activation of NF-κB, we infected HFFs with 27 F1 progeny derived from 
crosses between type II and type III strains and measured NF-κB activation by IF. Only HFFs 
infected with F1 progeny having type II alleles for the genetic markers ROP2 and GRA6 at the 
right end of Toxoplasma chromosome X contained nuclear NF-κB p65 (Fig. S2). Thus, the 
genomic region in the vicinity of genetic markers ROP2-GRA6 harbors one or more genes 
involved in the activation of NF-κB. We developed new RFLP markers to more accurately 
define the place of recombination in progeny that are recombinant for chromosome X around 
ROP2 and GRA6 and therefore limit the genomic region involved in the activation of NF-κB and 
the number of possible candidate genes. With these new markers, genotyping of STE7 refined 
the 3’ boundary of the region and genotyping of S26 refined the 5’ boundary of the region (Fig. 
S2). The refined region between the markers SAG2E and RC4 contains 45 predicted type II genes 
(ToxoDB.org, v6.0).  
 To identify the Toxoplasma gene responsible for NF-κB activation, we employed a 
candidate gene approach. From the 45 predicted type II genes, the SAG2CDXY (SRS49a/b/c/d) 
locus was excluded, as a type II strain with this locus deleted still activates NF-κB (Saeij et al., 
2008), data not shown). Our first criterion for a protein able to interface with the host cell and 
modulate host cell signaling was the presence of a signal sequence. Of the 41 remaining genes, 
17 are predicted to have a signal sequence. Of these 17 genes, four (ROP8, ROP2A, GRA6 and 
63.m00001) were consistently expressed in tachyzoites in infected macrophage cells, as 
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determined by Toxoplasma microarrays (data not shown). Our top candidate genes (ROP2A, 
GRA6 and 63.m00001) were then tested by adding a type II C-terminal HA-tagged copy of the 
candidate gene, including at least 1500 bp of the putative endogenous promoter, into a type I 
and/or III strain and we assayed whether these transgenic type I/III strains activate NF-κB. Type 
I and III strains stably expressing a copy of 63.m00001 activated NF-κB in HFFs, whereas 
strains expressing a copy of GRA6 or ROP2 did not, indicating that 63.m00001, hereafter 
referred to as GRA15, is the locus on chromosome X which mediates the strain-specific 
activation of NF-κB (Fig. 3 and Fig. S3). 
 
GRA15 mediates F-κB p65 translocation 
 We quantified the nuclear p65 immunofluorescence signal of cells infected with type I, 
II, or III strains, confirming that a subset of type II infected cells had a high level of nuclear p65 
(intensity > 800), resulting in a significant difference in the average nuclear p65 of type II 
infected cells compared to type I or type III infected cells (Fig. 3A, B). Type I (but not type III) 
infected cells did have significantly more nuclear NF-κB p65 than uninfected cells. Type I and 
type III strains engineered to stably express a type II, HA-tagged, copy of GRA15 (type I 
GRA15II and type III GRA15II) activated NF-κB (Fig. 3A, B). As with type II infected cells, a 
subset of type I GRA15II infected cells had very high levels of nuclear NF-κB, and the average 
nuclear p65 was significantly higher in these cells compared to type I infected cells. A time 
course experiment showed that this activation occurred starting four hours after infection (Fig. 
S4). 
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Figure 3. GRA15 mediates +F-κB p65 translocation. A. HFFs were infected with Toxoplasma strains for 18 
hours, fixed, and stained with α-NF-κB p65 (red), α-SAG1 (green), and Hoechst dye (blue). Scale bar represents 10 
µm. B. The amount of p65 in the nucleus was quantitated in at least 15 HFF cells for each strain. Asterix indicates 
significantly higher levels of nuclear p65 compared to uninfected cells (*p < 0.0001, two sample t-test).  C. Mouse 
BMDM (BALB/c) were infected with Toxoplasma strains for 24 hours, fixed, and stained with α-NF-κB p65 (red), 
α-SAG1 (green), and Hoechst dye (blue). Scale bar represents 10 µm. D. The level of nuclear p65 in infected cells 
was quantitated in at least 12 infected cells per strain. Asterix indicates significantly higher levels of nuclear p65 
compared to uninfected cells (*p < 0.005, two sample t-test). One replicate experiment was done in both HFFs and 
mouse BMDM with similar qualitative results. 
 
  To determine if type II GRA15 was necessary for NF-κB p65 translocation in host cells, 
we generated type II GRA15KO strains (Fig. S5). Removal of the GRA15 locus abolished p65 
translocation by type II parasites in host cells, eliminating the subset of infected cells with a high 
level of nuclear p65 (Fig. 3A, B). The level of nuclear p65 in cells infected with type II 
GRA15KO parasites was not significantly different from the level in uninfected cells (Fig. 3B). 
To confirm that GRA15 is responsible for the NF-κB activation phenotype, we transfected 
GRA15II back into a type II GRA15KO strain. NF-κB p65 nuclear translocation was rescued in 
this type II GRA15KO GRA15II strain (Fig. 3A, B). Additionally, a type I GRA15KO GRA15II 
strain activated translocation of p65, and infection with this strain or a type I GRA15II strain did 
not activate significantly different levels of nuclear p65, confirming that the type II copy of 
GRA15 alone was sufficient for the nuclear translocation of p65 by type I strains of Toxoplasma. 
Similarly, in mouse BMDM, infection with type II strains, but not type I/III strains, activated a 
high level of p65 nuclear translocation. This activation was also due to the type II GRA15 gene 
(Fig. 3C, D).  
 To examine if p65 was the only NF-κB family subunit activated by GRA15 we infected 
HFFs with type I GRA15II parasites for 24 hours, and examined p50, p52, RelB and c-Rel 
nuclear localization by IF (Fig. S6). Only p50 was specifically and significantly translocated to 
the nucleus by type I GRA15II strains (Fig. 6A). However, there was a significant increase in 
levels of nuclear c-Rel upon infection with both type I and type I GRA15II strains (Fig. 6D). 
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GRA15 activates F-κB-mediated transcription 
 To determine if the nuclear NF-κB p65 triggered by GRA15II is transcriptionally active, 
we infected HFFs with type II, type II GRA15KO, type I, type I GRA15II, type III, or type III 
GRA15II Toxoplasma, and hybridized RNA from the infections to Affymetrix human genome 
arrays to determine host cell gene expression. The expression of genes with NF-κB TFBS in their 
promoters and gene products belonging to an NF-κB related pathway was enriched in type II vs 
type II GRA15KO infections and type I/III GRA15II vs type I/III infections (Fig. 4A, Supp. data). 
146 transcripts were strongly regulated by GRA15, regardless of the Toxoplasma strain genetic 
background, and we defined these genes as core, GRA15-regulated genes (Fig. 4B). Network 
analysis of molecular relationships between these 146 genes and their gene products also 
demonstrated an enrichment of genes involved in cytokine and NF-κB signaling (Fig. 4C). 
 Type I Toxoplasma parasites also activate NF-κB p65 translocation in HFFs, although at 
a much lower level than type II strains (Fig. 3). Microarray analysis confirmed that a type I strain 
can cause the activation of NF-κB-mediated transcription. The expression of genes with NF-κB 
TFBS in their promoters and gene products belonging to an NF-κB related pathway was enriched 
in type I infected HFFs over uninfected HFFs (Supp. data). This activation is not dependent on 
GRA15; the expression of NF-κB regulated genes was enriched in a type I GRA15KO infection 
compared to uninfected cells, and not in a type I infection compared to a type I GRA15KO 
infection (data not shown). 
 We also infected wild-type and p65-/- MEFs with type II, type II GRA15KO, type I, or 
type I GRA15II Toxoplasma strains, and analyzed host cell gene expression by microarray (Fig. 
4D). In WT MEFs, we found 18 genes to be core, GRA15-regulated genes (more than 2-fold 
different in type II vs type II GRA15KO and type I GRA15II vs type I infections). Of these 18 
genes, only two are also GRA15-regulated in p65-/- host cells. This data indicates that the 
majority of host cell transcription induced by GRA15 was activated via the canonical p65/p50 
NF-κB heterodimer, however it is possible that a small subset of genes was activated by other 
NF-κB subunits, such as c-Rel/p50 dimers, or other transcription factors. 
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Figure 4. GRA15 activates +F-κB-mediated transcription. HFFs or MEFs were infected for 18-24 hours with 
type II, type II GRA15KO, type I, type III, type I GRA15II or type III GRA15II Toxoplasma strains, and host cell gene 
expression was analyzed by Affymetrix microarrays. At least two arrays were done per strain in HFFs and one array 
was done per strain in MEFs. A. The top three enriched, known TFBS from gene set enrichment analyses comparing 
type II versus type II GRA15KO and type I/III GRA15II versus type I/III infections are shown. B. For the 146 genes 
that are defined as core, GRA15-regulated genes, average log2 gene expression values were median-centered, genes 
were clustered by hierarchical clustering, and a heat map is presented. The complete set of genes is listed in Supp. 
data. C. Ingenuity pathway analysis was done for these 146 genes. The top two scoring networks are shown. D. In 
MEF arrays, 32 genes have the same expression level in WT and p65-/- cells and are regulated by GRA15. For these 
genes, log2 expression values were median-centered, genes were clustered by hierarchical clustering, and a heat map 
is shown. The complete set of genes is listed in Supp. data. 
 
GRA15 is a polymorphic secreted dense granule protein 
 The GRA15 coding region is predicted to be 1908 bp in type I and III strains, but only 
1653 bp in type II strains, due to either an insertion or deletion (indel) (ToxoDB.org, v6.0). An 
intron is predicted in the type I and type III copies, very close to the indel. We sequenced the 
region around this indel of both type I and type II cDNA. Neither strain was found to have an 
intron in this region, and the indel was confirmed. To determine the full transcript of GRA15II, 
we performed 5’ and 3’ RACE. Two GRA15II transcription start sites were found, one at -508 to 
-504 bp upstream of ATG and one at -277 bp upstream of ATG. Three polyadenylation sites 
were found, at +930, +992, and +1144 bp downstream of the stop codon.  
 ToxoDB.org currently contains sequences from one strain for each of the three North 
American/European clonal lineages of Toxoplasma: GT1 (type I), ME49 (type II), and VEG 
(type III). The genomic sequences of strains within the same lineage are thought to be very 
similar, however, we sequenced the GRA15 locus from RH (type I), Pru (type II), and CEP (type 
III) strains as well, three other strains that we have used in our experiments. While Pru and CEP 
have an identical sequence to ME49 and VEG, respectively, the RH sequence contains a 
frameshift mutation at base 872. This frameshift leads to the mutation of a stretch of 22 amino 
acids (2 remain conserved), followed by a premature stop codon, truncating the protein to 312 
amino acids, instead of 635 amino acids. The type I/III and II protein sequences differ most 
strikingly at the 84 amino acid indel near the C-terminus of the protein. Besides this indel, 5 
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other amino acids are polymorphic between types I/III and II and one other single amino acid is 
inserted or deleted (Fig. S7). 
 We next looked by IF at the localization of GRA15 in the parasite and infected host cells. 
To determine if GRA15 was secreted into the host cell, we performed evacuole staining on a five 
minute type I GRA15II-HA infection of HFF cells using an antibody against the HA tag (Fig. 
5A). HA staining is clearly present in evacuoles, partially co-localizing with evacuoles 
containing rhoptry proteins, indicating that GRA15 is a secreted protein. Evacuoles containing 
GRA15 can also be seen after attachment of cytochalasin D-treated parasites (data not shown). In 
parasitophorous vacuoles (PVs), co-staining of the GRA15II-HA protein with either a rhoptry 
marker, ROP1, or a dense granule marker, GRA7, showed co-localization of GRA15II-HA with 
GRA7, with almost no overlap between the HA tag and ROP1 (Fig. 5C). GRA15 staining 
overlaps GRA7 staining in the dense granules and within the PV. GRA15 also localizes to the 
outside of the parasitophorous vacuole membrane (PVM), and in a co-infection of type I (non-
GFP) and type I GRA15II-HA (GFP) parasites, HA staining can be seen localized in the PVM 
and on the outside of the PVM of a parasite expressing GRA15II-HA (GFP), as well as on the 
outside of the PVM of a parasite not expressing GRA15II-HA (Fig. 5B), which is consistent with 
dense granule localization. We therefore conclude that GRA15 is a dense granule protein. 
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Figure 5. GRA15 is a secreted dense granule protein. A. Parasites expressing GFP and an HA-tagged copy of 
GRA15II were added to HFFs for five minutes to allow attachment and evacuole formation. Cells were then fixed 
and stained with α-HA (red), α-ROP1 (green) and Hoechst dye (blue). The HA tag is present with ROP1 in 
evacuoles, indicating that GRA15 can be secreted into the host cell. This experiment was repeated once with 
cytochalasin D-treated parasites with the same results. B. Co-infection of type I (non-GFP) and type I GRA15II-HA 
(GFP) parasites, done once. Arrows indicate HA staining on the PVM of a non-GFP vacuole. C. Co-staining of 
GRA15II-HA with a dense granule marker, GRA7, shows co-localization of HA-staining and GRA7 in both the 
dense granules and the parasitophorous vacuole. Conversely, co-staining of GRA15II-HA with a rhoptry marker, 
ROP1, shows almost no overlap between the HA tag and the rhoptries. Co-staining was done once, but the same 
GRA15II-HA staining pattern has been observed in more than five independent experiments. Scale bars represent 5 
µm. 
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GRA15 affects total levels of phospho-IκBα, but does not affect PVM-associated phospho-
IκBα 
 The nuclear translocation of NF-κB transcription factor subunits is dependent on the 
phosphorylation and degradation of an inhibitory protein, IκBα. We determined if GRA15 
affected the overall levels of phospho-IκBα in infected cells by western blot, and quantified the 
fraction of phosphorylated IκBα compared to the total level of IκBα (Fig. 6A). Infection with a 
strain of Toxoplasma expressing GRA15II led to an increase in the fraction of total IκBα that was 
phosphorylated, although not to the extent of TNF-α-induced levels. This indicates that GRA15 
activates NF-κB through the phosphorylation of IκBα. 
 Previously, a type I Toxoplasma protein extract was found to have IκBα-phosphorylating 
activity in vitro (Molestina et al., 2003). There is also evidence that this kinase activity can occur 
in vivo, as PVM-associated phospho-IκBα can still be observed in infected IKKα/β double 
knockout MEFs (Molestina and Sinai, 2005b). However, in these IKKα/β double knockout cells, 
after type I Toxoplasma infection NF-κB does not translocate to the nucleus or bind to DNA in 
vitro, and NF-κB mediated gene expression is severely decreased (Molestina and Sinai, 2005a). 
To determine if the accumulation of phospho-IκBα on the PVM correlated with NF-κB 
activation we infected HFFs with Toxoplasma strains and stained infected cells with a phospho-
IκBα antibody. Although infection with type II parasites activated NF-κB to a much greater 
extent and lead to higher levels of total phospho-IκBα compared to type I parasite infection, in a 
mixed infection of type I (non-GFP) and type II (GFP) Toxoplasma, phospho-IκBα accumulated 
almost exclusively on type I vacuoles (Fig. 6B). We also found that the accumulation of 
phospho-IκBα at the PVM was independent of GRA15, as both type I and type I GRA15II PVMs 
accumulated phospho-IκBα, and neither type II nor type II GRA15KO PVMs accumulated visual 
levels of phospho-IκBα (Fig. 6C). Phospho-IκBα also did not accumulate on type III PVMs (Fig. 
6C). We conclude that the accumulation of PVM-associated phospho-IκBα is specific to type I 
parasites and is not correlated with the overall level of NF-κB activation in the host cell. 
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Figure 6. GRA15 activity affects total levels phospho-IκBα, but not PVM-associated phospho-IκBα. A. HFFs 
were infected with Toxoplasma strains for 24 hours or stimulated with TNF-α for indicated times, cell lysates were 
collected, run on an SDS-PAGE gel, and western blotted for phospho-IκBα, total IκBα, SAG1 (parasite loading 
control), and GAPDH (host cell loading control). From the total IκBα blot, the fraction of phosphorylated IκBα was 
determined by comparing the intensity of the upper band (phosphorylated form) to the total intensity of the lower 
and upper band. This experiment was repeated once with type I and type I GRA15II strains only with similar results. 
B. HFFs were co-infected with type I (non-GFP) and type II (GFP) parasites, fixed, and stained with α-phospho-
IκBα (red) and Hoechst dye (blue). A type I PVM (non-GFP, arrowhead) and a type II PVM (GFP, arrow) are 
indicated. Scale bar represents 5 µm. C. HFFs were infected with Toxoplasma strains expressing GFP for 24 hours, 
fixed, and stained with α-phospho-IκBα (red) and Hoechst dye (blue). This experiment has been done three times 
with similar results. Scale bars represent 1 µm. 
 
GRA15 is dependent on the IKK complex and TRAF6, but independent of MyD88 and TRIF 
 BLAST and Pfam searches for proteins with similar amino acid sequences or domains to 
GRA15II returned no significant results, providing no clues to the mechanism of GRA15 NF-κB 
activation (Altschul et al., 1990; Finn et al., 2008). To start to answer this question, we 
determined which components of the NF-κB signaling pathway were necessary for GRA15 
activity. When NF-κB is activated, IκB proteins are phosphorylated and then degraded by the 
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proteasome. We previously determined that GRA15 leads to the phosphorylation of IκBα (Fig. 
6), and to determine if GRA15 activity is dependent on the proteasome, we pre-treated cells with 
MG132, a proteasomal inhibitor. Our results show that activation of NF-κB by GRA15 required 
functional proteasomal degradation (Fig. 7A). IκB proteins are normally phosphorylated by the 
IKK complex, consisting of IKKα, IKKβ, and IKKγ (NEMO). IKKγ is a regulatory subunit in 
the complex, while the β and α subunits are active kinases. IKKβ has greater kinase activity than 
IKKα, and is the principal kinase responsible for the phosphorylation of IκBα (Ghosh and Karin, 
2002; Li and Verma, 2002). In WT MEFs, a type I GRA15II strain induces a 3.4 fold increase in 
nuclear p65 compared to uninfected cells. However, in IKKβ-/- MEFs, this increase is only 1.9 
fold (Fig. 7B). Many pathogens activate NF-κB via TLR agonists, and TLR signaling is 
mediated by the MyD88 and TRIF adaptor proteins. However, GRA15 is able to activate p65 
nuclear translocation in MyD88/TRIF double knockout cells, indicating that it is not just a TLR 
ligand (Fig. 7D). GRA15-mediated p65 activation is also not dependent on the RIP1 adaptor 
protein, but is dependent on TRAF6 (Fig. 7C, data not shown). Thus GRA15 appears to 
modulate NF-κB at a specific step in the pathway downstream of MyD88 and TRIF, but 
upstream of, or in a complex with, TRAF6 and IKK proteins. 
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Figure 7. GRA15 activity is dependent on IKKβ and TRAF6 and independent of MyD88 and TRIF. Cells 
were infected with type I GRA15II or type I parasites for four hours, stimulated with 20 ng/ml TNF-α for one hour, 
or left unstimulated and uninfected (US, UI). Cells were fixed and probed with an α-NF-κB p65 antibody and mean 
nuclear staining was measured. A. HFF cells were pre-incubated with media containing 20 ng/ml MG132 
proteasome inhibitor prior to infection and TNF-α stimulation. B-D. The activity of GRA15II in the absence of 
different components of the NF-κB pathway was assayed: B. IKKβ-/- MEFs, C. TRAF6-/- MEFs, D. MyD88-/-/TRIF-/- 
BMDM host cells. These experiments were repeated at least two times and quantification was performed on a 
representative experiment for each factor assayed. Asterix (*) indicates data are significantly different, (p-value < 
0.05, t-test), and n.s. indicates data are not significantly different. 
 
GRA15 expressed in Hela cells is sufficient to activate F-κB 
 We wanted to determine whether GRA15II alone is sufficient to activate p65 nuclear 
translocation, or if other Toxoplasma secreted factors that are common to all type I, II, and III 
strains are also needed for this process. When we transiently transfected HeLa cells with a vector 
expressing the type II copy of GRA15 N-terminally fused with GFP, the nuclei of transfected 
GFP-positive cells contained p65, while the nuclei of non-transfected, GFP-negative cells in the 
same culture did not (Fig. 8A). The level of this nuclear localization is equivalent with activation 
by intracellular type I GRA15II parasites (Fig. 8B). Expression of 55.m04955, an unrelated 
Toxoplasma protein, or Mob1A, a human protein present in the original vector, did not induce 
p65 translocation, indicating that this NF-κB activation is not due to cell stress from protein 
overexpression (Fig. 8A). GRA15II expression alone is therefore sufficient to recapitulate the 
induction of p65 nuclear translocation. 
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Figure 8. GRA15 expression alone is sufficient to activate +F-κB in HeLa cells. A. HeLa cells were transfected 
with GRA15II, an unrelated Toxoplasma gene (55.m04955), or an unrelated human gene (Mob1A), fused to GFP. 
Cells were then fixed and stained with α-NF-κB p65 (red) and Hoechst dye (blue). All cells expressing GRA15II-
GFP contain activated NF-κB p65, whereas cells expressing 55.m04955-GFP or Mob1A-GFP do not. Non-
transfected, non-GFP cells in the same culture also have no nuclear NF-κB p65. This experiment was repeated two 
more times with the same results. B. HeLa cells were infected with type I GRA15II or type I parasites for 24 hours, 
fixed, and stained with α-NF-κB p65 (red) and Hoechst dye (blue). Cells infected with a type I GRA15II strain 
contain comparable amounts of nuclear NF-κB p65 to transfected cells. This experiment was repeated a second time 
with similar results. 
 
GRA15 affects in vitro parasite growth 
 To assay the effect of GRA15 on in vitro parasite growth, we infected monolayers of 
fibroblasts with type I, type I GRA15II, type II or type II GRA15KO parasites, allowed the 
parasites to grow for 4-7 days, and then quantified the area of plaques formed on the monolayers. 
In HFF host cells, a type II GRA15KO strain formed significantly larger plaques than a type II 
strain (p = 0.002, t-test), and a type I strain formed significantly larger plaques than a type I 
GRA15II strain (p = 0.024, t-test) (Fig. S8A). However, in MEF host cells, type II and type II 
GRA15KO strains did not make significantly different size plaques (p = 0.841, t-test), and the 
48 
 
same was true of type I and type I GRA15II strains (p = 0.371, t-test) (Fig. S8A). This data 
indicates that GRA15 inhibits in vitro parasite growth in human fibroblasts, but not mouse 
fibroblasts. 
 
GRA15 affects IL-12 production in vitro 
 In vitro infection of macrophages with different strains of Toxoplasma results in different 
levels of IL-12p40 secretion, with type II strains inducing much higher levels of IL-12p40, and 
some of this variation has been suggested to be due to strain differences in NF-κB activation 
(Kim et al., 2006; Robben et al., 2004; Saeij et al., 2007). To examine the role of GRA15-
mediated NF-κB activation in the induction of IL-12p40 secretion, mouse BMDM were infected 
with type I, type I GRA15II, type II, or type II GRA15KO Toxoplasma, and levels of IL-12p40 in 
the supernatant were determined by cytokine ELISA (Fig. 9A). As expected, type I infected 
BMDM secrete a low level of IL-12p40 which is not significantly higher than the level secreted 
by uninfected cells, while type II induces a high level of IL-12p40 secretion. When GRA15 is 
removed from the type II strain, IL-12p40 secretion decreases more than 6-fold, implying a 
considerable role for this gene product in modulating host cell IL-12 signaling (p = 0.001, t-test). 
Similarly, the introduction of GRA15II in a type I strain leads to a significant increase in IL-
12p40 secretion by BMDM (p = 0.008, t-test). IL-12p70 secretion was also higher after type II 
infection compared to a type I infection and partially dependent on the presence of a type II copy 
of GRA15 (data not shown). 
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Figure 9. GRA15II promotes IL-12 secretion in vitro and affects parasite growth and host cytokine production 
in vivo. A. BALB/c BMDM were infected with Toxoplasma strains for 24 hours, supernatants were collected, and 
IL-12p40 levels were determined by cytokine ELISA. These experiments were performed at least three times in 
BMDM using triplicate samples, as well as in RAW264.7 macrophages, all with similar results. B-D. Mice were 
infected intraperitoneally with tachyzoites of either a type II or a type II GRA15KO strain. B. C57BL/6 or BALB/c 
mice were infected with 5,000 tachyzoites and survival of mice was monitored. In one experiment, 5 BALB/c mice 
were infected per strain, and in three separate experiments, a total of 25 C57BL/6 mice were infected per strain. C. 
BALB/c mice were infected with parasites which express the enzyme luciferase. Five days after infection, mice 
were intraperitoneally injected with luciferin, anesthetized, and the flux (photons/sec/cm2/sr) was determined as a 
measure of parasite burden. Mice infected with a type II GRA15KO strain had significantly greater total flux (p/s) 
and therefore significantly greater parasite burden than mice infected with a type II strain. This burden difference 
five days after infection was observed in three independent experiments. D. One or two days after infection, infected 
BALB/c mice were euthanized and an i.p. cavity wash was collected for IFN-γ, IL-12p70, and IL-12p40 cytokine 
ELISA. On day 2 after infection, mice infected with a type II GRA15KO strain had significantly lower levels of 
IFN-γ in the intraperitoneal cavity than mice infected with a type II strain (p = 0.05, two-sample t-test). Five mice 
were infected per strain per day. Day 2 cytokine levels were measured in a separate experiment with similar results. 
 
 The Toxoplasma polymorphic rhoptry kinase ROP16 also affects IL-12 secretion, and 
previous microarray analyses determined that the expression of many GRA15-regulated genes 
are also strongly affected by a locus on chromosome VIIb, where ROP16 resides (Saeij et al., 
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2007). In these analyses, some genes, such as SOCS2 and SOCS3, were regulated by loci on both 
chromosome VIIb and X (Fig. S9A). We wondered if the effect of ROP16 on these genes was 
through modulation of the NF-κB pathway. We infected a HEK293 NF-κB GFP reporter cell line 
with a type II strain or a type II transgenic strain expressing a type I copy of ROP16. A 
significantly greater percentage of type II infected cells than type II ROP16I infected cells are 
GFP-positive (p = 1.5 x 10-7, χ2 test), indicating that in a type II background, a type I copy of 
ROP16 significantly inhibits NF-κB activation (Fig. S9B). In a HEK293 NF-κB luciferase 
reporter cell line, infection with a type II ROP16I strain also induced significantly less luciferase 
activity than infection with a type II strain (data not shown). Thus, both GRA15 and ROP16 
affect NF-κB activity. 
 
GRA15 affects in vivo parasite growth and cytokine production 
 To assay the effect of GRA15 on parasite virulence we infected C57BL/6 or BALB/c 
mice by i.p. injection with 5,000 tachyzoites of a type II or a type II GRA15KO strain and 
monitored mouse survival during the acute phase of infection (days 0-20) (Fig. 9B). C57BL/6 
mice infected with either strain succumbed to infection at the same time, between days four and 
eighteen after injection. Additionally, the same percentage of mice in each group survived, 
~40%. BALB/c mice infected with either a type II or a type II GRA15KO strain did not die after 
infection.  
 To determine the effect of GRA15 on in vivo parasite burden, BALB/c mice infected i.p. 
with tachyzoites of either a type II or a type II GRA15KO strain that express the enzyme 
luciferase were imaged throughout infection. At day five after infection, mice infected with a 
type II GRA15KO strain had a significantly higher parasite burden than mice infected with a type 
II strain (Fig. 9C) (p = 0.01, t-test). Similarly, expression of GRA15II in a type I strain inhibited 
in vivo parasite growth (Fig. S8B). Together, these experiments indicate that GRA15 inhibits in 
vivo parasite growth in both a type I and a type II background. 
 GRA15 affects IL-12 secretion by BMDM in vitro, and we also assessed whether it 
affects cytokine secretion in vivo at the site of infection. BALB/c mice were infected i.p. with 
tachyzoites of either a type II or a type II GRA15KO strain. One or two days after infection, mice 
were sacrificed, the intraperitoneal cavity was washed, and cytokine levels in the wash were 
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determined by ELISA. On day 2 after infection, mice infected with a type II GRA15KO strain 
had significantly less IFN-γ in their i.p. cavities than mice infected with a type II strain (Fig. 9D) 
(p = 0.05, t-test). While differences in IL-12p40 or p70 were not significant on either day 1 or 
day 2 due to large variations between mice, the average cytokine levels in type II GRA15KO 
infected mice were consistently lower than cytokine levels in type II infected mice. At these 
early time points, there was not a significant difference in parasite load between mice infected 
with either strain, as determined by imaging (data not shown). 
 
Discussion 
 The modulation of the NF-κB pathway by Toxoplasma has long been an area of debate, 
with some reports stating that Toxoplasma activates NF-κB and others that Toxoplasma inhibits 
NF-κB activation. In this study, we have conclusively shown that the three North American 
clonal lineages of Toxoplasma differ in their activation of the host NF-κB pathway; type II 
strains activate a high level of NF-κB p65 translocation while type I and III strains do not (Fig. 
3). Using F1 progeny from a type II x type III cross, we found that a locus on chromosome X is 
responsible for this polymorphic phenotype, and identified the novel Toxoplasma factor GRA15 
at this locus (Fig. S2). The type II copy of GRA15 (63.m00001) is necessary in type II strains and 
sufficient in type I and III strains for NF-κB nuclear translocation and transcriptional activity 
(Fig. 3, 4). We have observed this activation in a variety of human, mouse, and rat cell types, 
indicating that GRA15’s activity is independent of host cell type and species. Additionally, when 
GRA15II is expressed in HeLa cells, it is sufficient to activate NF-κB.  
 It had been previously reported that infection with type I strains of Toxoplasma activates 
NF-κB in MEF and Henle 407 intestinal epithelial host cells (Ju et al., 2009; Molestina et al., 
2003). Careful quantification of IF experiments showed that type I strains do slightly activate 
NF-κB p65 translocation, but the level of nuclear p65 is much higher in type II infected cells 
than type I infected cells (Fig. 3). It is possible that other groups have concluded that type I 
strains do not activate NF-κB because this activation is so low compared to that of LPS or TNF-α 
stimulation (Butcher et al., 2001; Shapira et al., 2002, 2005). Our IF experiments also showed 
that a type I strain activates c-Rel nuclear translocation, which might also affect host cell 
transcription (Fig. S6). By microarray analysis, some NF-κB regulated genes are induced by type 
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I infection, but a much greater number are induced by type II infection, and infection with a type 
I strain does not activate detectable GFP or luciferase transcription from an NF-κB reporter cell 
line (data not shown), in concordance with another published report (Shapira et al., 2005). This 
low-level activation is also not dependent on GRA15, as there is no enrichment in NF-κB 
activation in a type I infection over a type I GRA15KO infection. Type III strains do not activate 
any p65 nuclear translocation or NF-κB-mediated transcription.  
 Our results agree with previous observations that phosphorylated IκBα accumulates on 
the PVM upon Toxoplasma type I infection (Butcher et al., 2001; Molestina et al., 2003; Shapira 
et al., 2005). However, levels of PVM-associated phospho-IκBα are not correlated with total 
levels of phospho-IκBα or the level of NF-κB transcriptional activity in the host cell. Phospho-
IκBα is not observed on type II PVMs, and, while infection with Toxoplasma strains expressing 
GRA15II leads to higher total levels of phospho-IκBα, the presence of GRA15 does not affect 
PVM-associated phospho-IκBα (Fig. 6). A type I Toxoplasma protein capable of phosphorylating 
IκBα may play a role in low-level activation of NF-κB in type I strains (Molestina and Sinai, 
2005b). However, it is clear that the GRA15 protein in type II strains activates NF-κB to a much 
greater extent. 
 On the other hand, some groups have reported that infection with type I Toxoplasma 
strains inhibits NF-κB activation after stimulation with the cytokine TNF-α or the TLR ligand 
LPS (Butcher et al., 2001; Kim et al., 2004; Shapira et al., 2002). This inhibition has been 
observed after less than 6 hours of infection in HFFs (Shapira et al., 2005), mouse BMDM (Kim 
et al., 2004; Shapira et al., 2002), and thioglycolate-elicited cells (Butcher et al., 2001), and was 
not observed after six or 12 hours of infection in mouse BMDM (Kim et al., 2004; Leng et al., 
2009). Our experiments confirm that type I Toxoplasma cannot inhibit LPS stimulated NF-κB 
nuclear translocation or TNF-α stimulated NF-κB transcriptional activity at a late time point in 
infection (Fig. 2A, C). But, after a short infection (< 5 hr), we also do not observe inhibition of 
NF-κB p65 nuclear translocation or NF-κB mediated-transcription, contradicting these reports 
(Fig. 2A, B). It is true that some infected cells do not respond to LPS or TNF-α stimulation, and 
this observation may have lead to the conclusion that type I strains can inhibit NF-κB signaling. 
However, quantification of NF-κB p65 translocation and NF-κB reporter transcription in many 
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uninfected and infected cells shows that pre-infection with Toxoplasma does not alter the 
response of populations of cells to these stimuli.  
 The GRA15 gene product is a novel Toxoplasma dense granule protein which is secreted 
into the host cell upon invasion (Fig. 5), representing the first identified Apicomplexan dense 
granule protein that can modulate host cell signaling pathways. Rhoptry proteins have already 
been identified as parasite factors that can alter host cell behavior, but our findings indicate that 
dense granule proteins should be viewed as candidate factors as well. It is still unclear why only 
the type II copy of GRA15 activates NF-κB. Amino acid polymorphisms between the type II and 
type I/III copies of GRA15, including an insertion/deletion and several single amino acid 
changes, or the expression level of GRA15 may be responsible for this polymorphic phenotype. 
 Although the GRA15 protein is secreted into the host cell upon parasite invasion, cells 
infected with type I GRA15II parasites did not have substantial p65 in their nuclei until 
approximately four hours post-infection (Fig. S4), and in our experiments NF-κB activation was 
usually assayed 18-25 hours post-infection. These slow kinetics are not unprecedented, Rac 
GTPase has been shown to initiate NF-κB nuclear translocation with a time course similar to that 
of GRA15 (Boyer et al., 2004). Additionally, the amount of GRA15 interacting with host cell 
proteins likely increases after PV formation as dense granule proteins are made and continuously 
secreted from intracellular parasites, and higher levels of GRA15 may be necessary to initiate 
NF-κB activation. 
 The precise mechanism by which GRA15 activates NF-κB has yet to be discovered. Our 
data suggests that GRA15 initiates canonical NF-κB activation, which preferentially induces the 
p65/p50 heterodimer (Hayden and Ghosh, 2004). A simple hypothesis is that GRA15 acts as a 
TLR ligand to activate the canonical NF-κB pathway, however the activation of p65 
translocation by GRA15 is not dependent on either MyD88 or TRIF, two proteins that are 
essential for TLR signaling. We did find that the activity of GRA15 is dependent on both IKKβ 
and TRAF6, suggesting that GRA15 acts either upstream of or in a complex with these proteins. 
A type I GRA15II strain activated more nuclear p65 translocation in WT MEFs than in IKKβ
-/- or 
TRAF6-/- MEFs, although in IKKβ-/- cells this difference was not significant (p = 0.12). This is 
probably because IKKα also has phosphorylating activity. Our microarray data further defines 
the placement of GRA15 in the NF-κB signaling pathway. GRA15 is able to constitutively 
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activate NF-κB, but this activation leads to the expression of negative feedback regulators, such 
as the deubiquitinating enzymes (DUBs) A20 (TFAIP3) and CYLD, which normally act to 
quickly downregulate NF-κB signaling. Since TRAF6 and the IKK complex are both targets of 
these DUBs, it is likely that GRA15 acts in concert with these proteins, rather than upstream 
(Sun, 2008). We are currently looking for direct binding partners of GRA15 by co-
immunoprecipitation. 
 We found that a type I copy of ROP16 can inhibit NF-κB activation in a type II strain 
(Fig. S9B). Why this inhibition occurs in a type II strain but not a type I strain is unknown, but 
the genetic backgrounds of type I and type II strains are very different and other polymorphic 
factors likely exist that affect STAT and/or NF-κB signaling pathways. How ROP16 inhibits NF-
κB activation is also unclear, but it is likely to be through its activation of STAT6 and/or STAT3 
(Butcher et al., 2005a; Hoentjen et al., 2005; Nelson et al., 2003; Ohmori and Hamilton, 2000). 
This inhibition has significant consequences, for example, GRA15 and ROP16 have opposing 
effects on the expression levels of many genes, including IL-12, a particularly important 
cytokine in Toxoplasma infection (Fig. 9A) (Gazzinelli et al., 1994; Saeij et al., 2007). In fact, 
the single amino acid difference in ROP16 which causes it to be less active in type II strains 
(Yamamoto et al., 2009) may have been selected for in type II strains specifically to increase NF-
κB activation by GRA15II. However, GRA15 and ROP16 are expected to have additive or 
synergistic effects on the expression of other genes, such as the SOCS genes (Supp Fig. 9A). In 
any case, the modulation of host cell gene expression will depend upon the exact allelic 
combination of a variety of factors that Toxoplasma possesses, including GRA15 and ROP16. 
 Early in infection (days 1-5), GRA15 affected both cytokine production and parasite 
growth in vivo. When a host is first infected by live parasites, type II strains expressing GRA15 
activate NF-κB in host cells and induce IL-12 secretion, whereas infection with type II 
GRA15KO parasites, or type I/III strains, does not cause this early activation. IL-12 stimulates 
NK cells and T cells to secrete IFN-γ, and the observed effect of GRA15 on IFN-γ levels was 
likely via an effect on IL-12. While levels of IL-12 in the intraperitoneal cavity were not 
significantly different between mice infected with a type II or type II GRA15KO strain, the levels 
were consistently lower in type II GRA15KO infected mice, and this difference may have been 
enough to lead to a significant difference in IFN-γ levels (Fig. 9D). IFN-γ is the main mediator 
55 
 
of host resistance to Toxoplasma, and differences in IFN-γ levels probably also explain the 
growth difference that we observed in vivo between a type II and type II GRA15KO strain at a 
slightly later time point, five days after infection (Fig. 9C). However, as the infection progresses 
and parasites lyse out of host cells, pathogen associated molecular pattern (PAMP) proteins 
within the PV such as profilin and cyclophilin are released, and NF-κB will be activated via TLR 
signaling and CCR5 signaling by all strains. At this stage, IL-12 production, IFN-γ production, 
and parasite growth are then independent of the GRA15 locus, which might explain why a type 
II strain does not differ in overall virulence from a type II GRA15KO strain (Fig. 9B). The 
location of GRA15 on chromosome X does indicate that it could represent a previously identified 
chromosome X virulence locus (Saeij et al., 2006). 
 Plaque assays showed that GRA15 also affects parasite growth in vitro (Fig. S8A). 
However, this in vitro effect occurred specifically in human cells and not in mouse cells. The 
cause of this difference is currently unknown, but one possibility is that genes affecting amino 
acid levels, lipid levels, or levels of other nutrients are partially NF-κB regulated in human cells 
but not in mouse cells. 
 GRA15II may also have other effects in vivo that remain untested. As an intracellular 
pathogen, Toxoplasma must use host cells to traffic through the body of the host animal. NF-κB 
activation by GRA15II increases expression of many chemokines and adhesion molecules (our 
microarray data), and strain differences in NF-κB activation may therefore lead to differences in 
the ability to induce migration of host cells, as previously reported (Lambert et al., 2006, 2009). 
Infection of hosts with other pathogens is also highly relevant to disease outcome, and the 
activation of NF-κB by Toxoplasma might increase transcription of HIV retroviral sequences 
with NF-κB binding sites in their promoters (Gazzinelli et al., 1996). Lastly, NF-κB activation 
leads to a pro-inflammatory Th1-type immune response which may promote inflammatory 
disease manifestations such as encephalitis and colitis, both of which have been observed mainly 
after type II strain infections (Hunter and Remington, 1994; Liesenfeld, 1999).   
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Materials and Methods 
Parasites and Cells 
 Parasites were maintained in vitro by serial passage on monolayers of human foreskin 
fibroblasts (HFFs) at 37°C in 5% CO2. RH or GT1 were used as representative type I strains, 
ME49 or Pru as representative type II strains and CEP or VEG as representative type III strains. 
A Pru strain engineered to express firefly luciferase and GFP (Pru ∆HXGPRT A7) (Kim et al., 
2007b), and CEP and RH strains engineered to express clickbeetle luciferase and GFP (CEP 
HXGPRT
- C22 and RH 1-1) (Boyle et al., 2007) have been described previously. Pru and RH 
strains expressing HXGPRT and generated from unsuccessful knockout transfections were used 
in assays comparing parasite growth. F1 progeny from type II x type III crosses were described 
previously (Khan et al., 2005; Sibley et al., 1992). A Pru strain expressing a type I copy of 
ROP16 was also described previously (Saeij et al., 2007). HFFs were grown in DMEM (GIBCO 
BRL) supplemented with 10% heat inactivated fetal bovine serum (FBS) (PAA), 2 mM L-
glutamine, 50 µg/mL each of penicillin and streptomycin, and 20 µg/ml gentamycin. Bone-
marrow derived macrophages (BMDM) were obtained from female BALB/c, C57BL/6, or 
MyD88/TRIF double knockout (a gift from Hidde Ploegh) mice. Bone marrow was isolated by 
flushing hind tibias and femurs using a 27 gauge needle and/or by crushing the bones using a 
mortar and pestle, followed by passage over a cell strainer. Cells were suspended in DMEM 
supplemented with 20% L929 cell-conditioned medium, 10% heat-inactivated FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, 1x MEM non-essential amino acids, and 50 µg/mL each of 
penicillin and streptomycin. 3-6 x 106 cells were plated in 10 cm non-tissue culture treated dishes 
(VWR) and incubated at 37°C, 5% CO2 in humidified air. After 6-7 days cells were washed with 
PBS to remove non-adherent cells, harvested by dislodging with a cell-scraper in PBS, and 
replated for the assay. HEK293 stable cell lines with four copies of the NF-κB consensus 
transcriptional response element driving the expression of GFP or GFP and luciferase (System 
Biosciences) were grown in DMEM supplemented with 10% heat-inactivated FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, 1x MEM non-essential amino acids, 10 mM HEPES, 50 
µg/mL each of penicillin and streptomycin, and 20 µg/ml gentamycin. HEK293 cells were 
passed every 2-4 days using 0.05% Trypsin-EDTA. Wild-type mouse embryonic fibroblasts 
(MEFs) were gifts from Michael Karin and Anthony Sinai, IKKβ-/- MEFs were a gift from 
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Michael Karin (Li et al., 1999), NF-κBp65-/- MEFs were a gift from Anthony Sinai, and TRAF6-
/- MEFs were kindly provided by Katherine Fitzgerald. MEFs were grown in DMEM (GIBCO 
BRL) supplemented with 10% non-heat inactivated fetal bovine serum (FBS) (PAA), 2 mM L-
glutamine, 1 mM sodium pyruvate, 1x MEM non-essential amino acids, 10 mM HEPES, and 50 
µg/mL each of penicillin and streptomycin. MEFs were passed using 0.05% Trypsin-EDTA.  All 
parasite strains and cell lines were routinely checked for Mycoplasma contamination and it was 
never detected. 
 
Reagents 
 Antibodies against HA (3F10, Roche), mouse NF-κB p65 (sc-8008), human NF-κB p65 
(sc-109), NF-κB p50 (sc-8414), NF-κB p52 (sc-7386), NF-κB RelB (sc-28689), NF-κB c-Rel 
(sc-71), Toxoplasma surface antigen (SAG)-1 (DG52) (Burg et al., 1988), Toxoplasma dense 
granule protein GRA7 (Dunn et al., 2008), Toxoplasma rhoptry protein ROP1 (Tg49) (Ossorio et 
al., 1992), phospho-IκBα (sc-8404), total IκBα (sc-847), and GAPDH (sc-32233), were used in 
the immunofluorescence assay or in western blotting. Immunofluorescence secondary antibodies 
were coupled with Alexa Fluor 488 or Alexa Fluor 594 (Molecular Probes). Secondary 
antibodies used in western blotting were conjugated to peroxidase (Kirkegaard & Perry 
Laboratories). Purified LPS (Calbiochem), recombinant mouse TNF-α (AbD Serotec), and 
recombinant human TNF-α (Invitrogen) were used to stimulate cells. MG132 (Calbiochem) was 
used in proteasomal inhibition. 
 
Immunofluorescence (IF) 
 Parasites were allowed to invade cells on coverslips and incubated for different time 
points. The cells were then fixed with 3% (v/v) formaldehyde in PBS for 20 minutes at room 
temperature, permeabilized with 100% ethanol and/or 0.2% (v/v) Triton-X 100, and blocked in 
PBS with 3% (w/v) BSA and 5% (v/v) goat serum. Coverslips were incubated with primary 
antibody for one hour at room temperature or overnight at 4°C, and fluorescent secondary 
antibodies and Hoechst dye were used for antigen and DNA visualization, respectively. 
Coverslips were mounted on a glass slide with Vectashield (Vector Laboratories), and 
photographs were taken using NIS-Elements software (Nikon) and a digital camera (Coolsnap 
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EZ; Roper Scientific) connected to an inverted fluorescence microscope (model eclipse Ti-S; 
Nikon). Quantification of nuclear signal was performed by randomly selecting at least 10 
infected cells per Toxoplasma strain and measuring the average signal intensity per nucleus using 
the NIS-Elements software and Hoechst dye to define nuclei. For evacuole staining, this standard 
immunofluorescence protocol was modified slightly. Parasites were added to HFFs on 
coverslips, spun down to bring them into contact with host cells, and allowed to attach to and 
invade host cells for five minutes at 37°C. Unattached parasites were washed off with PBS, and 
cells were fixed as above, blocked in PBS with 5% (v/v) fetal bovine serum and 5% (v/v) normal 
goat serum for one to two hours at room temperature, and permeabilized by incubation in PBS 
with 0.2% (w/v) saponin at 37°C for 20 min. For proteasomal inhibition HFF monolayers were 
pre-treated with 20 ng/mL of MG132 for one hour at 37°C. Cells were infected with parasites 
and spun down. Four hours following MG132 addition, cells were washed with PBS and fresh 
media containing no inhibitor was added. The monolayer was incubated for one additional hour 
prior to fixation. To synchronize infection during time course assays, HFF monolayers were 
incubated on ice with cold media for ten minutes prior to infection. For infection, supernatant 
from fully lysed parasite flasks were pelleted and washed three times with PBS and resuspended 
in cold media. Following infection, monolayers were incubated on ice for 30 minutes, then 
unattached parasites were washed off with cold PBS. Fresh pre-warmed media was added and 
cells were incubated at 37°C to allow invasion and infection for the determined length of time. 
 
Generation of transgenic parasites 
 The GRA15 coding region and putative promoter (1940 bp upstream of the start codon) 
was amplified from type II Toxoplasma genomic DNA by PCR (F: 5’- 
CCCAAGCTTGACTGCCACG TGTAGTATCC -3’; R: 5’- 
TTACGCGTAGTCCGGGACGTCGTACGGGTATGGAGTTACCGCTGATTGTG T -3’). 
Sequence coding for an HA-tag was included in the reverse primer (denoted with italics) to C-
terminally tag the protein. GRA15IIHA was then inserted into pCR8/GW (Invitrogen) by TOPO-
TA cloning. Gateway cassette A was ligated into pTKO at the EcoRV site, creating a Gateway 
destination vector (Invitrogen), pTKO-att (Fig. S12), and GRA15IIHA was cloned into pTKO-att 
by LR recombination (Invitrogen). The pTKO-att-GRA15IIHA vector was then linearized by 
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digestion with XhoI (NEB). XhoI cuts off 244 bp of the putative promoter, leaving 1696 bp 
intact upstream of the start codon. Linearized vector was transfected into RH ∆HXGPRT and 
CEP HXGPRT- C22 parasites by electroporation. Electroporation was done in a 2 mm cuvette 
(BioRad) with 2 mM ATP (MP Biomedicals), 5 mM GSH (EMD), in a GenePulser Xcell 
(BioRad), with the following settings: 25 µFD, 1.25 kV, ∞ Ω. Stable integrants were selected in 
media with 50 µg/ml mycophenolic acid (Axxora) and 50 µg/ml xanthine (Alfa Aesar) and 
cloned by limiting dilution. Expression of GRA15II was confirmed by IF for HA staining. 
Parasite strains already containing the HXGPRT gene (RH GRA15KO and Pru A7 GRA15KO) 
were co-transfected with 35 µg pTKO-att-GRA15II and 1 µg pTUB5-BLE (Soldati et al., 1995), 
containing the ble selectable marker. Stable integrants were selected extracellularly with 50 
µg/ml Phleomycin (InvivoGen), and HA staining was confirmed by IF. 
 The ROP2 and GRA6 coding regions and putative promoters (at least 1500 bp upstream 
of the start codon) were amplified from type II Toxoplasma genomic DNA by PCR (ROP2F: 5’- 
CACCGAGGTTGGAACTGTG -3’; ROP2R: 5’- 
CTTACGCGTAGTCCGGGACGTCGTACGGGTAGATTGCCGTAACCGCCT -3’; GRA6FW: 
5’- CCCAAGCTTGAAGGACTGCGTTGAGTGTTTT -3’; GRA6RV: 5’- 
GGAATTCTTACGCGTAGTCCGGGACGTCGTACGGGTAAAAATCAAACTCATTCACACT
TC -3’). Sequence coding for an HA-tag was included in the reverse primers (denoted with 
italics) to C-terminally tag the proteins. ROP2IIHA was then inserted into pENTR/D (Invitrogen) 
and GRA6IIHA was inserted into pCR8/GW (Invitrogen) by TOPO cloning, and then cloned into 
pTKO-att by LR recombination (Invitrogen). The pTKO-att-ROP2IIHA or GRA6IIHA vectors 
were then linearized by digestion with NotI (NEB). Linearized vector was transfected into 
parasites by electroporation. Electroporation and selection was done as above, and HA staining 
was confirmed by IF. 
 
Generation of GRA15 knockout 
 A targeting construct (Fig. S5A) was engineered using a modified pTKO-att vector, 
pTKO2, and MultiSite Gateway Pro 3-Fragment Recombination (Invitrogen). The hypoxanthine-
xanthine-guanine ribosyl transferase (HXGPRT) selectable marker was removed from pTKO-att 
by Cre recombinase (NEB) to form pTKO2 (Fig. S12). 5’ and 3’ flanking regions of GRA15 
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were cloned from type I and type II genomic DNA. Primers contained att recombination sites 
(denoted in primer sequence with italics), and amplified 2083 bp, 100 bp upstream of the GRA15 
start codon, and 2071 bp, 34 bp downstream of the GRA15 stop codon (5’F: 5’- 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAAGGGTCTGAACGTGTGCA-3’; 5’R: 5’-
GGGGACAACTTTGTATAGAAAAGTTGGGTGACCCGGCTTAAGTTGGTG-3’; 3’F: 5’-
GGGGACAACTTTGTATAATAAAGTTGCATGACCAAAAACCGATAA-3’;  
3’R: 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTACAAGTCGGCACATGCTTAGA-3’). 
These flanking regions were then cloned around the HXGPRT selectable marker flanked by 5’ 
and 3’ UTRs from DHFR, amplified from pTKO with primers containing att recombination sites 
(denoted in primer sequence with italics) (DHFR::HPT F: 
GGGGACAACTTTTCTATACAAAGTTGCTCAGCACGAAACCTTGCAT; DHFR::HPT R: 
GGGGACAACTTTATTATACAAAGTTGTGTGTCACTGTAGCCTGCC). Prior to transfection, 
the knockout vector was linearized with the restriction enzyme NotI (NEB). RH ∆HXGPRT, Pru 
∆HXGPRT, and Pru ∆HXGPRT A7 parasites were transfected with the knockout construct by 
electroporation, as described above. Stable integrants were selected as above and cloned by 
limiting dilution. PCR with a forward primer upstream of the 5’ flanking region (P1: 5’-
CATGGATGCTAATCGGCTTT-3’) and a reverse primer within the HXGPRT cassette (P2: 5’-
GATCCAGACGTCTTCAATGC-3’; P3: 5’- 
GGGGACAACTTTATTATACAAAGTTGTGTGTCACTGTAGCCTGCC-3’) confirmed a 
disruption in the GRA15 locus. Additionally, PCR was done to confirm the inability to amplify 
GRA15 (P4: 5’-GATGATGGATCCATAATTCGGTGGCTTGGG-3’; P5: 5’- 
GGGGACCACTTTGTACAAGAAAGCTGGGTATCGGCACATGCTTAGAAG -3’) (Fig. 
S5B). 
 
Microarray 
 For human arrays, Human Foreskin Fibroblasts (HFFs) were grown in a T25 to 
confluency. Parasite strains were syringe lysed and washed once with PBS. HFFs were infected 
with Pru ∆HXGPRT A7, Pru ∆HXGPRT, Pru A7 GRA15KO, Pru GRA15KO, RH 1-1, RH 
∆HXGPRT, RH GRA15II (a transgenic RH strain expressing a type II copy of GRA15), RH 
GRA15KO, CEP HXGPRT- C22, or CEP C22 GRA15II (a transgenic CEP strain expressing a 
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type II copy of GRA15) at varying MOIs. For mouse arrays, wild-type or p65-/- MEFs were 
grown in a 12-well plate to confluency. Parasite strains were syringe lysed and washed twice 
with PBS. MEFs were infected with Pru ∆HXGPRT A7, Pru A7 GRA15KO, RH 1-1, or RH 
GRA15II at varying MOIs.  
 Plaque assays were done to assess viability of parasites and infections with similar MOIs 
were chosen. Some samples were also stimulated with TNF-α. At least two biological replicates 
were done for every sample, except RH GRA15KO infection, TNF-α stimulation, RH ∆HXGPRT 
pre-infection followed by TNF-α stimulation, and all MEF samples. 18-24 hours after infection 
or six hours after stimulation, total RNA was isolated using TRIzol reagent (Invitrogen) 
according to the manufacturer’s protocol and cleaned up using RNeasy Mini or MinElute Kit 
(Qiagen). RNA was labeled and hybridized to a human or mouse Affymetrix array (Human 
U133A 2.0 or Mouse 430A 2.0) according to the manufacturer’s protocol. Probe intensities were 
measured with the Affymetrix GeneChip Scanner 7G and were processed into image analysis 
(.CEL) files with either Affymetrix GeneChip Operating Software or Affymetrix Expression 
Console Software. Intensity values were normalized using the MAS5 algorithm such that the 
median intensity on the array was 500 using Expression Console software. The MAS5 algorithm 
gives a signal intensity value for every probe as well as a present, marginal, or absent call, based 
on mismatch probes. For all probes called present, signal intensity values less than 50 were 
increased to a minimum value of 50. For all probes called marginal or absent, the signal intensity 
value was set to 50. Expression data was clustered using MultiExperiment Viewer (Saeed et al., 
2003, 2006). Microarray data has been uploaded to GEO Datasets under accession number 
GSE25476. 
 Gene set enrichment analysis (GSEA) was used to find candidate transcription factors 
and canonical pathways that are modulated differently between Toxoplasma infections (Mootha 
et al., 2003; Subramanian et al., 2005). This program uses a priori defined sets of genes and 
determines whether the members of these sets of genes are randomly distributed throughout a 
ranked list or primarily found at the top or bottom. As GSEA is generally used to generate 
hypotheses, gene sets enriched with a false discovery rate (FDR) < 0.25 were considered 
significant. Both transcription factor and canonical pathway gene sets from the Molecular 
Signatures Database were evaluated for enrichment (c2.cp.v2.5.symbols, 
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c3.tft.v2.5.symbols.gmt) (Subramanian et al., 2005). The gsea2 java release was run using all 
default settings. For analyses on RH GRA15KO, TNF-α, and RH ∆HXGPRT + TNF-α, and all 
MEF infections, for which we only did one array, MOI-matched arrays and the GSEA preranked 
function were used.  
 Distant Regulatory Elements of co-regulated genes (DiRE) (Gotea and Ovcharenko, 
2008) and Ingenuity pathway analysis (IPA) were also used. For every gene in a list, DiRE 
detects regulatory elements throughout the entire gene locus, and looks for enrichment of TFBSs. 
IPA takes a list of genes and overlays them onto a global molecular network developed from 
information contained in the Ingenuity Pathways Knowledge Base. Networks of these genes are then 
algorithmically generated based on their connectivity. A network is a graphical representation of the 
molecular relationships between genes/gene products. Genes or gene products are represented as 
nodes, and the biological relationship between two nodes is represented as an edge. All edges are 
supported by at least 1 reference from the literature, from a textbook, or from canonical information 
stored in the Ingenuity Pathways Knowledge Base. The two networks with the highest score are 
indicated. 
 
5’ and 3’ Rapid amplification of cDA ends (RACE) 
 Total RNA was isolated from HFFs infected with Pru parasites using TRIzol reagent 
(Invitrogen) and cleaned up using RNeasy Mini Kit (Qiagen). RACE-ready cDNA was 
synthesized using a GeneRacer Kit with SuperScript III RT (Invitrogen). Nested PCR was done 
on the RACE-ready cDNA to determine both 5’ and 3’ transcript ends using gene-specific 
primers (5’ GRA15R: 5’-AGTCCTCCCCGTTTTCGGTCTGTT-3’; 5’ GRA15 nestedR: 5’-
GACTCTGAACGGGGACGGGTAGTC-3’; 3’ GRA15F: 5’-
CTGTCCACTCAATAGACCCCGTTGT-3’; 3’ GRA15 nestedF: 5’-
AAGATGCCGTGCAAAGCCAACTTC-3’), provided GeneRacer 5’ and 3’ primers, and 
Phusion enzyme (Finnzymes). PCR products were cloned into the pCR4Blunt-TOPO vector 
(Invitrogen) and sequenced. Sequences were analyzed with Sequencher software (Gene Codes). 
 
Characterization of GRA15 sequence 
 The coding sequence for GRA15 from types I (GT1), II (ME49), and III (VEG) was 
predicted from ToxoDB genomic sequence using ORF Finder (NCBI). GRA15 genomic DNA 
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from additional strains (RH, Pru, CEP) was amplified by PCR and sequenced (F: 5’- 
TCCGACTCAGTGCGGGAAA -3’; R: 5’- ATCCAGGTCCCCAAAGG -3’). To check for the 
presence of a predicted intron in the type I/III ORF, type I cDNA was amplified by PCR and 
sequenced (F: 5’- CACGTACACAACCCATCTCG -3’; R: 5’- 
CGAATTCTCATGGAGTTACCGCTGATT -3’). 5’ and 3’ UTRs were determined by RACE, 
as described above. Amino acid alignments were done with ClustalW2 (EMBL-EBI). Similarity 
to known sequences was queried using BLAST (NCBI, (Altschul et al., 1990)) and PfamA (Finn 
et al., 2008). 
 
Western blot 
 HFFs in a 6-well plate were infected with parasites (MOI = 5) for 24 hours. Infected cells 
were washed with ice-cold PBS, lysed by addition of lysis buffer, boiled for five minutes and 
subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane, which was blocked 
in PBS/0.1% Tween-20/5% nonfat dry milk and incubated with primary and secondary 
antibodies. The blot was incubated with a luminal-based substrate (Immun-Star WesternC, 
BioRad) and chemiluminescence was detected using a CCD camera (Bio-Rad Chemidoc XRS). 
The bands were visualized using Quantity One 1-D analysis software and analyzed using ImageJ.  
 
GRA15 expression in HeLa cells 
 A type II copy of GRA15 or a type II copy of 55.m04955 was inserted into pIC242 (a gift 
from Ian Cheeseman), a Moloney Murine Leukemia Virus (MMLV) retroviral vector containing 
an N-terminal GFP protein fusion, by restriction/ligation. Amino acids 51-551 of GRA15II were 
included, as amino acids 1-50 were predicted to be a signal sequence by the signal peptide 
cleavage prediction server, SignalP (Bendtsen et al., 2004; Nielsen and Krogh, 1998). These 
insertions replaced the original gene insert, Mob1A. Expression of GFP fusion proteins was 
promoted by the endogenous retroviral long terminal repeats. HeLa cells were then transiently 
transfected with expression vectors by lipofection using Fugene 6 Plus Transfection Reagent 
(Roche). Confluent cell cultures were split 1:10 into a 24-well plate (BD Falcon) containing 
glass coverslips. The cells were allowed to incubate at 37°C and 5% CO2 for four hours. 
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Following incubation, the medium was replaced with 1 ml of fresh supplemented DMEM, and 
liposomes were added dropwise to the cells. Liposomes were generated according to 
manufacturer protocol. Briefly, 3 µl of Fugene reagent was mixed into 20 µl of unsupplemented 
DMEM and allowed to stand at room temperature for five minutes. Next, 0.5 µg of appropriate 
plasmid DNA for each transfection was added, mixed and incorporated into liposomes for 20 
minutes prior to addition to cells. Cells were left in contact with liposome for 24 hours until the 
cells were fixed and stained for NF-κB p65. This experiment was performed two times. 
 
In vitro cytokine ELISA 
 BALB/c BMDMs were seeded (105 per well) in 96-well plates and left to adhere 
overnight at 37°C 5% CO2. Cells were infected with freshly lysed Toxoplasma tachyzoites at 
multiplicity of infection 20, 10 and 5, supernatants (200 µL) were collected 24-48 h after 
infection, and stored at -20°C if necessary. IL-12p40 levels were determined, for the cells 
infected with equal numbers of viable parasites as determined by plaque assay, using a 
commercial available ELISA kit (BD Biosciences OptEIA™ Mouse IL-12 (p40) ELISA Set) 
following the manufacturer’s instructions. 
 
Infection of mice 
 Female BALB/c or C57BL/6 mice that were 6 to 10 weeks old (Jackson Laboratories, 
Bar Harbor, Maine) were used in all experiments. For intraperitoneal (i.p.) infection, tachyzoites 
were grown in vitro and extracted from host cells by passage through a 27-gauge needle, washed 
three times in PBS and quantified with a hemocytometer. Parasites were diluted in PBS, and 
mice were inoculated i.p. with tachyzoites of each strain (in 300 µl) by using a 28-gauge needle. 
To image mice infected with a parasite strain which expressed the enzyme luciferase, mice were 
injected i.p. with 3 mg firefly D-luciferin dissolved in PBS, anesthetized with isoflurane, and 
imaged with an IVIS Spectrum-bioluminescent and fluorescent imaging system (Xenogen 
Corporation). Images were processed and analyzed with Living Image software. The MIT 
Committee on Animal Care approved all protocols. All mice were maintained in specific 
pathogen-free conditions, in accordance with institutional and federal regulations. 
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Intraperitoneal wash and in vivo cytokine ELISA 
 One or two days after i.p. infection, mice were sacrificed and the i.p. cavity was washed 
with 5 ml PBS. The i.p. wash was spun at 450 xg for 5 minutes to pellet cells. Supernatant was 
collected and stored at -80°C if necessary. IFN-γ, IL-12p40, and IL-12p70 levels were 
determined using commercially available ELISA kits (eBioscience, ELISA Ready-SET-Go!) 
following the manufacturer’s instructions. 
 
Plaque Assay 
 For all assays comparing the effect of Toxoplasma on the host cell, cells were infected 
with different MOIs and a plaque assay was done to determine the viability of each strain. The 
infections with the closest MOIs were then used. For the plaque assay, one hundred parasites per 
well were added to confluent HFFs in a 24 well plate and were incubated for 5-7 days at 37°C. 
The number of plaques was counted using a microscope. Plaque assays were also performed to 
assess the viability of parasites used to infect mice. To assay in vitro parasite growth, plaque size 
was measured using NIS-Elements software (Nikon) and a digital camera (Coolsnap EZ; Roper 
Scientific) connected to an inverted fluorescence microscope (model eclipse Ti-S; Nikon).  
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Figure S1. A type II locus on chromosome X strain-specifically induces expression of +F-κB regulated genes. 
A, B. HFFs were infected with type I, II, or III Toxoplasma and host gene expression was determined by microarray 
analysis (three arrays per strain). A. 105 genes are more than 2-fold upregulated in type II strains compared to type 
I/III strains. Average log2 gene expression values were median-centered, genes and strains were clustered by 
hierarchical clustering, and a heat map is presented made. The complete set of genes is listed in Supp. data.  B. For 
this list of genes, the top three DiRE enriched TFBS and Molecular signatures database enriched TFBS are shown 
and the top two Ingenuity networks are shown. C. HFFs were infected with F1 progeny from a II x III cross and host 
gene expression was determined by microarray analysis (one array per strain). Top: For each chromosome X 
marker, F1 progeny were split into two groups based on their genotype. TFBS enriched in genes differentially 
expressed by infection with progeny with a type II genotype were determined. NF-κB gene sets, among others, were 
found to be significant. Bottom: Ingenuity pathway analysis was done using genes that had a sign LOD score for any 
chromosome X marker. The top two networks are shown. 
 
 
 
Figure S2. Mapping the strain-specific activation of +F-κB. The NF-κB activation phenotype of 27 F1 progeny 
derived from crosses between type II (NF-κB activating) and type III (NF-κB non-activating) strains was determined 
by IF. These progeny have also been genotyped at markers throughout the genome as either type II (red) or type III 
(yellow) (Toxomap.wustl.edu). New RFLP markers were developed and used to further genotype progeny STE7 and 
S26. A black box outlines the minimal region in which the locus responsible for strain-specific NF- κB activation 
must reside. 
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Figure S3. Type III strains complemented with GRA6 or ROP2 do not activate +F-κB. HFFs were infected 
with transgenic type III strains stably expressing an HA-tagged type II copy of either ROP2 or GRA6. Cells were 
fixed 18-24 hours later and stained with α-NF-κB p65 (red), α-HA (green), and Hoechst dye (blue). Scale bar 
represents 10 µm. This experiment was done once. 
 
 
Figure S4. Time course of +F-κB activation by GRA15II. HFF cells were infected with a type I GRA15II 
Toxoplasma strain, stimulated with TNF-α, or left unstimulated and uninfected (US, UI). For infections, cells were 
infected on ice with fully lysed parasites. Cells and parasites were kept on ice for 30 minutes, then allowed to infect 
host cells at 37°C. Coverslips were fixed every hour for four hours. A., B., C., and D. correspond to 1, 2, 3, and 4 
hour time points, respectively. The time course was repeated two times and quantification was performed on a 
representative experiment. Asterix (*) indicates mean nuclear p65 in infected cells was significantly different from 
in US, UI cells (p < 0.05, t-test). 
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Figure S5. Generation and confirmation of GRA15KO. A. Schematic of the GRA15 locus, not drawn to scale. 
Double homologous recombination between the knockout construct (pTKO2 GRA15KO) and genomic DNA 
replaces GRA15 with the HXGPRT (HPT) gene, which was used for positive selection. Primers used in PCRs to 
confirm a knockout are shown (P1-P5). B. After transfection of Toxoplasma strains with the GRA15KO vector, 
parasites were cloned by limiting dilution, and genomic DNA was isolated. This genomic DNA was then used as 
template in a PCR reaction to amplify a band that is only present in a successful knockout (top, P1 and P2 from Fig. 
3, amplifies a 4.1 kb fragment). The intact GRA15 locus was also amplified as a negative control (bottom, P4 and 
P5, amplifies a 3.9 kb fragment in type I/III strains and a 3.6 kb fragment in type II strains). 
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Figure S6. GRA15 activation of +F-κB family subunits. HFF cells were infected for 24 hours with type I or type 
I GRA15 II parasites, stimulated with TNF-α for one hour, or left unstimulated and uninfected (US, UI).  Cells were 
fixed and probed with antibodies to different NF-κB subunits: A. p50, B. p52, C. RelB, D. c-Rel, and mean nuclear 
staining was quantified. These experiments were repeated three times and quantification was performed on a 
representative experiment for each factor assayed. Asterix (*) indicates mean nuclear levels of the subunit are 
significantly different from levels in US, UI cells (p < 0.05). 
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Figure S7. GRA15 amino acid alignment. The coding sequence of GRA15 from types I (GT1), II (ME49), and III 
(VEG) was predicted by ToxoDB genomic sequence using ORF Finder (NCBI). GRA15 was also sequenced in RH 
(I), Pru (II), and CEP (III).  RH had a frameshift mutation at amino acid 290, resulting in the mutation of 20 amino 
acids and a premature stop codon at amino acid position 312. The type II sequence contains an 84 amino acid 
deletion of amino acids 519-602, as well as a single amino acid deletion and 5 single amino acid polymorphisms. 
Conserved (.) and missing (-) residues are indicated. The alignment was done by ClustalW2 (EMBL-EBI). 
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Figure S8. GRA15 affects in vitro parasite growth and inhibits in vivo parasite growth in a type I background. 
A. One hundred parasites of a type I, type I GRA15II, type II, or type II GRA15KO strain were added to confluent 
fibroblast monolayers (either HFFs or MEFs) in a 24-well plate and incubated at 37°C (four days for type I 
infections, six days for type II infections in MEF host cells, and seven days for type II infections in HFF host cells). 
The size of at least 15 plaques per strain per host cell was measured. This experiment was done three times in HFF 
host cells and twice in MEF host cells with similar results. P-values are from a two-sample t-test. B. One BALB/c 
mouse and one C57BL/6 mouse were co-infected with 500 type I GFP+ parasites and 500 type I GRA15II GFP
- 
parasites by i.p. injection. A plaque assay was done to confirm the ratio of GFP+ : GFP- parasites at injection. Five 
days later, mice were sacrificed, an i.p. wash was done, and the spleen and a lung were isolated. The spleen and lung 
were ground through a cell strainer (70 µm and 100 µm, respectively), and then spun along with the i.p. wash to 
pellet parasites. Pellets were resuspended in fresh media, added to HFF monolayers in T175 flasks, and incubated at 
37°C. 4-7 days later, T175s were scraped, parasites were pelleted, counted, and 2,000 parasites were added to HFF 
monolayers in T25 flasks. After 3-4 days at 37°C, GFP+ and GFP- plaques were counted. Competitive index values 
were calculated and the averages from two mice are presented. Asterix indicates the CI is significantly different 
from 1 (p < 0.05, one sample t-test). This experiment was done once. 
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Figure S9. ROP16 can affect the expression of GRA15-regulated genes. A. SOCS2 and SOCS3 map to loci on 
chromosome VIIb and X. Previously, microarrays and QTL analysis were done on F1 progeny from a type II x type 
III cross to map the differential expression of host genes (Saeij et al., 2007). LOD scores for the SOCS2 and SOCS3 
human genes are plotted for markers across the Toxoplasma genome. B.  ROP16 inhibits GRA15-activated NF-κB 
in a reporter cell line. A HEK293 NF-κB GFP reporter cell line was infected with type II or type II ROP16I 
parasites. For each strain, the GFP level of at least 50 cells infected with only one vacuole containing at least two 
parasites was determined. The percent of GFP positive and GFP negative host cells for each strain is shown. The 
relative percentages of GFP positive and GFP negative cells after infection with these two strains is significantly 
different (p = 1.5 x 10-7, χ2 test). This experiment has been done twice, and in two additional experiments similar 
results were obtained after infection of a HEK293 NF-κB luciferase reporter cell line. 
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Figure S10. pTKO, pTKO-att, and pTKO2 vectors. pTKO contains the HXGPRT selectable marker, flanked by 
the DHFR promoter and UTRs. Gateway cassette A, containing the ccdB and Cm(R) genes flanked by attR1 and 
attR2 recombination sites, was ligated into pTKO at the EcoRV site, creating a Gateway destination vector, pTKO-
att. The HXGPRT cassette was also removed from the pTKO-att vector by Cre recombination at loxP sites to form 
pTKO2. 
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Abstract 
 Host defense against the parasite Toxoplasma gondii requires the cytokine interferon-
gamma (IFN-γ). However, Toxoplasma inhibits the host cell transcriptional response to IFN-γ, 
which is thought to allow the parasite to establish a chronic infection. It is not known whether all 
strains of Toxoplasma block IFN-γ responsive transcription equally and whether this inhibition 
occurs solely through the modulation of STAT1 activity or whether other transcription factors 
are involved. We find that strains from three North American/European clonal lineages of 
Toxoplasma, types I, II, and III, can differentially modulate specific aspects of IFN-γ signaling 
through the polymorphic effector proteins ROP16 and GRA15. STAT1 tyrosine phosphorylation 
is activated in the absence of IFN-γ by the Toxoplasma kinase ROP16, but this ROP16-activated 
STAT1 is not transcriptionally active. Many genes induced by STAT1 can also be controlled by 
other transcription factors and therefore using these genes as specific readouts to determine 
Toxoplasma inhibition of STAT1 activity might be inappropriate. Indeed, GRA15 and ROP16 
modulate the expression of subsets of IFN-γ responsive genes through activation of the NF-
κB/IRF1 and STAT3/6 transcription factors, respectively. However, using a stable STAT1-
specific reporter cell line we show that strains from the type I, II, and III clonal lineages equally 
inhibit STAT1 transcriptional activity. Furthermore, all three of the clonal lineages significantly 
inhibit global IFN-γ-induced gene expression. 
 
Introduction 
 The cytokine interferon-gamma (IFN-γ) and the transcription factor it activates, signal 
transducer and activator of transcription (STAT) 1, are critical to host defense against the 
obligate intracellular parasitic pathogen Toxoplasma gondii; mice deficient in elements of this 
pathway are acutely susceptible to Toxoplasma infection (Lieberman et al., 2004; Scharton-
Kersten et al., 1996; Yap and Sher, 1999). Activated STAT1 induces the expression of genes 
with gamma activated sequence (GAS) elements in their promoters, including the interferon 
regulatory factor (IRF) 1 transcription factor. STAT1 and IRF1 together induce a broad 
transcriptional program including effector mechanisms that mediate pathogen destruction or 
inhibition of pathogen growth (Saha et al., 2010).  
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 However, Toxoplasma infection can inhibit IFN-γ-induced gene expression in host cells, 
and was first shown to inhibit the basal and IFN-γ-induced expression of MHC class II 
molecules, in a variety of cell types (Lüder et al., 1998, 2003; Yang et al., 1996). Since then, 
Toxoplasma has also been shown to inhibit the expression of IRF1 (Lang et al., 2006; Lüder et 
al., 2001), class II transactivator (CIITA) (Lang et al., 2006; Lüder et al., 2001, 2003), inducible 
nitric oxide synthase (iNOS/NOS2) (Rozenfeld et al., 2005; Seabra et al., 2002), interferon 
inducible GTPase 1 (IIGP1) (Zimmermann et al., 2006), and chemokine (C-X-C motif) ligand 9 
(MIG/CXCL9) (Zimmermann et al., 2006). This inhibition occurs in a variety of cell types, 
including human foreskin fibroblasts (HFFs), human glioblastoma cells, murine bone marrow-
derived macrophages (BMDMs), RAW264.7 murine macrophages, murine dendritic cells, and 
murine microglial cells. Microarray analyses showed that Toxoplasma infection can dysregulate 
the entire IFN-γ-induced gene expression program in both HFFs (Kim et al., 2007a) and 
BMDMs (Lang et al., 2012). 
 Toxoplasma infects virtually all warm-blooded animals, including ~30% of the 
worldwide human population (Montoya and Liesenfeld, 2004). Many different strains of 
Toxoplasma have been isolated from various hosts, and in North America and Europe the 
majority of Toxoplasma isolates from humans and livestock belong to three main clonal lineages: 
types I, II, and III (Howe and Sibley, 1995). These strains differ in the modulation of multiple 
host cell signaling pathways through polymorphic effectors secreted into the host cell from 
rhoptry and dense granule organelles (Melo et al., 2011). While all of these strains can inhibit the 
expression of at least certain IFN-γ-induced genes, it is unknown whether all of the strains can 
inhibit global IFN-γ-induced gene expression and STAT1 transcriptional activity, or whether the 
degree of inhibition varies between Toxoplasma strains.  
  Many STAT1 regulated genes can be induced or repressed by other transcription factors, 
for example NF-κB and STAT3/6, and such genes might not be the best readouts to determine if 
Toxoplasma specifically inhibits STAT1 activity. Another question that is still unanswered is 
whether the activation of other transcription factors by Toxoplasma affects the IFN-γ response. 
Specifically, the modulation of STAT3/6 and NF-κB transcription factors through the effector 
proteins ROP16 (Saeij et al., 2007) and GRA15 (Rosowski et al., 2011), respectively, might 
affect this response. 
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 The polymorphic rhoptry kinase ROP16 from type I and III strains activates the 
transcription factors STAT3 and STAT6 (Ong et al., 2010; Saeij et al., 2007; Yamamoto et al., 
2009). In STAT3 deficient cells (Costa-Pereira et al., 2002) or cells with STAT6 knocked down 
(Baus et al., 2009), increased transcription of STAT1 target genes has been found, suggesting 
that STAT3 and STAT6 can antagonize STAT1 activity. STAT6 can also compete for promoter 
sites with STAT1 (Ohmori and Hamilton, 1997). It is therefore possible that the activation of 
STAT3/6 by ROP16 helps to suppress IFN-γ-induced signaling.  
 SOCS family proteins are important negative regulators of the IFN-γ response and in 
Socs1
-/- BMDM, Toxoplasma could not inhibit the IFN-γ response as well as in wild-type 
BMDM (Zimmermann et al., 2006). ROP16 is a strong activator of SOCS family gene 
expression; in murine BMDM, Socs1, 2, and 3 are more than 10-fold induced by ROP16 
expression (Jensen et al., 2011). It is therefore possible that ROP16 plays a role in the inhibition 
of the IFN-γ response through the induction of Socs genes. Furthermore, the expression of genes 
that are co-regulated by both STAT1 and STAT3/6 transcription factors could also be affected by 
ROP16. If the expression level of such a gene was chosen to measure STAT1 activity, incorrect 
conclusions might be drawn. 
 The type II version of the dense granule protein GRA15 activates the host cell NF-κB 
pathway (Rosowski et al., 2011). NF-κB also co-regulates many of the same genes as STAT1, 
and NF-κB activation combined with STAT1 activation synergistically induces IRF1 expression 
and activity (Robinson et al., 2006). It is therefore possible that strains possessing an active copy 
of GRA15 do not inhibit IFN-γ-induced gene expression as well as other strains, or differentially 
inhibit subsets of IFN-γ responsive genes. In fact, a type II ∆gra15 strain grows faster in vivo 
than a type II strain (Rosowski et al., 2011), and GRA15 corresponds to a Toxoplasma virulence 
locus (Rosowski et al., 2011; Saeij et al., 2006). 
 In this report we show that the polymorphic effectors GRA15 and ROP16 do contribute 
to strain differences in the modulation of IFN-γ/STAT1 signaling. Type II GRA15 induces the 
expression of IRF1, which can induce a subset of IFN-γ responsive genes. ROP16 induces the 
tyrosine phosphorylation and nuclear translocation of STAT1 but this STAT1 is not 
transcriptionally active. In spite of these differences, type I, II, and III parasites can all inhibit 
global IFN-γ-induced transcription as determined by microarray analysis. Because many 
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STAT1-regulated genes can be controlled by other transcription factors we directly measured 
STAT1 activity with a stable STAT1 specific reporter cell line and find that neither GRA15 nor 
ROP16 affects the ability of Toxoplasma to inhibit STAT1 transcriptional activity.  
 
Results 
A type II strain activates IRF1 via GRA15 and F-κB 
 Infection of HFFs with a type II Pru strain of Toxoplasma was previously shown to 
induce the expression of 46 genes that were also defined as IFN-γ regulated (Kim et al., 2007a), 
raising the possibility that type II strains are not as good at inhibiting IFN-γ-induced gene 
expression as other clonal lineages. To compare the ability of type I, II, and III strains to inhibit 
the IFN-γ response we pre-infected HFFs with RH(I), Pru(II), or CEP(III) strains, or left cells 
uninfected, and subsequently stimulated the cells with IFN-γ or left them unstimulated. We then 
visualized and quantified the amount of IRF1 in the nucleus by immunofluorescence. IRF1 is a 
primary response gene induced directly by STAT1 upon IFN-γ stimulation. After three hours of 
infection, with IFN-γ stimulation for the last two hours, cells pre-infected with either RH(I), 
Pru(II), or CEP(III) all had significantly lower levels of IRF1 in their nuclei than uninfected cells 
(Fig. 1A, B), as was previously seen for type I, II, and III strains (Kim et al., 2007a; Lang et al., 
2006; Lüder et al., 2001). However, after 24 hours of infection, with IFN-γ stimulation for the 
last six hours, while RH(I), Pru(II), and CEP(III) infection all significantly inhibited IRF1 
expression compared to uninfected cells, cells pre-infected with a Pru(II) strain had significantly 
higher IRF1 in their nuclei than cells pre-infected with a RH(I) strain (Fig 1A, B). Cells pre-
infected with a Pru(II) strain also had higher levels of IRF1 than cells pre-infected with a 
CEP(III) strain but this difference was not statistically significant. These data suggest that a 
Pru(II) strain does not inhibit IRF1 expression as well as RH(I) or CEP(III) strains. 
 We next determined IRF1 levels after infection in the absence of IFN-γ. In unstimulated 
cells infected with Pru(II) for 24 hours, we find ~2.5 fold higher nuclear IRF1 levels than in 
uninfected cells or cells infected with either RH(I) or CEP(III) (Fig 1A, B). These data suggest 
that the different IRF1 protein levels observed in Pru(II) and RH(I) infected cells after IFN-γ 
treatment may not be due to differences in the ability of these strains to inhibit IFN-γ-induced 
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gene expression but instead due to the induction of IRF1 by Pru(II) infection, independently of 
IFN-γ. 
 Although IRF1 is primarily induced by interferons it also has three NF-κB binding sites 
in its promoter (Saha et al., 2010) and these are important for the synergistic induction of genes 
by IFN-γ and TNF-α (Robinson et al., 2006). Type II parasites activate NF-κB-mediated 
transcription via the dense granule protein GRA15 (Rosowski et al., 2011) and we hypothesized 
that GRA15-mediated NF-κB activation could drive the expression of IRF1. To test this 
hypothesis, we also infected HFFs with a Pru ∆gra15 strain (Fig. 1A, B). After 24 hours of 
infection, this strain induced significantly less IRF1 protein than a Pru strain (p < 0.001) and Pru 
∆gra15 infected cells have similar IRF1 levels as cells infected with RH(I) and CEP(III) strains 
which possess inactive copies of GRA15 (Rosowski et al., 2011). An RH(I) strain ectopically 
expressing a type II copy of GRA15 also induced IRF1 expression in HFF host cells (Fig. 1C).  
 To determine whether this GRA15-mediated activation of IRF1 is dependent on STAT1, 
we infected U3A STAT1-deficient cells (McKendry et al., 1991; Müller et al., 1993) with either 
Pru(II) or Pru ∆gra15 parasites, or stimulated the cells with IFN-γ. While IFN-γ treatment, which 
relies on STAT1 signaling, does not activate IRF1 expression in these cells, infection with 
Pru(II) parasites does, and this activation is again dependent on the presence of GRA15 (Fig. 
1D), demonstrating that the GRA15-mediated induction of IRF1 is through a different 
transcription factor. GRA15 is known to activate the NF-κB p65 transcription factor (Rosowski 
et al., 2011), and since it is also known that NF-κB can activate the expression of IRF1 
(Robinson et al., 2006; Saha et al., 2010), we hypothesized that GRA15 was inducing IRF1 
through the activation of NF-κB p65. Indeed, in a previous microarray analysis (Rosowski et al., 
2011), while Irf1 transcript was induced by infection of wild-type MEFs with GRA15-expressing 
Pru(II) parasites, infection with this strain did not induce Irf1 transcript in p65-/- MEFs, strongly 
suggesting that induction of IRF1 expression by GRA15 is through the NF-κB p65 transcription 
factor. 
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Figure 1. Type II GRA15 affects the expression of IRF1. HFFs were infected with RH(I), RH GRA15II, Pru(II), 
Pru ∆gra15, or CEP(III) parasites and/or stimulated with 100 U/ml IFN-γ, subsequently fixed and permeabilized and 
stained with an antibody against IRF1 (red) and with Hoechst dye (blue, nucleus). A, B. HFFs were infected for 
three or 24 hours with GFP-expressing parasites (green), or left uninfected, and stimulated with IFN-γ for the last 
two or six hours, or left unstimulated. Nuclear localization of IRF1 was quantified in at least 12 randomly selected 
cells per condition and normalized to uninfected, unstimulated cells (A) and a representative cell for each condition 
is shown (B). Scale bar represents 10 µm. This experiment was performed three times with similar results. Data and 
standard deviation from one representative experiment are shown. Asterisk (*) indicates p < 0.05 compared to 
uninfected cells, dollar sign ($) indicates p < 0.05 compared to type II infected cells. C. HFFs were infected with an 
RH(I) or RH GRA15II strain, left uninfected, or left uninfected and stimulated with IFN-γ for 24 hours. Nuclear 
localization of IRF1 was quantified in at least 30 randomly selected cells and normalized to uninfected, unstimulated 
cells. Data and standard deviation from one experiment are shown. Asterisk (*) indicates p < 0.05 compared to 
uninfected cells or as represented by brackets. D. U3A STAT1-deficient cells were infected with Pru(II) or Pru 
∆gra15 parasites for 20 hours, left uninfected, or stimulated with IFN-γ for one hour. Nuclear localization of IRF1 
was quantified in at least 8 randomly selected cells per condition, and normalized to uninfected, unstimulated cells. 
This experiment was performed twice with similar results, data from one representative experiment are shown. 
Asterisk (*) indicates p < 0.05 compared to uninfected cells, dollar sign ($) indicates p < 0.05 compared to type II 
infected cells.  
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 IRF1 is itself a transcription factor and to test whether GRA15 might be responsible for 
more than just the expression of IRF1, but also the expression of other IFN-γ regulated genes 
that were found to be induced by Pru infection (Kim et al., 2007a), we re-analyzed the 
microarray data from which this observation was made. We found 775 oligonucleotide probes 
that were at least two-fold induced in HFFs by IFN-γ treatment and by Pru infection. These 775 
probes correspond to 374 genes also present in a microarray analysis of HFFs infected with 
GRA15-deficient and GRA15-overexpressing Toxoplasma strains (Rosowski et al., 2011). Of 
these 374 genes, 43 were previously found to be at least two-fold GRA15-regulated in at least 
one parasite genetic background (Rosowski et al., 2011), a significant enrichment (p = 0.03, 
hypergeometric test), indicating that GRA15 does induce the expression of a subset of IFN-γ 
responsive genes (Supp. data). Therefore, while type I, II, and III Toxoplasma strains can all 
inhibit the IFN-γ-induced expression of IRF1, type II strains also induce IRF1 expression, 
independently of STAT1, most likely through GRA15-mediated activation of NF-κB p65. This 
IRF1 induction also leads to the expression of a small subset of other IFN-γ responsive genes. 
 
Toxoplasma infection affects STAT1 phosphorylation 
 After IFN-γ treatment, STAT1 is tyrosine phosphorylated in the cytoplasm which allows 
it to traffic to the nucleus. Most recently, it was shown that infection of cells with type II Pru 
(Kim et al., 2007a) or NTE parasites (Lang et al., 2006, 2012) does not inhibit IFN-γ-induced 
STAT1 trafficking into the nucleus. Previously however, the nuclear translocation of STAT1 was 
reported to be inhibited by type II (NTE) Toxoplasma infection (Lüder et al., 2001); the tyrosine 
phosphorylation of STAT1 was reported to be inhibited by type I (BK) infection (Zimmermann 
et al., 2006), and type I (RH), type II (Pru), and type III (CL14) Toxoplasma strains were 
suggested to cause dephosphorylation of STAT1 in the nucleus (Kim et al., 2007a).  
 To determine if there are strain differences in the effect of infection on IFN-γ-induced 
STAT1 phosphorylation and localization, we infected HFFs for one hour with either RH(I), 
Pru(II), or CEP(III) parasites, subsequently stimulated the cells for two hours with IFN-γ, and 
quantified STAT1 tyrosine phosphorylation and nuclear translocation by immunofluorescence 
(Fig. 2A, B). Quantification of the immunofluorescence signal revealed that levels of IFN-γ-
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induced nuclear phospho-STAT1Tyr were actually higher in infected cells compared to uninfected 
cells (Fig. 2A). We therefore find that none of the tested Toxoplasma strains inhibit the tyrosine 
phosphorylation or nuclear accumulation of phospho-STAT1Tyr after IFN-γ treatment, which 
agrees with the majority of previous results. 
 Since we observed higher levels of phospho-STAT1Tyr in infected cells as compared to 
uninfected cells after IFN-γ stimulation, we wondered whether infection with type I, II, or III 
parasites induces nuclear phospho-STAT1Tyr in the absence of IFN-γ. We infected HFFs for 
three hours with either RH(I), Pru(II), or CEP(III) parasites, and quantified STAT1 tyrosine 
phosphorylation and nuclear translocation by immunofluorescence. Indeed, we observed nuclear 
phospho-STAT1Tyr in unstimulated cells infected with three or more RH(I) or CEP(III) parasites, 
and to a lower level in cells infected with three or more Pru(II) parasites (Fig. 2B). We quantified 
this signal in cells infected with three or more parasites and find that infection results in a 
significant increase in nuclear phospho-STAT1Tyr levels in RH(I) and CEP(III) infected cells 
(Fig. 2A). Pru(II) infection also significantly induces phospho-STAT1Tyr, although not as highly 
as RH(I) or CEP(III) parasites (Fig. 2A). 
 We next sought to determine what parasite factor induces phospho-STAT1Tyr after host 
cell infection. It is known that the secreted rhoptry kinase ROP16 from type I and III strains can 
directly tyrosine phosphorylate STAT3 and STAT6 (Ong et al., 2010; Yamamoto et al., 2009). 
The first 700 amino acid residues of STATs 1-6 share up to 40% identity (Schindler and Darnell, 
1995), raising the possibility that ROP16 also induces the tyrosine phosphorylation of STAT1. 
To determine if ROP16 is required for the tyrosine phosphorylation of STAT1 by RH(I) parasites 
in non-IFN-γ-stimulated conditions, we also infected HFFs with RH ∆rop16 parasites and again 
visualized phospho-STAT1Tyr nuclear accumulation by immunofluorescence. As compared to 
cells infected with RH(I) parasites, cells infected with RH ∆rop16 parasites had significantly less 
phospho-STAT1Tyr in their nuclei, with levels almost as low as in uninfected cells (Fig. 2A, B). 
We next infected HFFs with a Pru strain that overexpresses the type I copy of ROP16. The 
ectopic expression of ROP16I in a type II background led to an increase in phospho-STAT1
Tyr 
after infection (Fig. 2A, B). However, deletion of ROP16 from a type I parasite background or 
overexpression of ROP16I in a type II parasite background did not affect the level of phospho-
STAT1Tyr in infected cells after IFN-γ treatment, indicating that the increase in phospho-
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STAT1Tyr in infected cells after IFN-γ stimulation occurs independently of ROP16 (Fig. 2A, B). 
Together, these results demonstrate that in the absence of IFN-γ, ROP16 can induce the tyrosine 
phosphorylation of STAT1. 
 
 
Figure 2. ROP16 activates STAT1 tyrosine phosphorylation and nuclear translocation  
A, B. HFFs were infected with a GFP (green) expressing RH(I), RH ∆rop16, Pru(II), Pru ROP16I, or CEP(III) 
strain, or left uninfected, for three hours, and 100 U/ml IFN-γ was added for the last two hours of infection, or cells 
were left unstimulated. Cells were fixed, permeabilized, and stained with α-phospho-STAT1Tyr (red) and Hoechst 
dye (nucleus, blue). Nuclear localization of phospho-STAT1Tyr was quantified in at least 30 randomly selected cells 
infected with at least three parasites (A) and a representative cell for each condition is shown (B). Scale bar 
represents 10 µm. This experiment was performed for each condition at least two times with similar results. Data 
and standard deviation from one representative experiment are shown. Asterisk (*) indicates p < 0.05 compared to 
uninfected cells or as indicated by brackets.  
 
ROP16 activated STAT1 is not transcriptionally active 
 Our results indicate that ROP16 can directly activate STAT1 and it is therefore possible 
that strains with an active ROP16 (I and III) might be less efficient in inhibiting IFN-γ mediated 
STAT1 activation. On the other hand, ROP16 also activates STAT3 and STAT6, both of which 
can induce SOCS gene expression, which might inhibit IFN-γ/STAT1 signaling (Hebenstreit et 
al., 2003; Naka et al., 1997). Indeed, we previously showed that Socs1, a potent inhibitor of the 
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IFN-γ/STAT1 signaling pathway, is one of the host genes most highly induced by ROP16 
expression (Jensen et al., 2011). To determine if ROP16 might play a role in the modulation of 
the IFN-γ response, we infected HFFs with an RH(I) or RH∆rop16 strain for three hours, or left 
cells uninfected, and subsequently stimulated with IFN-γ for one hour, or left cells unstimulated, 
and analyzed IRF1 protein levels by Western blot. While only RH(I) infection induced the 
tyrosine phosphorylation of STAT1 in the absence of IFN-γ (Fig. 3A), RH(I) and RH ∆rop16 
parasites both completely inhibited IFN-γ-induced IRF1 expression (Fig. 3A), indicating that 
ROP16-induced phospho-STAT1Tyr is not transcriptionally active and that ROP16 is not required 
for the ability of Toxoplasma infection to block IFN-γ-induced STAT1-mediated gene 
expression. These results were confirmed in an immunofluorescence assay. After two hours of 
infection with either RH or RH ∆rop16 parasites, HFFs were subsequently stimulated with IFN-γ 
for two hours, cells were fixed and permeabilized, and IRF1 expression and STAT1 tyrosine 
phosphorylation were visualized. As seen previously (Fig. 2A, B), after IFN-γ treatment, cells 
infected with either RH or RH ∆rop16 had higher nuclear phospho-STAT1Tyr than uninfected 
cells (Fig. 3B). But, as in the Western blot results (Fig. 3A), both strains clearly inhibited IFN-γ-
induced IRF1 expression (Fig. 3B).  
 In addition to STAT1 tyrosine phosphorylation at residue 701, which is required for 
dimerization and nuclear translocation, STAT1 also must be serine phosphorylated at residue 
727 for full transcriptional activity (Platanias, 2005). We wondered whether ROP16 or type I, II, 
or III strains of Toxoplasma affect this serine phosphorylation. It was previously shown that 
infection with a Pru(II) strain of Toxoplasma does not interfere with IFN-γ-induced serine 
phosphorylation of STAT1 in HFFs (Kim et al., 2007a), but this has not been shown for any type 
I or III strains. We infected HFFs with an RH(I), RH ∆rop16, Pru(II), or CEP(III) strain, or left 
cells uninfected, for three hours, subsequently stimulated cells with IFN-γ for one hour, or left 
cells unstimulated, and analyzed lysates by Western blot. We first blotted for IRF1 as a control to 
confirm that infection with any of these strains inhibited the IFN-γ-induced accumulation of 
IRF1 (Fig. 3C), as we have shown by immunofluorescence (Fig. 1A, B, Fig. 3B). IRF1 was not 
inhibited as strongly in this infection as compared to the previous Western blot (Fig. 3A) due to a 
lower MOI. Additionally, Pru(II) infection alone led to the induction of IRF1 protein, in 
concordance with previous immunofluorescence experiments (Fig. 1A,B). We next analyzed 
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STAT1 phosphorylation in these lysates. Consistent with our immunofluorescence data (Fig. 
2A,B), infection with RH(I) or CEP(III) led to a high level of phospho-STAT1Tyr as compared to 
uninfected cells while a Pru(II) strain also induced phospho-STAT1Tyr but to a lesser extent (Fig. 
3C). Deletion of ROP16 from RH almost completely abolished this tyrosine phosphorylation 
(Fig. 3C). In addition, none of these strains inhibited the IFN-γ-induced accumulation of 
phospho-STAT1Tyr. Looking next at STAT1 serine phosphorylation, we found that infection with 
any of the Toxoplasma strains that we tested induced the serine phosphorylation of STAT1 
slightly, but none of these strains strongly inhibited IFN-γ induced serine phosphorylation of 
STAT1 (Fig. 3C). These results indicate that ROP16 does not play a role in serine 
phosphorylation of STAT1 and that type I, II, and III strains do not differentially modulate 
STAT1 serine phosphorylation. Thus, Toxoplasma infection alone can induce low levels of 
STAT1 serine phosphorylation independently of ROP16 and ROP16 mediates the tyrosine 
phosphorylation and subsequent nuclear translocation of STAT1, but this nuclear phospho-
STAT1Tyr701/Ser727 does not seem to be transcriptionally active. 
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Figure 3. ROP16-activated STAT1 is not transcriptionally active A. HFFs were infected with RH(I) or RH 
∆rop16 parasites at an MOI ~7, or left uninfected, for four hours. Cells were stimulated, or not, with 100 U/ml 
human IFN-γ for the last hour of infection and cell lysates were collected, run on an SDS-PAGE gel, and Western 
blotted for phospho-STAT1Ser727, phospho-STAT1Tyr701, total STAT1α, IRF1, GAPDH (host cell loading control) 
and SAG1 (parasite loading control). This experiment has been performed three times with similar results. B. HFFs 
were infected with RH(I) or RH ∆rop16 parasites for four hours, stimulated with 100 U/ml IFN-γ for the last two 
hours of infection, fixed, and stained with α-IRF1 (red), α-phospho-STAT1Tyr (green), and Hoechst dye (nucleus, 
blue). Parasites also express GFP (green). Scale bar represents 10 µm. This experiment was performed three times 
with similar results. C. HFFs were infected with RH(I), RH ∆rop16, Pru(II), or CEP(III) parasites at an MOI ~1, or 
left uninfected, for four hours. Cells were stimulated, or not, with 100 U/ml human IFN-γ for the last hour of 
infection and cell lysates were collected, run on an SDS-PAGE gel, and Western blotted for phospho-STAT1Ser727, 
phospho-STAT1Tyr701, total STAT1α, IRF1, GAPDH (host cell loading control) and SAG1 (parasite loading 
control). This experiment has been performed two times with similar results.  
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Type I, II, and III strains all inhibit STAT1 transcriptional activity 
 While our results demonstrate that type I, II, and III parasites can all inhibit the IFN-γ-
induced expression of IRF1, we have also shown that type I, II, and III parasites can 
differentially modulate specific aspects of the IFN-γ/STAT1 signaling pathway. The type II 
GRA15 protein induces IRF1 expression independently of STAT1 (Fig. 1D), and the rhoptry 
kinase ROP16 induces STAT1 tyrosine phosphorylation (Fig. 2, 3). Additionally, the expression 
of many IFN-γ-regulated genes can be induced by transcription factors other than STAT1; for 
example the activation of IRF1 by GRA15 via NF-κB (Fig. 1A, B) and the induction of Socs1 by 
ROP16 via STAT3 or 6 (Jensen et al., 2011). It is therefore difficult to interpret the modulation 
of the STAT1 transcriptional response by different Toxoplasma strains using the expression of 
particular genes as a read out. We instead decided to use a stable STAT1 reporter cell line to 
determine the ability of the Toxoplasma clonal lineages to interfere with STAT1’s activity in the 
nucleus. One previous report used two different luciferase reporters to demonstrate that infection 
with Toxoplasma inhibits STAT1 transcriptional activity (Lang et al., 2006). However, one of 
these reporters was a stable reporter but comprised the entire CIITA pIV promoter, containing 
binding sites for IRF1, AP-1, and NF-GMa transcription factors and an E-box site as well as a 
GAS site, making it difficult to determine whether STAT1 activity itself was being affected by 
Toxoplasma infection or if one of the other transcription factors was being affected. The second 
reporter measured STAT1 activity more clearly as it contained only a minimal GAS site, 
however the reporter vector was transiently transfected into cells. Given recent results that 
indicate that chromatin remodeling factors such as Brahma-related gene (BRG)-1 are 
differentially recruited to GAS sites after Toxoplasma infection to inhibit STAT1-mediated 
transcription (Lang et al., 2012), and that Toxoplasma infection can modulate chromatin 
modifications resulting in changes in gene expression (Leng et al., 2009), a transient plasmid 
reporter that is not integrated into the genome and does not have a normal chromatin structure 
also may not be an accurate measure of STAT1 transcriptional activity (Hebbar and Archer, 
2008; Smith and Hager, 1997). Additionally, potential strain differences in the inhibition of these 
reporters were not investigated.  
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Figure 4. Characterization of HEK293 GAS reporter cell line. A HEK293 GAS luciferase reporter 
cell line was left unstimulated or stimulated with 100 U/ml IFN-γ, 100 U/ml IFN-β, 20 ng/ml TNF-α, or 
50 ng/ml IL-4. Cells were lysed 6-20 hours later and luciferase activity was measured. Average luciferase 
induction normalized to unstimulated cells from three experiments is shown and error bars represent 
SEM. 
 
 We therefore developed a stable GAS reporter cell line in the easily transduced HEK293 
cell line to measure STAT1 transcriptional activity directly. Treatment of this GAS reporter cell 
line with IFN-γ, but not IFN-β, TNF-α, or IL-4, results in the robust induction of luciferase 
activity (Fig. 4). We infected this cell line with RH(I), RH ∆rop16, Pru(II), Pru ∆gra15, or 
CEP(III) parasites, stimulated the cells with IFN-γ, and measured the induction of luciferase 
activity. Infection with any of these strains significantly inhibited IFN-γ-induced luciferase 
activity, and the extent of this inhibition did not vary significantly between the strains (Fig. 5A). 
These reporter experiments also confirmed that while ROP16 can activate the tyrosine 
phosphorylation and nuclear translocation of STAT1 (Fig. 2), this STAT1 is not transcriptionally 
active; infection of this cell line with any of these strains did not result in the induction of 
luciferase (Fig. 5A). To verify that this ability to inhibit STAT1 transcriptional activity is 
common to the type I, II, and III clonal lineages and not just RH(I), Pru(II), and CEP(III) strains, 
we also infected this cell line with other representative strains from these lineages, GT1(I), 
ME49(II), or VEG(III), as well as RH(I) again (Fig. 5B). Again, all of these strains were able to 
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inhibit IFN-γ-induced luciferase activity. These results indicate that type I, II, and III strains can 
all inhibit IFN-γ-induced STAT1 transcriptional activity to a similar extent. 
 
 
Figure 5. All three clonal lineages of Toxoplasma inhibit STAT1-mediated gene expression. A, B. A HEK293 
GAS luciferase reporter cell line was infected with RH(I), RH ∆rop16, GT1(I), Pru(II), Pru ∆gra15, ME49(II), 
CEP(III), or VEG(III) parasites, or left uninfected, and subsequently stimulated, or not, with 100 U/ml IFN-γ. Cells 
were then lysed and luciferase activity was measured. Results are from 2-8 experiments per condition, with a pre-
infection time of one to five hours followed by a stimulation of 12-24 hours, and represent the average induction 
over uninfected, unstimulated samples. Error bars represent SEM. Asterisk (*) indicates p < 0.05 compared to 
uninfected cells in the same condition.  
 
Type I, II, and III strains all inhibit global IF-γ-induced transcription 
 Although all Toxoplasma strains that we have tested inhibit a stable GAS reporter cell 
line, we have seen that Toxoplasma strains can differentially affect particular aspects of the IFN-
γ signaling pathway through GRA15 and ROP16, and it is therefore unclear whether the ability 
to inhibit STAT1 activity corresponds to the ability of type I, II, and III strains to similarly 
inhibit global IFN-γ induced gene expression. We therefore analyzed the effect of infection with 
an RH(I), Pru(II), or CEP(III) strain on IFN-γ-induced transcription using microarray analysis. 
As more genes have been found to be induced by IFN-γ in macrophages than fibroblasts (Kim et 
al., 2007a; Lang et al., 2012), we pre-infected a murine macrophage cell line (RAW264.7) with 
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the above strains for 24 hours, adding IFN-γ for the last six hours. We isolated RNA from these 
cells as well as uninfected control cells, with and without IFN-γ stimulation, and analyzed gene 
expression with Affymetrix microarrays. In this macrophage cell line, 514 genes were more than 
2-fold upregulated by IFN-γ treatment, while the expression of 481 genes was more than 2-fold 
repressed (Fig. 6). In the pre-infected samples, 431 of the 514 induced genes were at least 2-fold 
inhibited by at least one strain, with 314 genes being inhibited by all strains (Fig. 6). 
Interestingly, the expression of genes that are important for control of Toxoplasma infection, 
os2 (Khan et al., 1997), Iigp1/Irga6 (Liesenfeld et al., 2011; Martens et al., 2005), Iigp2/Irgm2 
(Hunn et al., 2008), and Tgtp/Irgb6 (Hunn et al., 2008) were at least 2-fold inhibited by all three 
strains. Of the 481 IFN-γ-repressed genes, the repression of 312 of them was more than 2-fold 
inhibited by at least one strain while 147 genes were inhibited by all three strains (Fig. 6). It 
seems then that while Toxoplasma strains may differentially inhibit small subsets of IFN-γ 
responsive genes, all three of the clonal lineages significantly inhibit global IFN-γ-induced gene 
expression. 
 
Figure 6. All three clonal lineages of Toxoplasma inhibit global IF+-γ-induced gene expression. RAW264.7 
macrophages were infected with RH(I), Pru(II), or CEP(III) parasites, or left uninfected (UI) for 24 hours with 100 
U/ml IFN-γ added for the last 6 hours of infection, and host gene expression was analyzed by microarray analysis. 
Greater than 2-fold IFN-γ-induced (left) and repressed (right) genes were determined from the uninfected samples. 
Boxplots are shown of the log2 expression of these genes in all samples. Data are from two arrays for the uninfected 
conditions and one array for each infected sample. 
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Discussion 
 The expression level of many genes is regulated by multiple transcription factors 
allowing more precise control and responsiveness to varying stimuli. While we find that strains 
representing three Toxoplasma clonal lineages, types I, II, and III, can all inhibit IFN-γ-induced 
STAT1 transcriptional activity, these strains also differentially modulate certain IFN-γ 
responsive genes through the activity of at least two known polymorphic effectors, GRA15 and 
ROP16. In studying the ability of Toxoplasma to inhibit the IFN-γ response, the choice of 
readout for IFN-γ-induced gene expression is therefore very important, as some IFN-γ 
responsive genes are also activated by Toxoplasma through GRA15, ROP16, and likely other 
secreted proteins. 
 GRA15II-mediated activation of NF-κB can induce expression of IRF1, and the levels of 
IRF1 in Pru(II) infected cells stimulated with IFN-γ are virtually identical to those of Pru(II) 
infected cells that were not stimulated (Fig. 1A). This indicates that Pru(II) parasites can inhibit 
IFN-γ-induced expression of IRF1, even though they induce IRF1 through GRA15-mediated 
activation of NF-κB (Fig. 1A, D). Similarly, ROP16I/III induces Socs1 expression by 10-fold in 
murine BMDM (Jensen et al., 2011), likely through STAT3 or STAT6. But, our microarray data 
from the murine macrophage RAW264.7 cell line shows that pre-infection with RH(I) parasites 
can still inhibit IFN-γ-induced Socs1 transcript by two-fold. Thus, although Toxoplasma is able 
to inhibit the STAT1-mediated induction of genes such as IRF1 and Socs1, it does not inhibit the 
expression of these genes activated by other transcription factors. This indicates that whatever 
mechanism Toxoplasma employs to inhibit the IFN-γ-induced transcriptional response must 
specifically target STAT1-mediated transcriptional activation of genes.  
 While neither GRA15 nor ROP16 affects the ability of Toxoplasma strains to inhibit the 
STAT1-mediated global induction of IFN-γ responsive gene expression, it is unclear how large 
of an effect GRA15 and ROP16 have on subsets of IFN-γ responsive genes as our experiments 
were done in a different cell line than previous transcriptional analyses on GRA15 and ROP16. 
However, IRF1 is an important secondary transcription factor in the response to IFN-γ. 
Additionally, NF-κB is likely to co-regulate other IFN-γ responsive genes besides IRF1. A 
significant number of genes induced by both IFN-γ and Pru(II) infection are GRA15-regulated 
(Supp. data). While one microarray analysis in HFFs found that IFN-γ responsive genes that 
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were also induced by Pru(II) infection alone were associated with TNF-α signaling and included 
many NF-κB target genes (Kim et al., 2007a), another microarray analysis in murine BMDM did 
not find an enrichment in NF-κB target genes among genes induced by both IFN-γ and another 
type II strain, NTE (Lang et al., 2012). However, it is unknown whether the NTE(II) strain has 
an active copy of GRA15 and activates NF-κB. 
 The strongest effect of ROP16 on IFN-γ signaling seems be on the phosphorylation status 
of STAT1 (Fig. 2). Since ROP16 directly tyrosine phosphorylates STAT3 and STAT6 (Ong et 
al., 2010; Yamamoto et al., 2009), it is likely that tyrosine 701 on STAT1 is also a direct target. 
It seems that either the affinity or catalytic efficiency of ROP16 for STAT1 is lower than for at 
least STAT6 because clear phospho-STAT1Tyr activation was only observed in cells infected 
with at least three parasites, whereas only one parasite needs to inject its rhoptry contents into a 
host cell to activate STAT6 (Koshy et al., 2012).  
 It is still unclear why we observe a higher level of IFN-γ-induced phospho-STAT1Tyr 
after pre-infection with any strain of Toxoplasma (Fig. 2A). This phenotype is not dependent on 
ROP16 as it also occurs in RH∆rop16 infected cells. The transcripts of the main components of 
this pathway, IFN-γ receptor 1 and 2, JAK1 and 2, and STAT1, are not upregulated by type I 
Toxoplasma infection in HFFs, according to previous microarray data (Rosowski et al., 2011). 
Additionally, SOCS proteins that can downregulate JAK and STAT1 phosphorylation are 
actually induced by Toxoplasma infection (Zimmermann et al., 2006), and the expression of the 
protein tyrosine phosphatases (PTPs) that are known to dephosphorylate JAK1, JAK2, or STAT1 
(Shuai and Liu, 2003) are not downregulated by infection alone (Rosowski et al., 2011). 
 Our data suggest that the type I, II, and III strains use a similar mechanism to inhibit 
STAT1 transcriptional activity in the nucleus. This inhibition is independent of how STAT1 is 
activated; Toxoplasma can also inhibit the activity of ROP16-induced phospho-STAT1Tyr, and 
this interference is specific for STAT1, as ROP16-activated STAT3 and STAT6 are 
transcriptionally active (Jensen et al., 2011; Saeij et al., 2007). A recent study, which focused 
mainly on the IFN-γ induced expression of CIITA and MHC class II genes, concluded that 
Toxoplasma inhibits IFN-γ-induced gene expression through impaired BRG-1 chromatin 
remodeling (Lang et al., 2012). Although that may be the mechanism for CIITA, the IFN-γ-
induced expression of IRF1 does not require BRG-1 remodeling (Wang et al., 2011). It is 
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therefore important for future studies to determine the mechanism by which Toxoplasma inhibits 
the STAT1-mediated induction of primary response genes such as IRF1. 
 
Materials and Methods 
Parasites and cells 
Parasites were maintained in vitro by serial passage on monolayers of human foreskin fibroblasts 
(HFFs), as described previously (Rosowski et al., 2011). RH or GT1 were used as representative 
type I strains, Pru or ME49 as representative type II strains and CEP or VEG as representative 
type III strains. A Pru strain engineered to express firefly luciferase and GFP (Pru ∆hxgprt A7) 
(Kim et al., 2007b), and CEP and RH strains engineered to express clickbeetle luciferase and 
GFP (CEP hxgprt - C22 and RH 1-1) (Boyle et al., 2007) have been described previously. An RH 
∆rop16 strain (provided by John Boothroyd, Stanford University) (Ong et al., 2010), an RH 
∆rop16 strain expressing firefly luciferase and GFP (clone 1A2) (Jensen et al., 2011), a PruA7 
ROP16I strain (Jensen et al., 2011), and Pru ∆gra15, PruA7 ∆gra15, and RH GRA15II strains 
(Rosowski et al., 2011) have been described previously. HFFs (provided by John Boothroyd, 
Stanford University) and RAW264.7 (ATCC) cells were grown as described previously (Jensen 
et al., 2011; Rosowski et al., 2011). 293FT and HEK293 cells were grown with additional 10 
mM HEPES. U3A STAT1-null cells (McKendry et al., 1991; Müller et al., 1993) (provided by 
George Stark, Cleveland Clinic Foundation Research Institute, Ohio) were grown with 10 mM 
HEPES, 1 mM sodium pyruvate, and MEM non-essential amino acids. All parasite strains and 
cell lines were routinely checked for Mycoplasma contamination and it was never detected. 
 
Reagents 
Antibodies against IRF1 (BD Biosciences #612046), phospho-STAT1Tyr701 58D6 (Cell Signaling 
#9167), phospho-STAT1Ser727 (Cell Signaling #9177), total STAT1α p91 (C-24) (Santa Cruz 
#345), GAPDH (6C5) (Santa Cruz #32233), and Toxoplasma surface antigen (SAG)-1 (kindly 
provided by John Boothroyd, Stanford University) were used in immunofluorescence and 
Western blot assays. Secondary antibodies coupled with either Alexa Fluor 488 or Alexa Fluor 
594 (Molecular Probes) for immunofluorescence assay or conjugated to peroxidase (Kirkegaard 
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& Perry Laboratories) for Western blots were used. Recombinant human IFN-γ (100 U/ml, AbD 
serotec) and murine IFN-γ (100 U/ml, Calbiochem) were used to stimulate cells.  
 
Immunofluorescence assay 
Immunofluorescence assay was performed as described previously (Rosowski et al., 2011). 
Briefly, cells were fixed with 3% formaldehyde, permeabilized with 100% ethanol and/or 0.2% 
Triton-X 100, and blocked with 3% BSA and 5% goat serum. Coverslips were incubated with 
primary antibody at 4°C, and fluorescent secondary antibodies and Hoechst dye were used for 
antigen and DNA visualization, respectively. Photographs were taken using NIS-Elements 
software (Nikon) and a digital camera (Coolsnap EZ; Roper Scientific) connected to an inverted 
fluorescence microscope (model eclipse Ti-S; Nikon). Quantification of nuclear signal was 
performed by randomly selecting cells in each condition and measuring the average signal 
intensity per nucleus using the NIS-Elements software and Hoechst dye to define nuclei. The 
minimum number of cells measured is indicated in the figure legends for each experiment. 
 
Western blot 
Western blots were performed as described previously (Rosowski et al., 2011). Briefly, HFFs 
were left uninfected or infected with RH ∆hxgprt, RH 1-1, RH ∆rop16, RH ∆rop16 1A2, Pru 
∆hxgprt A7, or CEP hxgprt - C22 parasites for three hours. Samples were subsequently 
stimulated with human IFN-γ for one hour, or left unstimulated, and then lysed in buffer 
containing sodium dodecyl sulfate (SDS) and either β-mercaptoethanol (βME) or dithiothreitol 
(DTT). After immunoblotting, membranes were stripped with boiling 2% SDS and 0.7% βME 
and reprobed.  
 
Reporter cell line construction  
A GAS (TR027PA-1, 5’-AGTTTCATATTACTCTAAATC -3’) pGreenFire1 (pGF1) lentiviral 
reporter vector containing a Neo selection cassette and a minimal CMV promoter followed by 
four tandem consensus GAS sites driving the expression of Firefly luciferase was purchased 
from System Biosciences. The vector was co-transfected into 293FT cells with vectors 
containing gag, pol, and VSV-G proteins using FuGENE reagent (Roche) according to the 
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manufacturer’s protocol. Supernatant containing virus was collected two and three days after 
transfection, filtered with a 0.45 µm surfactant-free cellulose acetate filter (Nalgene), and added 
to HEK293 cells (ATCC) with 8 µg/ml polybrene (Sigma). HEK293 cells containing the pGF1 
construct were then selected with 750 µg/ml Geneticin (Invitrogen). Cells were cloned by 
limiting dilution and were confirmed to be responsive to IFN-γ but not to IFN-β, TNF-α, or IL-4. 
 
Luciferase assay 
HEK293 pGF1-GAS cells were plated in 96-well plates, 3.5-4x104 cells/well, and grown for four 
to 20 hours. Cells were then infected with RH ∆hxgprt, RH ∆rop16, GT1, Pru ∆hxgprt, Pru 
∆gra15, ME49, CEP ∆hxgprt, or VEG parasites at varying MOIs for one to four hours, and 
subsequently stimulated with human IFN-γ for 12-24 hours. Cells were lysed with 20 µl Cell 
Culture Lysis Reagent (Promega) containing 1x protease inhibitors (Roche), and plates were 
frozen at -80°C. Luciferase activity in plates was detected using a Varioskan Flash Reader 
(Roche) after addition of 100 µl Luciferase assay substrate (Promega), according to the 
manufacturer’s instructions. Data were normalized to the uninfected, unstimulated sample and 
averaged over at least two experiments per condition.  
 
Microarray 
1.5x106 RAW264.7 cells were plated in 6-well plates and grown for 24 hours. The cells were 
then left uninfected or infected with RH 1-1, Pru ∆hxgprt A7, or CEP hxgprt- C22 parasites at an 
MOI ~5 for 18 hours and subsequently stimulated with murine IFN-γ for six hours. The RH 
infection was done at one time and Pru and CEP infections were done together at a later time. 
Uninfected controls were included for both sets of infections. RNA was isolated and microarray 
analysis, including analysis with the DiRE server, was performed as described previously 
(Rosowski et al., 2011), with Mouse 430A 2.0 Affymetrix gene chips. Microarray data has been 
uploaded to NCBI Gene Expression Omnibus and are accessible through GEO Series accession 
number GSE34913. 
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Plaque assay 
For Western blot, luciferase reporter, and microarray assays, a plaque assay was done to 
determine the viability of each strain and the actual MOI. One hundred parasites per well were 
added to confluent HFFs in a 24-well plate and were incubated undisturbed for 5-7 days at 37°C, 
and the number of plaques was counted. Samples with similar MOIs were then picked for 
analysis. 
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Abstract  
 The IFN-γ response, mediated by the STAT1 transcription factor, is crucial for host 
defense against the intracellular pathogen Toxoplasma gondii, but prior infection with 
Toxoplasma can inhibit this response. Recently it was reported that the Toxoplasm NTE strain of 
Toxoplasma prevents the recruitment of chromatin remodeling complexes containing Brahma 
related gene (BRG)-1 to promoters of IFN-γ-induced secondary response genes such as CIITA 
and MHC class II genes in murine macrophages, thereby inhibiting their expression. Here we 
report that a type I strain of Toxoplasma does not require the activity of histone deacetylases to 
inhibit the expression of IFN-γ-induced primary response genes such as IRF1 nor does it inhibit 
the binding of STAT1 to promoters of either primary or secondary response genes in human 
fibroblasts. In fact, infection increases the IFN-γ-induced association of STAT1 with chromatin. 
We find that Toxoplasma infection also inhibits IFN-β-induced interferon-stimulated gene factor 
(ISGF) 3 mediated gene expression and that this is also associated with increased association of 
STAT1 with chromatin. The secretion of proteins into the host cell by Toxoplasma without 
complete parasite invasion is not sufficient to block STAT1 induction of IFN-γ-induced gene 
expression, suggesting that the effector protein responsible for this inhibition is not derived from 
the rhoptries. 
 
  
Introduction 
 Interferon-gamma (IFN-γ) is a critical cytokine in both the innate and adaptive immune 
response to infection (Boehm et al., 1997; Saha et al., 2010). The cellular response to IFN-γ 
includes many effector mechanisms that inhibit pathogen growth and survival, especially of 
intracellular pathogens. These include the p47 immunity-related GTPases (IRGs), p65 guanylate 
binding proteins (GBPs), iNOS/os2, indoleamine 2,3-dioxygenase 1 (IDO1), and major 
histocompatibility complex (MHC) genes (Hunn et al., 2011; Pfefferkorn et al., 1986; Saha et al., 
2010; Scharton-Kersten et al., 1997; Yamamoto et al., 2012).  Mice deficient in multiple 
components of the IFN-γ pathway are acutely susceptible to many pathogens, including the 
parasite Toxoplasma gondii (Khan et al., 1996; Lieberman et al., 2004; Scharton-Kersten et al., 
1996; Yap and Sher, 1999; Yap et al., 2000).  Toxoplasma gondii is an obligate intracellular 
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protozoan parasite which infects virtually all warm-blooded animals, including mice and humans 
(Sibley et al., 2009). 
 It is well-documented that Toxoplasma actively inhibits the cellular response to IFN-γ in 
infected cells (Kim et al., 2007a; Lang et al., 2006, 2012; Rosowski and Saeij, 2012), and it is 
thought that this inhibition is required for survival of the parasite and conversion to the chronic 
cyst stage. IFN-γ stimulation activates the signal transducer and activator of transcription 
(STAT) 1 transcription factor and induces a broad transcriptional program (Platanias, 2005), 
however, pre-infection with Toxoplasma parasites globally inhibits the induction of this program 
in multiple cell types of multiple species, including human foreskin fibroblasts (HFF) (Kim et 
al., 2007a), murine bone-marrow derived macrophages (BMDM) (Lang et al., 2012), and 
RAW264.7 murine macrophages (Rosowski and Saeij, 2012). The mechanism by which this 
inhibition occurs remains a matter of contention. A recent study showed that in murine 
macrophages at IFN-γ-induced secondary response genes, such as class II transactivator (CIITA) 
and MHC class II genes, brahma related gene (BRG)-1-mediated chromatin remodeling is 
impaired by Toxoplasma infection leading to inhibition of gene expression (Lang et al., 2012). 
Treatment of these cells with histone deacetylase inhibitors decreased the inhibition of secondary 
response genes by the type II NTE strain of Toxoplasma (Lang et al., 2012). However, the IFN-
γ-induced expression of primary response genes such as IRF1 does not require BRG-1-mediated 
remodeling (Wang et al., 2011), suggesting that Toxoplasma utilizes a different mechanism to 
inhibit the expression of primary STAT1 induced genes.   
 In this study we have further characterized the mechanism of this direct inhibition of 
STAT1 transcriptional activity by measuring each step of IFN-γ-induced STAT1 activation to 
determine where in the pathway Toxoplasma acts. Since three clonal lineages of Toxoplasma, 
types I, II, and III, all equally inhibit STAT1 transcriptional activity (Rosowski and Saeij, 2012), 
it is likely that all of these strains utilize a similar mechanism of inhibition and we have focused 
our study on just one of these strains, the type I RH strain. Toxoplasma infection also equally 
inhibits STAT1 activity and IFN-γ-induced primary (IRF1) gene expression in a variety of cell 
types, including HFFs, HEK293 cells, murine macrophages, and murine dendritic cells 
(Rosowski and Saeij, 2012; Schneider et al., 2013), and we have therefore focused our study on 
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two readouts of primary STAT1-induced gene expression: HEK293 STAT1 luciferase reporter 
cell lines and the expression of IRF1 in human fibroblasts.  
 We find that Toxoplasma infection increases the association of IFN-γ-induced STAT1 
with chromatin and with the promoters of primary IFN-γ response genes such as IRF1 in 
particular. Toxoplasma infection can also inhibit IFN-β-induced gene expression, likely through 
a similar mechanism involving increased association of STAT1, STAT2, and IRF9 with 
chromatin. In contrast to findings by Lang et al. on the role of histone deacetlyases (HDAC) in 
the inhibition of IFN-γ secondary response genes by Toxoplasma, we find that Toxoplasma can 
still inhibit the expression of IFN-γ primary response genes in the presence of various HDAC 
inhibitors. The Toxoplasma factor responsible for this inhibition is also unknown, however our 
results indicate that it is unlikely to be secreted into the host cell from the rhoptry secretory 
organelle. While the exact mechanism by which Toxoplasma inhibits the expression of IFN-γ-
induced primary response genes is still not clear, it is likely that this mechanism acts directly on 
DNA-bound STAT1 and is distinct from the mechanism by which secondary response genes are 
inhibited in murine macrophages. 
 
Results 
Toxoplasma infection does not interfere with IF+-γ-induced STAT1 dimerization 
 The pathway by which IFN-γ activates STAT1 transcriptional activity is well described. 
When IFN-γ binds to its receptors, IFNGR1 and 2, the receptors oligomerize and cause 
constitutively associated Janus activated kinase (JAK) 1 and JAK2 to be activated (Bach et al., 
1997; Darnell et al., 1994).  Activated JAKs tyrosine-phosphorylate the IFN-γ receptor, creating 
a docking site for the transcription factor STAT1.  STAT1 is then phosphorylated by the JAKs at 
tyrosine 701, causing it to homo-dimerize and translocate to the nucleus. Once in the nucleus and 
stably associated with DNA, STAT1 is serine phosphorylated at residue 727 (Sadzak et al., 
2008), and this additional serine phosphorylation is required for maximal STAT1 activity 
(Varinou et al., 2003). Toxoplasma infection does not interfere with STAT1 tyrosine or serine 
phosphorylation or nuclear translocation (Kim et al., 2007a; Lang et al., 2006; Rosowski and 
Saeij, 2012), suggesting that homo-dimerization is also not inhibited. However it is possible that 
113 
 
a Toxoplasma protein containing a nuclear localization sequence directly binds to single tyrosine 
phosphorylated STAT1 proteins and carries STAT1 into the nucleus. 
 To determine the predominant complex(es) within which STAT1 is found in infected 
cells and therefore distinguish between these two possibilities, we visualized STAT1-containing 
complexes in non-denaturing conditions by native PAGE and Western blot. We infected HFFs 
with the RH Toxoplasma strain for three hours, subsequently stimulated the cells with IFN-γ for 
one hour, lysed the cells in non-denaturing conditions, ran the lysates on native PAGE, and 
blotted for STAT1.  In uninfected, unstimulated cells, STAT1α runs at a size between 66 and 146 
kD, but upon IFN-γ treatment the majority of STAT1α protein shifts into complex which runs at 
a size between 146 and 242 kD (Fig. 1).  These sizes are consistent with STAT1α monomers (91 
kD) and STAT1 homodimers, respectively. Additional blotting for the phospho-tyrosine form of 
STAT1 also demonstrated that the majority of phosphorylated STAT1 is found in the slower 
migrating band, consistent with this band representing the dimer as tyrosine phosphorylation is 
required for STAT1 dimerization (Fig. 1). In cells pre-infected with RH parasites, STAT1α again 
runs at two different bands of exactly the same size as in uninfected cells, indicating that 
Toxoplasma does not inhibit STAT1 homo-dimerization, and suggesting that a putative 
Toxoplasma effector does not strongly bind STAT1 under these conditions (Fig. 1). In type I 
Toxoplasma strains the rhoptry kinase ROP16 can also phosphorylate and induce the nuclear 
translocation of STAT1 (Rosowski and Saeij, 2012), and our results also show that this ROP16-
activated STAT1 can dimerize (Fig. 1). We therefore also performed this experiment with RH 
parasites deficient for ROP16 to specifically measure IFN-γ-induced STAT1 dimerization and 
find that RH ∆rop16 parasites also do not inhibit the dimerization of STAT1 (Fig. 1). 
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Figure 1. Toxoplasma infection does not inhibit IF+-γ-induced STAT1 dimerization. HFFs were infected with 
RH or RH ∆rop16 parasites, or left uninfected, for four hours. Cells were then stimulated with 100 U/ml human 
IFN-γ for the last hour of infection (+IFN-γ) or left unstimulated (US). Cell lysates were collected in non-denaturing 
buffer and analyzed by native PAGE followed by Western blotting.  Cells were infected at two different MOIs and 
the actual MOIs for each sample calculated after plaque assay are indicated. Blots were probed for phospho-
STAT1Tyr, stripped, and reprobed for total STAT1α. This experiment has been performed three times with similar 
results. 
 
 
Toxoplasma infection increases IF+-γ-induced STAT1 D+A association 
 We next wondered whether STAT1 in infected, IFN-γ-stimulated host cells is able to 
bind DNA, and specifically the gamma-activated sequence (GAS) sites in the genome it 
normally targets. Previous EMSA experiments suggested that this STAT1 species is still able to 
bind GAS sites in vitro, although in one study the binding was weaker in extracts from infected 
cells (Lüder et al., 2001) and in two other studies STAT1 seemed to bind with other proteins in 
an aberrant complex in infected cells compared to uninfected cells (Lang et al., 2012; Schneider 
et al., 2013). Conversely, Toxoplasma was recently reported to inhibit STAT1 binding to the Irf1 
promoter in murine BMDCs (Schneider et al., 2013). To determine whether STAT1 binds GAS 
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sites in the promoters of IFN-γ-responsive genes in HFFs, we performed STAT1 chromatin 
immunoprecipitation (ChIP) experiments. We infected HFFs with either RH or RH ∆rop16 
parasites for four hours, or left cells uninfected, and subsequently stimulated cells with IFN-γ for 
one hour, or left cells unstimulated. Coverslips were included in sample plates to measure 
STAT1 phosphorylation and the inhibition of IRF1 expression by pre-infection as controls (Fig. 
S1). In uninfected cells, we detected a significant increase in STAT1 binding after IFN-γ 
treatment at all loci, except for a negative control locus, CCD2 (Fig. 2A). Infection with RH 
parasites, in the absence of IFN-γ treatment, also resulted in a significant increase in STAT1 
binding at all except one of these loci (Fig. 2A). We hypothesized that the STAT1 binding to 
DNA after RH infection was due to ROP16-activated STAT1 and we therefore also infected cells 
with an RH ∆rop16 strain.  In cells infected with RH ∆rop16 parasites, STAT1 binding at these 
loci is not significantly higher than in uninfected cells, suggesting that the STAT1 activated by 
ROP16 is not only tyrosine phosphorylated, dimerized, and nuclear, but that it is also able to 
bind to the promoters of IFN-γ-induced genes (Fig. 2A). Most importantly, previous infection 
with either RH or RH ∆rop16 parasites did not inhibit STAT1 binding upon IFN-γ stimulation at 
six of the seven IFN-γ induced loci (Fig. 2A), suggesting that Toxoplasma infection inhibits 
STAT1 activity downstream of STAT1 DNA binding. 
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Figure 2. IF+-γ-induced STAT1 D+A association is increased upon infection with Toxoplasma. HFFs were 
infected with RH or RH ∆rop16 parasites, or left uninfected (UI), for four to five hours. Cells were stimulated with 
100 U/ml human IFN-γ for the last hour of infection or left unstimulated (US). A. Samples were fixed with 1% 
formaldehyde and collected for chromatin immunoprecipitation. qPCR of STAT1-binding regions of the promoters 
of IFN-γ-responsive genes was performed on both the immunoprecipitated STAT1-bound DNA and total input 
DNA. Percent of the total DNA bound by STAT1 was calculated. A promoter region where STAT1 is not known to 
bind (CCND2) was also included as a negative control. The average and s.e.m. of three experiments is shown. 
Average MOI in the three experiments = 8. Asterix (*) indicates p<0.05 vs the uninfected, unstimulated sample, or 
as indicated by bars. B-D. Samples were fractionated in cytoplasmic, nuclear extract, and chromatin fractions. A 
portion of each fraction was diluted in 2x reducing sample buffer, boiled, and protein levels were analyzed by SDS-
PAGE and Western blot (B, C). STAT1 was then immunoprecipitated from all three fractions and mass 
spectrometry was performed. From each sample, the percentage of the total STAT1 peptides that were found in the 
chromatin fraction was calculated (D). Cells were infected with RH at MOIs of ~8 (B, D) and ~1.5 (D) and with RH 
∆rop16 at an MOI of ~5 (C, D) in three independent experiments. 
 
 To confirm that Toxoplasma does not inhibit STAT1’s association with DNA and 
chromatin, we again infected HFFs with RH parasites, or left cells uninfected, and subsequently 
stimulated cells with IFN-γ. We then isolated cytoplasmic, nuclear extract, and chromatin 
fractions from these cells, and analyzed protein levels in these fractions by SDS-PAGE and 
Western blot. As expected, in unstimulated, uninfected cells, STAT1 is present exclusively in the 
cytoplasmic fraction, and upon IFN-γ treatment STAT1 is both tyrosine phosphorylated and 
present in the nuclear extract (Fig. 2B). Only a very small amount of this STAT1 is stably 
associated with the chromatin (Fig. 2B). In cells pre-infected with RH and stimulated with IFN-
γ, levels of STAT1 in both the nuclear extract and chromatin fraction are significantly higher 
than in uninfected cells (Fig. 2B). We obtained similar results from cells pre-infected with an RH 
∆rop16 strain (Fig. 2C), suggesting that this increased association is not simply due to ROP16-
activated STAT1. This again indicates that Toxoplasma infection does not prevent the IFN-γ-
induced binding of STAT1 to chromatin and, in fact, infection increases this association. To 
quantify the relative amount of STAT1 in the chromatin fraction in each of these samples, we 
immunoprecipitated STAT1 from each of the cytoplasmic, nuclear extract, and chromatin 
fractions, and performed mass spectrometry on the pulled-down proteins. We then calculated the 
percent of STAT1 peptides present in the chromatin fraction compared to the total STAT1 
peptides measured in each sample. Consistent with our Western blot results, pre-infection with 
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Toxoplasma resulted in substantially more IFN-γ-induced STAT1 in the chromatin fraction, 
regardless of the presence of STAT1 on the chromatin in unstimulated cells due to ROP16 (Fig. 
2C). Under the conditions of these immunoprecipitations, we did not consistently find any 
infection-induced change in the human or Toxoplasma proteins pulled down with STAT1 in any 
of the fractions (data not shown).  
 
Toxoplasma infection also inhibits IF+-β-induced STAT1 transactivation activity 
 Next, we wondered whether Toxoplasma’s inhibition of STAT1 transcriptional activity is 
specific for STAT1 homodimers, the complexes primarily activated by IFN-γ stimulation.  From 
previous research it is clear that the interference is specific for STAT1, as ROP16-activated 
STAT3 and STAT6 are transcriptionally active (Jensen et al., 2011; Saeij et al., 2007).  
However, STAT1 can also be present in a complex with STAT2 and IRF9, which is primarily 
activated by type I interferons, IFN-α and IFN-β (Platanias, 2005).  This complex is called 
interferon-stimulated gene factor 3 (ISGF3) and binds to IFN-stimulated response elements 
(ISREs) in DNA to induce the expression of a subset of genes that partially overlaps with the set 
of genes induced by IFN-γ (Platanias, 2005). To test whether Toxoplasma infection can inhibit 
the activity of type I interferon activated STAT1, we developed a lentivirally transduced ISRE 
reporter cell line in HEK293 cells.  We infected this cell line with RH parasites, or left cells 
uninfected, subsequently stimulated the cells with IFN-β, or left cells unstimulated, and 
measured the induction of luciferase activity.  Treatment with IFN-β led to the induction of 
luciferase by ~3.5-fold, and pre-infection with RH parasites significantly inhibited this induction 
(Fig. 3A), suggesting that RH parasites can inhibit IFN-β-induced STAT1 activity.  However, 
this reporter cell line also responds to IFN-γ treatment (Fig. 3A, Fig. S2A), and IFN-β treatment 
can induce STAT1 homodimers in addition to ISGF3. 
 To directly test the ability of Toxoplasma to inhibit ISGF3-mediated gene expression, we 
analyzed the expression of genes specifically induced by IFN-β and not by IFN-γ.  We infected 
HFFs with RH parasites, or left cells uninfected, subsequently stimulated the cells with either 
IFN-γ or IFN-β, or left cells unstimulated, isolated RNA from cells, and analyzed transcript 
levels by RT-qPCR. IRF1 expression was induced strongly by IFN-γ treatment but also slightly 
induced by IFN-β treatment (Fig. 3B), likely via STAT1 homodimers in both conditions. Pre-
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infection with RH significantly decreases this expression in both conditions (Fig. 3B). The 
expression of genes that are specifically induced by IFN-β: RSAD2, MX2, and OASL (Indraccolo 
et al., 2007), were also significantly inhibited by pre-infection with RH parasites (Fig. 3B). 
Normalization of qPCR data to a different control gene gave virtually identical results (Fig. S3). 
 In the ISGF3 complex, IRF9 contributes most of the DNA binding activity (Sadzak et al., 
2008; Veals et al., 1992) while STAT1’s transactivation domain is necessary for strong induction 
of target gene expression (Pilz et al., 2003). Our data indicate that Toxoplasma does not inhibit 
STAT1 DNA binding activity but instead acts downstream, targeting STAT1 transactivation, 
suggesting that Toxoplasma infection could inhibit IFN-β- and IFN-γ-induced gene expression 
by similar mechanisms. To assess the similarity of these mechanisms, we first determined 
whether Toxoplasma inhibits IFN-β-induced phosphorylation of STAT1. We infected HFFs with 
RH parasites, or left cells uninfected, for three hours and subsequently stimulated cells with IFN-
γ or IFN-β for one hour, or left cells unstimulated. As measured by SDS-PAGE and Western 
blot, infection with RH parasites does not inhibit IFN-β-induced STAT1 tyrosine or serine 
phosphorylation, even at an MOI which inhibits IFN-γ-induced IRF1 induction (Fig. 3C). Next, 
we measured the association of the ISGF3 complex with chromatin by isolating cytoplasmic, 
nuclear extract, and chromatin fractions from these cells and analzying protein levels by SDS-
PAGE and Western blot. The nuclear translocation and chromatin association of IFN-β-induced 
STAT1 and STAT2 was not inhibited by prior infection with Toxoplasma, and in fact we 
observed an increase in IFN-β-induced STAT1 in the chromatin fraction after infection (Fig. 
3D). IRF9 was found in the nuclear extract fraction in all samples, but we observed a slight 
increase in chromatin association after IFN-γ or IFN-β stimulation or RH infection, and the 
combination of RH infection and IFN-β treatment together led to a strong increase in the 
chromatin association of IRF9 (Fig. 3C). These results indicate that as with IFN-γ-induced 
STAT1, Toxoplasma infection does not inhibit the association of IFN-β-induced STAT1, 
STAT2, or IRF9 with host cell chromatin. 
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Figure 3. Toxoplasma also inhibits IF+-β-induced gene expression through a similar mechanism. A. A 
HEK293 ISRE reporter cell line was infected with RH parasites for three to five hours, or left uninfected, 
subsequently stimulated with 100 U/ml IFN-γ, 100 U/ml IFN-β, or left unstimulated (US) for 14-17 hours, lysed, 
and luciferase activity was measured. Data were normalized within each experiment to the uninfected, unstimulated 
sample and data shown are the average fold induction and s.e.m. from three experiments. Asterix (*) indicates 
p<0.05. B. HFFs were plated in 6-well plates, infected with RH parasites for four hours, and subsequently stimulated 
with 100 U/ml IFN-γ or 100 U/ml IFN-β for 15-20 hours. Cells were also left uninfected (UI) and unstimulated 
(US). Transcript levels of three ISGF3-induced (ISRE promoter) genes and one STAT1 homodimer-induced (GAS 
promoter) gene were analyzed by RT-qPCR and normalized to ACTB levels. Averages of three independent 
experiments are shown; error bars represent s.e.m.; asterix (*) indicates p<0.05 vs uninfected sample with the same 
stimulation. C, D. HFFs were plated in 60 cm dishes, infected with RH parasites for three hours, and subsequently 
stimulated with 100 U/ml IFN-γ or 100 U/ml IFN-β for one hour. Cells were also left uninfected (UI) and 
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unstimulated (US). A portion of the sample was lysed, boiled, separated by SDS-PAGE, and subjected to Western 
blotting (C). The rest of the samples were fractionated into cytoplasmic, nuclear extract, and chromatin fractions, 
diluted in 2x reducing SDS sample buffer, boiled, and protein levels were analyzed by SDS-PAGE and Western blot 
(D). These experiments (C,D) were performed twice from two independent infections with similar results. 
 
 
Histone deacetylase activity is not required for Toxoplasma inhibition of IRF1 expression 
or STAT1 transcriptional activity 
 We next looked at steps downstream of STAT1 DNA binding where Toxoplasma could 
inhibit STAT1 transcriptional activity.  It was recently reported that Toxoplasma infection 
inhibits the expression of IFN-γ-induced secondary response genes such as CIITA and MHC 
class II genes by activating histone deacetylases (HDACs) and preventing the recruitment of 
chromatin remodeling complexes to gene promoters (Lang et al., 2012). The recruitment of 
histone acetyltransferases and increased histone H4 and H3 acetylation is associated with the 
formation of euchromatin and accessibility of DNA to transcription factors and RNA pol II 
(Kouzarides, 2007), and actively transcribed STAT1 target genes have increased H3 and H4 
acetylation upon IFN-γ treatment (Lang et al., 2012). However, many stimulus-induced primary 
response genes do not require chromatin remodeling to be expressed (Medzhitov and Horng, 
2009), and it is unclear if Toxoplasma could use this mechanism to inhibit the expression of 
primary IFN-γ-induced genes. We therefore decided to test whether HDAC inhibitors affect the 
ability of Toxoplasma to inhibit the IFN-γ-induced expression of IRF1 or activation of STAT1 
reporter cell lines. 
 First, we pretreated HFFs in coverslips with trichostatin A (TSA), a class I/II HDAC 
inhibitor, subsequently infected the cells with RH parasites, and then stimulated the cells with 
IFN-γ.  Cells were then fixed and stained for IRF1 expression and acetylated-histone H4. TSA 
treatment in all conditions increased the intensity of acetylated-histone H4 staining in the host 
nucleus indicating that under these conditions it potently inhibits host HDACs (Fig. 4A). 
However, infection with RH parasites either in the presence or absence of TSA strongly inhibited 
the IFN-γ induced expression of IRF1, indicating that the activity of class I and class II HDACs 
is not required for Toxoplasma’s inhibition of IRF1 expression (Fig. 4A). 
122 
 
 However, IRF1 is just one gene and the chromatin environments of all IFN-γ-induced 
genes may not be regulated in the same manner.  Therefore we tested the ability of Toxoplasma 
infection to inhibit STAT1 activity in two different stable HEK293 reporter cell lines, a “GAS” 
line and a “STAT1” line. These cell lines contain slightly different consensus STAT1 binding 
sites, both driving the expression of luciferase. Treatment of either of these reporters with IFN-γ, 
but not IFN-β, TNF-α, or IL-4, results in the induction of luciferase activity (Rosowski and Saeij, 
2012) (Fig. S2B). We pretreated both of these cell lines with a variety of HDAC inhibitors: TSA, 
MC1568, MS-275, or sodium butyrate, or with DMSO as a control. We then infected the lines 
with RH parasites, subsequently stimulated the cells with IFN-γ, and measured the induction of 
luciferase activity. In the DMSO control, prior infection with RH parasites significantly inhibited 
the IFN-γ-stimulated induction of luciferase activity in both cell lines (Fig. 4B), in agreement 
with previous results (Rosowski and Saeij, 2012). In the GAS reporter line, pretreatment with 
MC1568, MS-275, or sodium butyrate did not affect the ability of RH infection to inhibit this 
induction (Fig. 4B).  Treatment with TSA by itself inhibited the induction of luciferase after 
IFN-γ treatment in this cell line, although prior infection with RH still lowered the IFN-γ induced 
luciferase activity further (Fig. 4B). Conversely, in the STAT1 reporter line treatment with TSA 
or MS-275 strongly induced luciferase activity even in the absence of IFN-γ treatment (Fig. 4B).  
Prior infection with RH still inhibited IFN-γ induced luciferase activity in all conditions (Fig. 
4B). These results suggest that the mechanism by which a type I strain of Toxoplasma inhibits 
the expression of STAT1-induced primary response genes is distinct from the mechanism of 
inhibition of secondary response genes, and does not involve the activation of HDACs. 
Additionally, we find that inhibition of HDAC activity has both positive and negative effects on 
basal and IFN-γ-induced STAT1 transcriptional activity, depending on the exact promoter and 
the different HDACs that are targeted.  
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Figure 4. HDAC activity is not required for Toxoplasma to inhibit IF+-γ-induced IRF1 expression or 
induction of IF+-γ-responsive reporter cell lines. A. HFFs were plated on coverslips, pre-treated with 3 µM 
trichostatin A (TSA), an HDAC inhibitor, for one hour, then infected with RH parasites for one hour, and 
subsequently stimulated with 100 U/ml IFN-γ for two hours. Control cells were also left unstimulated (US) and/or 
uninfected (UI). Cells were fixed, permeabilized, and stained with α-acetyl-histone H4 (green), α-IRF1 (red), and 
with Hoechst dye (nucleus, blue). A representative cell from each condition is shown. Scale bar represents 10 µM. 
This experiment was performed twice with similar results. B. HEK293 GAS (top) or STAT1 (bottom) reporter cell 
lines were pre-treated with a variety of HDAC inhibitors (TSA, MC1568, MS-275, sodium butyrate) or left 
untreated (DMSO, vehicle only control) for one hour. Cells were left uninfected (UI) or infected with RH parasites 
for one to three hours, subsequently stimulated with 100 U/ml IFN-γ for 14-20 hours, or left unstimulated (US), 
lysed, and luciferase activity was measured. Data was normalized within each experiment to the sample with the 
maximum luciferase activity and data shown are the average and s.e.m. from three independent experiments. Asterix 
(*) indicates p<0.05 or p-values are shown as indicated by bars. 
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+ew host cell protein synthesis is dispensable for the inhibition of IF+-γ-induced primary 
response gene expression by Toxoplasma 
 Another mechanism by which Toxoplasma could inhibit STAT1 transcriptional activity 
in the nucleus is through the transcriptional or translational activation of host negative regulatory 
proteins which target STAT1, such as suppressors of cytokine signaling (SOCS) family proteins, 
protein tyrosine phosphatases (PTPs), and protein inhibitor of activated STAT1 (PIAS) family 
proteins (Shuai and Liu, 2003). To test the role of proteins whose expression is induced by 
Toxoplasma infection in inhibiting STAT1 activity, we pre-treated HFFs with the protein 
translation inhibitor cyclohexamide (CHX) for 40 minutes prior to infecting the cells with an RH 
strain for one hour and subsequently stimulating with IFN-γ for one hour. Under these 
conditions, infection-induced and IFN-γ-induced protein expression is prevented, and cell 
viability is not affected (Fig. S4).  We then determined IFN-γ-induced IRF1 mRNA levels by 
RT-qPCR.  IFN-γ treatment increased IRF1 mRNA levels ~13-fold, and this induction was 
decreased in samples pre-infected with RH parasites (Fig. 5A).  Pre-infection with RH parasites 
also inhibited IFN-γ-responsive IRF1 mRNA accumulation in the presence of CHX (Fig. 5A). 
However, conclusions from the IRF1 qPCR are complicated by the fact that both CHX treatment 
(~5-fold) and RH infection combined with CHX treatment (~12-fold) induce IRF1 mRNA 
transcription in the absence of IFN-γ (Fig. 5A). We therefore calculated the fold inhibition of 
IRF1 expression by RH pre-infection in each of these conditions. The presence of CHX did not 
significantly alter the ability of RH to inhibit IRF1 gene expression (Fig. 5B). Similar results 
were obtained when IRF1 qPCR data was normalized to a different control gene (Fig. S5). 
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Figure 5. Toxoplasma can inhibit IF+-γ-responsive gene expression in the presence of cyclohexamide. HFFs 
were pre-treated with 50 µg/ml CHX for 40 minutes, infected with an RH strain for one hour, and stimulated with 
100 U/ml IFN-γ for one hour.  CHX was left on the treated cells for the entire experiment. Cells were also left 
untreated (UT) and/or uninfected (UI).  Induction of IRF1 mRNA was determined by RT-qPCR analysis and 
normalized to ACTB transcript levels.  A. Averages of two experiments are shown; error bars represent s.e.m. B. 
Fold inhibition by RH infection in each of the conditions was calculated for each experiment and averages of two 
experiments are shown; error bars represent s.e.m. 
 
Inhibition of STAT1 activity does not depend on the proteasome 
 Besides activating histone deacetylases or inducing the expression of STAT1 inhibitory 
proteins, Toxoplasma infection could also cause the degradation of a co-activator that is 
necessary for STAT1 to recruit general transcription machinery and RNA polymerase II. To 
determine whether the ability of Toxoplasma to inhibit STAT1 transcriptional activity depends 
on the proteasome, we treated our HEK293 STAT1 and GAS reporter cell lines with MG132, 
which inhibits the proteolytic activity of the 26S proteasome. We then infected the cell lines with 
RH parasites, subsequently stimulated the cells with IFN-γ, and measured the induction of 
luciferase activity. In both the GAS and STAT1 reporter cell lines, treatment with increasing 
concentrations of MG132 inhibited the induction of luciferase activity even in the absence of 
infection (Fig. 6). However, in the STAT1 reporter line this inhibition was only partial, and pre-
infection with RH parasites significantly inhibited IFN-γ-induced luciferase activity even further 
(Fig. 6). This result indicates that Toxoplasma-induced inhibition of STAT1-mediated gene 
expression does not require proteolytic activity of the proteasome. 
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Figure 6. Toxoplasma can inhibit IF+-γ-responsive gene expression in the presence of MG132. HEK293 GAS 
or STAT1 reporter cell lines were pre-treated with MG132 or left untreated for 40 minutes. Cells were then infected 
with RH parasites for three to five hours, subsequently stimulated with 100 U/ml IFN-γ for 15 hours, lysed, and 
luciferase activity was measured. MG132 was left on the treated cells for the entire experiment. Data was 
normalized within each experiment to the uninfected, unstimulated (US) sample and data shown are the average fold 
induction and s.e.m. from three independent experiments. Asterix (*) indicates p<0.05. 
 
Toxoplasma rhoptry secretion is not sufficient for STAT1 inhibition 
 The Toxoplasma effector(s) responsible for the inhibition of IFN-γ-induced, STAT1-
mediated primary response gene expression remains unknown. It was previously reported that 
UV-treated parasites which are unable to replicate can still inhibit the IFN-γ-induced 
upregulation of MHC class II molecules (Lang et al., 2006).  Similarly, we have found that with 
just three hours of infection, before the parasites have replicated, Toxoplasma consistently 
inhibits the IFN-γ-induced expression of IRF1 (Rosowski and Saeij, 2012) .  We therefore 
wondered if the Toxoplasma effector(s) that modulate STAT1 transcriptional activity are 
secreted factors, which the parasite injects into the host cell upon invasion (Boothroyd and 
Dubremetz, 2008). To test this hypothesis, RH parasites were pre-treated with cytochalasin D, an 
inhibitor of actin polymerization which allows parasites to attach to a host cell and secrete 
rhoptry contents, but inhibits active invasion, which requires Toxoplasma actin polymerization 
(Håkansson et al., 2001).  Pre-treated parasites were added to HFFs and allowed to attach for one 
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and a half hours, after which the cells were stimulated with IFN-γ for 18 hours and the 
expression of IRF1 was measured by immunofluorescence.  Cytochalasin D-treated parasites did 
not invade the HFF host cells but still attached and secreted rhoptry proteins including ROP16, 
as demonstrated by the presence of phospho-STAT6 in host cell nuclei (Saeij et al., 2007) (Fig. 
7A).  However, the injection of rhoptry contents into a cell was not sufficient to inhibit IFN-γ-
induced IRF1 expression (Fig. 7A). 
 Similarly, parasites pre-treated with cytochalasin D were unable to prevent IFN-γ-
induced luciferase activity in our GAS reporter cell line (Fig. 7B).  Cytochalasin D is a reversible 
inhibitor and must be kept on the cells for the entire experiment, also inhibiting host actin 
polymerization.  Because it was recently shown that host actin plays a role in chromatin 
remodeling at IFN-γ-induced promoters (Lang et al., 2012), we also pre-treated parasites with 
mycalolide B, an irreversible actin depolymerizing agent, which was washed away before 
parasites were added to host cells.  Parasites pre-treated with mycalolide B also were unable to 
inhibit IFN-γ-induced STAT1 transcriptional activity in the GAS reporter cell line (Fig. 7B).  
Thus, our results suggest that secretion of rhoptry proteins by a type I parasite into an uninvaded 
host cell is not sufficient to inhibit IFN-γ-induced STAT1 transcriptional activity. 
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Figure 7. Invasion is required for Toxoplasma’s ability to inhibit IF+-γ-induced gene expression. RH parasites 
were pre-treated with 1µM cytochalasin D (cytoD) or 3µM mycalolide B (mycaB) or left untreated (UT) and added 
to host cells for 1.5 hours.  Cells were then stimulated with 100 U/ml IFN-γ, or left unstimulated (US) for 18 hours.   
A. HFFs were fixed and stained for IRF1 (green), phospho-STAT6 (red), and with Hoechst dye (nucleus, blue).  
Scale bar represents 10 µm.  Arrow indicates infected cell, arrowhead indicates uninfected cell with parasites 
attached and rhoptry proteins secreted. This experiment was performed three times with similar results.  B. A 
HEK293 GAS luciferase reporter cell line was then lysed and luciferase activity was measured.  Results from two 
experiments per condition, except for the uninfected mycalolide B treated condition for which only one experiment 
was done, were normalized to the maximum luciferase activity within the experiment and then averaged.  In these 
experiments, 100% maximum induction represents an average of 10-fold induction over uninfected, unstimulated 
samples.  Error bars represent s.e.m.  Asterisk (*) indicates p<0.05 compared to uninfected control. 
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Discussion 
 In this study we have further elucidated the mechanism by which type I Toxoplasma 
parasites inhibit STAT1 activity at primary IFN-γ response genes. This mechanism appears to be 
distinct from how Toxoplasma inhibits the expression of secondary IFN-γ response genes, such 
as CIITA, H2-Eβ, and GBP2 (Lang et al., 2012), as it does not require the activity of histone 
deacetylases (Fig. 4). In fact, treatment of two different STAT1 reporter cell lines with various 
HDAC inhibitors illustrated that altering histone acetylation can affect both basal and IFN-γ-
induced STAT1-mediated gene expression, both positively and negatively (Fig. 4B). This has 
been found previously; the expression of subsets of IFN-α- and IFN-β-stimulated genes are 
known to be sensitive to TSA treatment (Chang et al., 2004; Nusinzon and Horvath, 2003; 
Sakamoto et al., 2004) and IFN-γ-induced MHC class II gene expression can be increased by 
TSA treatment (Zika et al., 2003). While acetylation in general is thought to increase chromatin 
accessibility and gene expression, histones are acetylated at multiple residues with each of these 
modifications having slightly different consequences, and deacetylation of histones can also 
correlate with increased gene expression (Shahbazian and Grunstein, 2007). While Toxoplasma 
may target histone acetylation to inhibit the expression IFN-γ-induced secondary response genes, 
our results suggest that it is unlikely that Toxoplasma activates histone deacetylases to inhibit 
IFN-γ-induction of primary response genes such as IRF1. 
 To map out where in the IFN-γ pathway Toxoplasma acts to inhibit STAT1 activity, we 
have measured multiple steps of STAT1 activation: phosphorylation, dimerization, nuclear 
translocation, and DNA binding (Fig. 8). It was previously demonstrated that Toxoplasma 
infection does not inhibit STAT1 tyrosine phosphorylation or nuclear translocation (Kim et al., 
2007a; Lang et al., 2006, 2012; Rosowski and Saeij, 2012). We report that STAT1 dimerization 
as measured by native PAGE (Fig. 1) and STAT1 DNA binding in vivo as measured by ChIP-
qPCR (Fig. 2A) are also not inhibited by type I Toxoplasma pre-infection. In support of this, 
previous studies have reported that Toxoplasma does not inhibit STAT1 DNA binding activity in 
vitro by EMSA (Lang et al., 2012; Lüder et al., 2001; Schneider et al., 2013). Toxoplasma 
infection also does not inhibit STAT1 serine phosphorylation (Kim et al., 2007a; Rosowski and 
Saeij, 2012) which can only occur when STAT1 is chromatin-associated (Sadzak et al., 2008). 
These results differ from a ChIP experiment recently reported in murine BMDCs, where it was 
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found that pre-infection with type I Toxoplasma parasites did inhibit STAT1 binding at the Irf1 
promoter (Schneider et al., 2013). This could be due to differences in the species and cell type 
tested, although Toxoplasma infection can equally inhibit STAT1-mediated transcription in both 
human fibroblasts and murine macrophages (Rosowski and Saeij, 2012).  
 At one of the seven STAT1 binding sites we tested in the ChIP assay, the IDO1 promoter, 
Toxoplasma pre-infection did inhibit IFN-γ-induced STAT1 binding. Many secondary IFN-γ 
response genes, such as CIITA and MHC class I and II genes, require the IRF1 transcription 
factor in addition to STAT1 for maximal induction (Hobart et al., 1997) and IRF1 can directly 
contact and recruit RNA polymerase II to promoters (Ramsauer et al., 2007). IDO1 also requires 
IRF1 for full expression (Silva et al., 2002), and we hypothesize that at this promoter STAT1 
cannot stably bind in the absence of IRF1, whose expression is inhibited by Toxoplasma 
infection. It is also possible that Toxoplasma infection dysregulates the binding of STAT1 to 
DNA across the genome such that binding is inhibited at certain regions and not at others. 
 We report for the first time that type I Toxoplasma infection also inhibits the expression 
of IFN-β-induced genes (Fig. 3A,B). IFN-β signals through a transcription factor complex, 
ISGF3, consisting of STAT1, STAT2, and IRF9. Our data suggests that type I Toxoplasma 
infection inhibits STAT1 homodimer and ISGF3 activity by similar mechanisms. Type I 
Toxoplasma infection does not prevent the IFN-β-induced tyrosine or serine phosphorylation of 
STAT1 (Fig. 3C), or the chromatin-association of STAT1, STAT2, or IRF9 (Fig. 3D). In the 
ISGF3 complex, IRF9, not STAT1, is responsible for the majority of DNA binding (Sadzak et 
al., 2008; Veals et al., 1992), supporting the idea that STAT1 DNA binding is not the step at 
which Toxoplasma infection inhibits STAT1 activity.  
 Toxoplasma likely targets STAT1 transcriptional activity directly in any complex. The 
requirements for global STAT1-mediated transcription beyond its binding to DNA are not 
entirely clear, except that STAT1 must recruit RNA polymerase II, possibly through the binding 
of co-activators. Our data suggests that a Toxoplasma effector blocks STAT1 transcriptional 
activity at this step (Fig. 8). This effector likely specifically targets DNA-bound STAT1, as our 
native PAGE experiments do not suggest that STAT1 is stably bound to any other proteins upon 
Toxoplasma infection, while in previous EMSA assays a more slowly migrating unknown 
STAT1 complex was observed (Lang et al., 2012; Schneider et al., 2013). The fact that infection 
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can also inhibit IFN-β-induced gene expression by a similar mechanism suggests that the effector 
can target chromatin-associated STAT1 in multiple complexes, making it unlikely that a specific 
DNA-binding induced STAT1 conformational change is recognized. It is possible that the 
effector targets serine-phosphorylated STAT1, as STAT1 is serine phosphorylated exclusively 
on the DNA after both IFN-γ and IFN-β treatment (Sadzak et al., 2008). 
 Cell fractionation experiments indicate that either type I or type I ∆rop16 Toxoplasma 
infection actually increases overall IFN-γ- and IFN-β-induced association of STAT1 with 
chromatin (Fig. 2B-D). Specific STAT1 mutants have been identified that enhance STAT1 DNA 
binding both at GAS sites and at non-canonical sites, and these mutations decrease STAT1 
transcriptional activity (Koch et al., 2012). Turnover and degradation of other transcriptional 
activators has also been linked to increased target gene expression (Geng et al., 2012; Lipford et 
al., 2005). This suggests that Toxoplasma could inhibit STAT1 transcriptional activity simply by 
inhibiting its disassociation with DNA and/or its degradation.  
 The Toxoplasma effector could directly target STAT1 itself or it could act upon a host 
protein to indirectly target STAT1. Experiments with a proteasomal inhibitor (MG132) and a 
protein translation inhibitor (CHX) exclude several possible mechanisms of inhibition via 
modulation of a host factor. The ability of Toxoplasma to inhibit STAT1 activity in the presence 
of MG132 rules out the possibility that Toxoplasma infection induces the proteasomal 
degradation of a necessary STAT1 co-activator. IFN-γ-induced activation of both of our 
HEK293 STAT1 reporter cell lines was inhibited by MG132 treatment alone (Fig. 6), which has 
been observed before (Li and Hassel, 2001), actually arguing for a role of the proteasome in 
STAT1 activation. Toxoplasma also does not require new host protein synthesis to inhibit 
STAT1-mediated primary response gene expression (Fig. 5), ruling out the transcriptional or 
translational activation of a host negative regulatory protein or transcriptional repressor as a 
possible mechanism of inhibition of STAT1 activity. Toxoplasma infection does induce the 
expression of SOCS proteins which regulate STAT activity (Zimmermann et al., 2006), but these 
proteins target the phosphorylation of the JAK and STAT proteins (Fujimoto and Naka, 2003), 
while infection inhibits STAT1 activity downstream of these steps (Fig. 8). In this CHX 
experiment, CHX treatment and CHX treatment in combination with infection resulted in the 
expression of IRF1 independent of IFN-γ treatment (Fig. 5A). This expression likely occurs via a 
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different transcription factor, as IRF1 can also be induced by NF-κB (Robinson et al., 2006; 
Rosowski and Saeij, 2012; Saha et al., 2010), and CHX treatment leads to the activation of NF-
κB by preventing synthesis of inhibitory IκB proteins (Casado and Díaz-Guerra, 1997; Hershko 
et al., 2004). The activation of another transcription factor such as NF-κB could also explain the 
synergistic induction of IRF1 transcript by the combination of CHX and IFN-γ.  
 The best way to determine the exact mechanism of inhibition may be to find the 
Toxoplasma effector that is responsible. Our results suggest that this factor is not secreted into 
the host cell upon invasion, as cytochalasin D or mycalolide B treated parasites cannot inhibit 
IFN-γ-induced gene expression (Fig. 8). Three major possibilities remain for the identity of the 
Toxoplasma effector: 1) a rhoptry or dense granule protein that is secreted into the host cell upon 
invasion but must traffic back to the PV to be modified or to act, 2) a small molecule or 
metabolite that can diffuse or be transported into the host cell from the PV that activates a host 
cell protein such as a nuclear receptor, or 3) a protein that is secreted into the host cell post 
invasion. Our data suggests that the Toxoplasma effector must act within the host nucleus, as 
STAT1 is inhibited after binding to DNA, making the first possibility seem unlikely. 
Additionally, in order to traffic back to the exterior of the nascent PVM a secreted protein must 
contain an arginine-rich amphipathic helix, which only a few Toxoplasma proteins possess 
(Reese and Boothroyd, 2009). These proteins all belong to the ROP2-family, several of which 
have been extensively characterized and are not known to be involved in STAT1 modulation 
(Niedelman et al., 2012). It also seems unlikely that infection activates the STAT1-inhibiting 
nuclear receptors that are best characterized, the liver X receptors (LXRs), as these proteins 
inhibit STAT1 DNA binding (Lee et al., 2009), which is upstream of where Toxoplasma acts. 
eospora caninum is an apicomplexan parasite related to Toxoplasma that does not inhibit IFN-
γ-induced gene expression (Kim et al., 2007b) but has a very similar metabolism (Reid et al., 
2012), also making it less likely that the effector is a metabolite.  
 We favor the third hypothesis, that the effector protein is secreted into the host cell post-
invasion. In addition to the rhoptries, Toxoplasma possesses another type of secretory organelle, 
the dense granules. Dense granule proteins are known to accumulate in the host cell, including 
GRA15 which activates the host cell NF-κB pathway (Rosowski et al., 2011) and GRA16 which 
accumulates in the host cell nucleus post-invasion and targets host HAUSP and PP2A enzymes 
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(Bougdour et al., 2013). These proteins contain a protein motif similar to one found in 
Plasmodium called a PEXEL motif which targets proteins for export across the PVM into the 
host cell post invasion (Hiller et al., 2004; Marti et al., 2004). Many other uncharacterized 
Toxoplasma proteins capable of interacting with host cell signaling pathways are likely to be 
exported into the host cell in this manner, possibly including a protein which can target STAT1 
on the host cell DNA.  
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Figure 8. Intersection of IF+-STAT1 pathways and Toxoplasma. IFN-β and IFN-γ activate the expression of 
downstream target genes through ISGF3 and STAT1 homodimer complexes, respectively. The activation pathways 
of these cytokines are outlined. In a cell pre-infected with Toxoplasma, the STAT1 mediated expression of both 
IFN-γ- and IFN-β-induced target genes is inhibited. We have measured multiple steps of these pathways and 
indicate here whether each step is inhibited by Toxoplasma infection or still occurs in a Toxoplasma-infected cell. 
Arrows indicate activation, inhibitory arrows indicate negative regulation, X marks indicate steps which do not 
occur in Toxoplasma-infected cells, and check marks indicate steps that do still occur in Toxoplasma-infected cells. 
We find that the Toxoplasma effector responsible for the inhibition of STAT1 activity and the expression of IFN-γ 
primary reponse genes is unlikely to be a protein secreted from the Toxoplasma rhoptry organelle prior to invasion, 
and that the unknown effector does not depend on the activity of histone deacetlyases, which can have both negative 
and positive effects on IFN-stimulated gene expression. While Toxoplasma infection induces the expression of 
SOCS family proteins, which negatively regulate JAK/STAT activation, this induction is not necessary for 
Toxoplasma to inhibit STAT1 mediated gene expression. We hypothesize that Toxoplasma infection targets the 
recruitment of co-activators or RNA polymerase II by STAT1. 
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Materials and Methods 
Parasites and cells 
Parasites were maintained in vitro by serial passage on monolayers of human foreskin fibroblasts 
(HFFs), as described previously (Rosowski et al., 2011). An RH strain engineered to express 
clickbeetle luciferase and GFP (RH 1-1) (Boyle et al., 2007),  an RH ∆rop16 strain (provided by 
John Boothroyd, Stanford University) (Ong et al., 2010), and an RH ∆rop16 strain expressing 
firely luciferase and GFP (Jensen et al., 2011) have been described previously.  HFFs were 
cultured as previously described (Rosowski et al., 2011).  293FT and HEK293 cells were 
cultured with additional 10 mM HEPES.  A HEK293-pGreenFire1-GAS IFN-γ responsive 
reporter cell line has been previously described (Rosowski and Saeij, 2012). All parasite strains 
and cell lines were routinely checked for Mycoplasma contamination and it was never detected. 
 
Reagents 
Antibodies against total STAT1α p91 (C-24) (Santa Cruz #345), phospho-STAT1Tyr701 58D6 
(Cell Signaling #9167), phospho-STAT1Ser727 (Cell Signaling #9177), STAT2 (H-190) (Santa 
Cruz #22816), IRF1 (BD Biosciences #612046), IRF9/ISGF-3γ p48 (C-20) (Santa Cruz #496), 
GAPDH (6C5) (Santa Cruz #32233),  Toxoplasma surface antigen (SAG)-1 (kindly provided by 
John Boothroyd, Stanford University), Toxoplasma GRA7 (Dunn et al., 2008), Histone H3 
(Abcam #1791), Acetyl Histone H4 Lys12 (Cell Signaling #2591), and phospho-STAT6Tyr641 
(Santa Cruz #11762-R) were used in immunofluorescence and Western blot assays.  Secondary 
antibodies coupled with either Alexa Fluor 488 or Alexa Fluor 594 (Molecular Probes) for 
immunfluorescence assay or conjugated to peroxidase (Kirkegaard & Perry Laboratories) for 
Western blots were used.  Recombinant human IFN-γ (AbD serotec), IFN-β (Peprotech), IL-4 
(Peprotech), and TNF-α (GIBCO/Life Technologies) were used to stimulate cells.  
Cyclohexamide (50 µg/ml, Sigma), cytochalasin D (1 µM, Enzo), mycalolide B (3 µM, Wako), 
trichostatin A (3-9 µM, Sigma), MS-275 (2-10 µM, Selleck), MC1568 (2-10 µM, Selleck), 
sodium butryate (2-10 µM, Sigma), and MG132 (0.5-2.5 µM, Sigma) were also used to treat 
cells. 
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ative PAGE and Western blot 
HFFs were infected with either RH ∆hxgprt or RH ∆rop16 parasites at two different MOIs 
(actual MOIs = five and seven for RH ∆hxgprt and seven and nine for RH ∆rop16 ) for three 
hours, or left uninfected, and subsequently stimulated with 100 U/ml human IFN-γ for one hour, 
or left untreated.  Cells were then lysed in non-denaturing buffer containing 1% sodium 
deoxycholate and lysates were run on 7.5% PAGE gels in Tris-glycine buffer with 1% sodium 
deoxycholate in the cathode chamber, at 4C. Western transfer and blotting were performed as 
described previously (Rosowski et al., 2011). Blots were stained with Ponceau S to visualize 
protein standard (NativeMark, Life Technologies). After immunoblotting, membranes were 
stripped with 2% SDS and 0.7% β-mercaptoethanol and reprobed. 
 
Chromatin immunoprecipitation (ChIP) and qPCR 
ChIP experiments were performed following the protocol of Lee et al. (Lee et al., 2006) with 
several modifications. HFFs were grown in 15 cm dishes to ~90% confluency (~107 cells). 
Coverslips were placed in dishes to measure nuclear phospho-STAT1Tyr and IRF1 as controls 
and processed after fixation according to immunofluorescence assay methods below. HFFs were 
infected with RH ∆hxgprt or RH ∆rop16 parasites for four hours, or left uninfected, subsequently 
stimulated with 100 U/ml human IFN-γ for one hour, or left unstimulated, and fixed with 1% 
formaldehyde.  ~5x106 cells were used for each immunoprecipitation.  After cell lysis, DNA was 
sheared with a Bioruptor (Diagenode).  Immunoprecipitation was performed using an IP-Star 
(Diagenode) and 3 µg antibody (total STAT1α p91 (C-24) (Santa Cruz #345)). After DNA 
purification, quantitative PCR was performed using SYBR Green reagent (Kapa Biosciences) 
and a LightCycler 480 II real-time PCR machine (Roche).  Primers were designed to amplify 
STAT1 binding sites in the promoters of IFN-γ-induced genes as well as negative control regions 
in the promoters of genes unaffected by IFN-γ where STAT1 is not known to bind from 
published STAT1 ChIP-seq data (Robertson et al., 2007). Primer efficiencies were calculated 
using Real-time PCR Miner (Zhao and Fernald, 2005) and are listed with primer sequences in 
Table S1. Percent of total DNA bound by STAT1 was calculated by comparing qPCR results 
from immunoprecipitated and input samples. 
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Cell fractionation, STAT1 immunoprecipitation, and mass spectrometry 
Cells were fractionated into cytoplasmic, nuclear extract, and chromatin fractions using a Qiagen 
Qproteome Nuclear Protein Kit according to the manufacturer’s instructions. For Western blot 
analysis, samples were diluted in 2x reducing sample buffer and boiled before SDS-PAGE 
analysis and Western blotting as described previously (Rosowski et al., 2011). For STAT1 
immunoprecipitations, all fractions were diluted to have a final concentration of 150 mM NaCl. 
Rabbit α-total STAT1α p91 (C-24) (Santa Cruz #345) (~1 µg per 106 cells) was crosslinked to 
protein A Dynabead slurry (Life Technologies) (~20 µl per µg antibody) with 5 mM 
Bis(Sulfosuccinimidyl) suberate (BS3) (Pierce) as described previously (Niedelman et al., 2012). 
Samples were incubated with the bead-antibody slurry for 1.5 hr at 4C, rotating. Beads were 
then washed three times with IP wash buffer (10 mM HEPES-KOH pH 7.5, 150 mM NaCl, 0.5% 
NP-40/IGEPAL, 2.5 mM EGTA-KOH, 20 mM β-glycerophosphate), washed two times with 
HEPES-buffered saline (HBS), and boiled in 2x reducing sample buffer. Mass spectrometry 
analysis was performed as described previously (Niedelman et al., 2012). 
 
Reporter cell line construction  
The construction of a HEK293-pGreenFire1-GAS IFN-γ responsive reporter cell line has been 
previously described (Rosowski and Saeij, 2012).  pGreenFire1-ISRE and STAT1 cell lines were 
constructed by the same method from ISRE (TR016PA-1, 5’-CAGTTTCACTTTCCCTTT-3’) 
and STAT1 (TR015PA-1, 5’-GATTTCCGGGAAATGGGGAAGG-3’) vectors purchased from 
System Biosciences.  Briefly, lentivirus containing the vector was produced in 293FT cells and 
added to HEK293 cells (ATCC).  Cells containing the construct were selected with 750 g/ml 
Geneticin (Invitrogen), cloned by limiting dilution, and assayed for responsiveness to IFN-γ, 
IFN-β, TNF-α, and IL-4 (Fig. S2). 
 
Luciferase assay 
Luciferase assay of HEK293 pGF1-GAS, STAT1, or ISRE cells was done as previously 
described using the Promega Luciferase Assay System (Rosowski and Saeij, 2012).  For all 
experiments, 3.5-4x104 cells were plated in 96-well plates for at least four hours before any 
treatment or infection. Exact treatment and infection times varied slightly between experiments 
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but we obtained similar results for all time points and present averaged data with standard error. 
For ISRE experiments, cells were infected with RH parasites at an MOI~1.5 for three to five 
hours, and subsequently stimulated with 100 U/ml of either IFN-γ or IFN-β for 14-17 hours 
before lysis. For HDAC inhibitor experiments, cells were pretreated with HDAC inhibitors for 
one hour, infected with RH parasites at an MOI ~4 for one to three hours, and subsequently 
stimulated with 100 U/ml IFN-γ for 14-20 hours before lysis. For MG132 experiments, cells 
were pretreated with MG132 for 40 minutes, infected with RH parasites at an MOI~1.5 for three 
to five hours, and subsequently stimulated with 100 U/ml IFN-γ for 15 hours before lysis. HDAC 
inhibitors and MG132 were kept on the cells for the entire experiment. For cytochalasin D 
experiments, parasites were pre-teated with 1 µM cytochalasin D for 15 minutes, and 
cytochalasin D was kept on the parasites for the entire experiment. For mycalolide B 
experiments, parasites were pre-treated with 3 µM mycalolide B for 10 minutes then pelleted and 
resuspended in normal media. Pre-treated parasites were added to cells for one and a half hours 
and cells were subsequently stimulated with 100 U/ml IFN-γ for 18 hours before lysis. 
 
RT-qPCR 
For IFN-β infections, ~9x105 HFFs were grown in 6-well plates, infected with RH 1-1 parasites 
for four hours, and subsequently stimulated with 100 U/ml IFN-γ or IFN-β for 15-20 hours. The 
exact treatment was between 15 and 20 hours, varying slightly between experiments, but we 
obtained similar results for all time points and present averaged data with standard error. For 
CHX infections, 1.5-2x105 HFFs were grown in 12-well plates, pre-treated with CHX for 40 
minutes, infected with RH 1-1 for one hour, and stimulated with human IFN-γ for one hour.  
Cells were also left untreated and uninfected.  RNA was isolated using TRIZOL reagent 
(Invitrogen) according to the manufacturer’s instructions. Samples from the CHX experiments 
were cleaned and concentrated using RNeasy MinElute kit (QIAGEN).  Genomic DNA was 
removed from RNA preparations by DNase I treatment (Invitrogen), and first-strand cDNA was 
synthesized with SuperScript II or III RT (Invitrogen) and oligo-dT (Ambion), according to the 
manufacturer’s protocol.  Quantitative PCR was performed using SYBR Green reagent (Kapa 
Biosciences) and a LightCycler 480 II real-time PCR machine (Roche) according to the 
manufacturer’s instructions. For IFN-β experiments, genes specifically induced by IFN-β and not 
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by IFN-γ in human fibroblasts (RSAD2, MX2, OASL) were chosen from published microarray 
results (Indraccolo et al., 2007). Primer efficiencies were calculated using Real-time PCR Miner 
(Zhao and Fernald, 2005) and are listed with primer sequences in Table S2. Fold change was 
calculated using the ∆∆Ct method (Livak and Schmittgen, 2001), comparing expression to two 
different control genes that were not affected by Toxoplasma infection in previous gene 
expression analyses, ACTB and FE2L1 (Rosowski et al., 2011). Similar results were obtained 
from both normalizations.  
 
Immunofluorescence assay 
Immunofluorescence assay was performed as described previously (Rosowski et al., 2011). 
Quantification of nuclear signal was performed by randomly selecting at least 30 cells per 
condition and measuring the average signal intensity per nucleus using the NIS-Elements 
software and Hoechst dye to define nuclei. 
 
Plaque assay 
For native PAGE, ChIP, cell fractionation and immunoprecipitation, luciferase reporter, and RT-
qPCR experiments, a plaque assay was done to determine parasite viability and the actual MOI.  
One hundred parasites per well were added to confluent HFFs in a 24-well plate and were 
incubated undisturbed for 5-7 days at 37°C, and the number of plaques was counted. 
 
Statistical analyses 
Two sample t-tests, either paired or unpaired as applicable, were performed to assess statistical 
significance for ChIP-qPCR, luciferase reporter, and RT-qPCR assays. 
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Supplementary Figures 
 
Figure S1. Infection of cells for ChIP inhibits IRF1 expression and activates phosphorylation of STAT1. 
Coverslips were placed in 15 cm dishes prior to plating of HFFs for the ChIP assay. HFFs were infected with an RH 
or RH ∆rop16 strain for five hours, or left uninfected, with 100 U/ml IFN-γ added for the last hour of infection, or 
cells were left unstimulated. After fixation, coverslips were removed from the plates and the remaining HFFs were 
used for ChIP assays (Fig. 2). Coverslips were then permeabilized and stained for IRF1 and phospho-STAT1Tyr. The 
intensity of IRF1 (A) and phospho-STAT1Tyr (B) nuclear staining was quantified in at least 30 cells, regardless of 
infection status. Each dot represents one cell and black bars represent average staining. This experiment was 
performed for all three biological replicates of the ChIP assay with similar results, data shown are from one 
experiment. 
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Figure S2. Characterization of HEK293 reporter cell lines.  HEK293 luciferase reporter cell lines were left 
unstimulated or stimulated with 100 U/ml IFN-γ, 100 U/ml IFN-β, 20 ng/ml TNF-α, or 50 ng/ml IL-4. Cells were 
lysed 6-20 hours later and luciferase activity was measured and normalized to levels in unstimulated cells. A. 
HEK293 ISRE reporter cell line. Data and standard deviation from one experiment are shown. Unstimulated, IFN-γ, 
and IFN-β conditions have been repeated four times with similar results. B. HEK293 STAT1 reporter cell line. 
Average luciferase induction from three experiments is shown and error bars represent SEM. 
 
 
 
 
Figure S3. IF+b qPCR data normalized to +FE2L1. RT-qPCR data from one experiment from Fig. 3B are 
shown  normalized to two different control genes, ACTB and FE2L1. 
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Figure S4. CHX treatment prevents the expression of IF+-γ-induced IRF1. HFFs on coverslips were pre-treated 
with 50 µg/ml CHX for one hour and 40 minutes and subsequently stimulated with 100 U/ml IFN-γ for two and a 
half hours. Cells were also left untreated and/or unstimulated. Cells were fixed, permeabilized, and stained for IRF1 
(red) and with Hoechst dye (nucleus, blue). 
 
 
 
 
Figure S5. CHX qPCR data normalized to +FE2L1. RT-qPCR data from Fig. 5A,B are shown  normalized to a 
different control genes, FE2L1. 
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Table S1. STAT1 ChIP-qPCR primers. Primers were designed to amplify 150-180 bp regions of STAT1 binding 
sites in the promoters of IFN-γ induced genes as well as a negative control region where STAT1 is not known to 
bind. Published STAT1 ChIP-seq data was used to determine regions of STAT1 binding (Robertson et al., 2007). 
Primer pair efficiencies were calculated using Real-time PCR Miner (Zhao and Fernald, 2005). 
 
 
 
 
Table S2. RT-qPCR primers. Primers were designed to amplify 100-300 bp near the 3’ ends of genes, spanning 
intron-exon boundaries if possible. Primer pair efficiencies were calculated using Real-time PCR Miner (Zhao and 
Fernald, 2005). 
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Chapter 5. Discussion and Future Directions 
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The interplay between Toxoplasma and its host is a balancing act, not a battle  
 Host-pathogen interactions are often described as an arms race, with each side evolving 
better and better strategies to kill or evade the other. But for a parasite such as Toxoplasma 
gondii, which must persist within its host and form a chronic infection, this interaction is actually 
more of a balancing act. Toxoplasma partially evades the innate immune response of its host to 
survive and grow. At the same time, it cannot grow uncontrollably as it must convert to the slow-
growing chronic encysted bradyzoite stage, the only asexual stage of the parasite that can be 
transmitted to a new host through oral infection. Therefore, Toxoplasma must activate the host 
immune response to some extent and allow its host to survive. Another important factor to 
consider is the wide host range of Toxoplasma, comprising basically every warm-blooded 
animal, including both mammals and birds. Different animals have different complements of 
immune mechanisms that are known to act against Toxoplasma, including TLRs (Roach et al., 
2005), IRGs and GBPs (Hunn et al., 2011), and iNOS (Schneemann and Schoeden, 2006; 
Schneemann et al., 1993), and a successful Toxoplasma strain must be equipped with an array of 
effectors that can modulate the immune response of each host it encounters. For example, while 
in mice the IRGs are crucial for survival of an acute Toxoplasma infection, humans have a very 
restricted complement of these GTPases. Humans also do not possess active copies of TLR11 or 
12, the two main TLRs that activate NF-κB in response to Toxoplasma infection in mice. The 
genetic diversity of Toxoplasma is probably dictated by the different niches that these strains live 
within, and the population genetics and history of these niches. In North America and Europe, 
Toxoplasma strains are largely clonal, whereas in South America the genetic diversity of 
Toxoplasma is much greater (Minot et al., 2012). 
 A Toxoplasma strain therefore must possess a wide array of effector molecules that drive 
a partial evasion of the immune response in multiple hosts. Mice are the most well studied host 
of Toxoplasma, and one of the hosts contributing to the parasite niche and Toxoplasma evolution 
in North America and Europe, where the clonal type I, II, and III lineages predominate. In the 
mouse, the innate immune response to Toxoplasma consists of two main phases: 1) the activation 
of NF-κB and production of the cytokine IL-12 in macrophages and dendritic cells and 2) the 
production of the cytokine IFN-γ by T cells and NK cells and induction of IFN-γ responsive 
effector mechanisms in multiple cells types (Chap. 1 Fig. 3). In my work I have studied how 
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Toxoplasma modulates both phases of this response. We found that type II strains carry an active 
copy of the novel dense granule protein GRA15, which activates the host innate immune 
response by directly activating NF-κB, and expression of GRA15 leads to increased cytokine 
production and decreased parasite growth early in infection (Chap. 2 Figs. 3 and 9). Conversely, 
type I and III strains of Toxoplasma carry an active copy of the rhoptry kinase ROP16 which 
activates host STAT3, 5, and 6 transcription factors, and acts in opposition to GRA15 to promote 
alternative activation of macrophages and decreased host inflammation (Jensen et al., 2011, 
2013). In the second phase of the innate immune response, the transcriptional response to IFN-γ, 
some strains of Toxoplasma can directly inhibit the activity of a major IFN-γ-induced 
toxoplasmacidal mechanism, the IRGs, through different combinations of the polymorphic 
effectors ROP18 and ROP5 (Behnke et al., 2012; Fleckenstein et al., 2012; Niedelman et al., 
2012). However, Toxoplasma infection can also inhibit the upregulation of IFN-γ-induced genes 
through direct inhibition of the activity of the transcription factor STAT1, and we found that all 
three clonal lineages can equally inhibit STAT1 transcriptional activity (Chap. 3 Fig. 5) and have 
further characterized the mechanism by which this inhibition occurs (Chap. 4). Further research 
on the mechanism of action of all of these effectors and their functions in vivo will provide 
insights into the strategies each Toxoplasma strain has evolved to achieve this balancing act 
between the host and the pathogen. 
 
Elucidating the role of GRA15 in vivo 
 One major question that is still unanswered is the full role of GRA15 in vivo. We found 
that the expression of GRA15 in type II parasites increases host pro-inflammatory cytokine 
secretion and decreases parasite growth early in infection (days 1-5), but later in infection these 
differences seem to disappear, as mouse survival after infection with either a type II or type II 
∆gra15 parasite was virtually identical (Chap. 2 Fig. 9). We hypothesize that early in infection, 
when the first parasites infect host cells, the presence of GRA15 in type II parasites activates NF-
κB earlier than strains that do not carry an active copy of GRA15, leading to an early difference 
in IL-12 and IFN-γ levels and therefore host control of parasite growth (Fig. 1). Later in 
infection, after parasites have undergone multiple rounds of growth, host cell lysis, and 
reinvasion, multiple PAMPs and DAMPs will be released independently of the presence of 
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GRA15, including the parasite protein profilin which activates TLR11 and 12 (Fig. 1). These 
PAMPs and DAMPs will strongly activate NF-κB in many cells, not just parasite infected cells, 
allowing the host to initiate a strong innate immune response and control growth of any parasite 
strain. 
 
Figure 1. Model of the effect of GRA15 on IL-12 production in vivo. Illustration by Mariane Melo. 
 
 However, it is likely that GRA15 has other effects in vivo that we have not yet studied. 
For example, NF-κB upregulates the expression of chemokines and chemokine receptors and 
promotes cell migration (Newton and Dixit, 2012). It is possible that GRA15 increases migration 
of its host cell, helping the parasite to move throughout the host, a process that is necessary for 
Toxoplasma to form tissue cysts in muscle and brain tissue, regions far removed from the initial 
infection site, either the intraperitoneal cavity or the small intestine (Tardieux and Ménard, 
2008). Studies in the lab have not found any differences in the number of cysts formed in the 
brain in type II versus type II ∆gra15 chronic infections (Kirk Jensen, unpublished). This implies 
that GRA15 does not affect the ability of Toxoplasma to cross the blood-brain barrier. But, 
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GRA15 might still affect cell migration during other stages of infection. I did find a difference in 
the number of type II versus type II ∆gra15 parasites in the lung and spleen after an 
intraperitoneal injection, but it is unclear whether this is due to differences in growth or 
migration (Chap. 2 Fig. S8). I briefly tried in vitro cell migration assays, and I think that 
optimizing these assays and testing the effect of GRA15 on cell migration in different cell types 
at least in vitro could be an interesting follow-up study. GRA15 might also play a role after a 
chronic infection has been established, possibly in reactivation of cysts or in the level of 
inflammation. To investigate this phase, I infected mice with a sublethal dose of either type III or 
type III GRA15II parasites to allow them to establish a chronic infection. I then 
immunosuppressed the mice by treating them with dexamethasone, following an established 
protocol (Saeij et al., 2005b), but I did not detect any parasite reactivation as measured by whole 
body luciferase imaging. However, the mice did become sick and had enlarged abdomens. I did 
sacrifice these mice and dissect out their brains for histology but did not follow up on this 
experiment as I was not convinced that there was any parasite reactivation, but rather the mice 
likely suffered from a bacterial infection. I am also not sure about the choice of dexamethasone 
as an immunosuppressant as its mode of action is through the inhibition of NF-κB signaling 
(Wissink et al., 1998), which could possibly mask any effects of GRA15 on NF-κB.   
 Toxoplasma can infect a wide range of cell types in vivo, including macrophages, 
dendritic cells, neutrophils, NK cells, T cells, and B cells. It is possible that GRA15 has 
important effects only within some of these cells, and it would be interesting to look at 
differences in the numbers of cells infected and the cytokines secreted specifically by each cell 
type after infection with a type II versus a type II ∆gra15 strain. Cell-type specific effects could 
be either cell-intrinsic or -extrinsic. In terms of cell-autonomous responses, we initially found 
that GRA15 affected growth of parasites in vitro in HFFs, but not MEFs (Chap. 2 Fig. S8). At 
the time, these experiments were repeatable and performed with multiple clones of type II 
∆gra15 and type I GRA15II parasites and heterologous controls expressing the HXGPRT 
selection marker. However, later, neither I nor others in the lab were able to recapitulate these 
results. Whether this is due to differences in the passage or age of host cells, media composition, 
growth conditions, or something else, is unknown, but as of now we cannot attribute any effects 
of GRA15 in vivo to such a growth defect. 
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 Work by Kirk Jensen has shown that GRA15, through its activation of NF-κB, and 
another Toxoplasma effector, ROP16, which activates STAT3 and 6, oppositely regulate many 
of the same genes (Jensen et al., 2011). In an oral infection model, expression of ROP16 
decreases infection-induced small intestinal inflammation and increases mouse survival, but 
interestingly, this effect is dependent on the co-expression of GRA15 (Jensen et al., 2011, 2013). 
How the combined action of these antagonistic effectors achieves this infection outcome is 
unknown. It might be that the presence of both effectors creates a general balance between pro- 
and anti-inflammatory cytokines and effectors in the host. By itself, ROP16 might decrease 
inflammation too much, and the opposite might be true of GRA15. It is also unknown whether 
the effects of these proteins that achieve this balance occur cell-autonomously within the infected 
cell or through secretion of cytokines and chemokines that affect uninfected cells. We do know 
that ROP16 inhibits GRA15-induced NF-κB activity (Chap. 2 Fig. S9), but this doesn’t seem to 
be through an independent effect of ROP16 on NF-κB, as infection of cells with a type I strain, 
which possesses an active copy of ROP16, does not inhibit TNF-α- or LPS-mediated activation 
of NF-κB (Chap. 2 Fig. 2). Perhaps these proteins directly interact within the cell, or perhaps 
GRA15 activates NF-κB by a fundamentally different mechanism than TNF-α or LPS. This latter 
possibility seems unlikely as GRA15-mediated activation of NF-κB follows the canonical NF-κB 
activation pathway through the IKK complex and proteasome-mediated degradation of IκBα 
(Chap. 2 Fig. 6,7). It might be that continuous activation of NF-κB by GRA15, as opposed to 
transitory activation by TNF-α or LPS, is more susceptible to ROP16-induced STAT3 and 
STAT6 downregulation. 
 One question that follows is, if these effectors work so well together to promote both 
parasite and host survival in the mouse oral infection model, why do none of the successful 
clonal lineages have active copies of both? As these strains arose from crosses between parental 
strains (Boyle et al., 2006), it is almost certain that siblings of these strains carried both effectors, 
yet somehow were not successful. A possible answer to this question is that although GRA15 
and ROP16 together decrease host inflammation and increase host survival, they also decrease 
parasite numbers in the intestine, and this might decrease later parasite transmission. One other 
answer is that GRA15 and ROP16 are not required for host control of intestinal infection in all 
mouse strains, as type II oral infection of A/J mice does not result in intestinal pathology (Jensen 
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et al., 2013). It seems likely then that the wild hosts that make up the Toxoplasma niche in North 
American and Europe have immune responses that are more similar to A/J mice than B6 mice, 
the mouse strain in which these effectors synergistically decrease inflammation.  
 In fact, we don’t know what host niche type II parasites, which express an active copy of 
GRA15, co-evolved to live within, and it is possible that GRA15 has much greater effects on 
parasite survival and transmission in hosts other than the mouse, such as rats or birds. While 
humans are usually a dead-end host in the parasite life cycle, human infections are important to 
consider from a medical standpoint, and type II parasites are the strain commonly found in 
human infections (Dardé, 2004). These strains therefore might have evolved to live in a species 
that has a similar immune system to humans. Additionally, based on our model of how GRA15 
affects early parasite growth through induction of IL-12 (Fig. 1), we hypothesize that GRA15 has 
a greater effect on the immune response in hosts, such as humans, that do not have functional 
copies of TLR 11 and 12. These two TLRs recognize the most prominent Toxoplasma TLR 
ligand, profilin, and strongly activate NF-κB and IL-12 secretion in response (Koblansky et al., 
2013; Yarovinsky et al., 2005). Mice that are doubly deficient in TLR 11 and 12 have recently 
been generated and are extremely susceptible to Toxoplasma infection, even with a type II strain 
ME49 that possesses an active copy of GRA15 (Koblansky et al., 2013). Based on our model, we 
hypothesize that infection of these mice with a type II ∆gra15 strain would result in even greater 
morbidity and mortality. Additionally, in humans, TNF-α signaling, which activates NF-κB, is a 
much more important pathway for combating Toxoplasma infections (Janssen et al., 2002), as 
opposed to in mice where IFN-γ is the main mediator of resistance (Suzuki et al., 1988).  
 
What role does Toxoplasma’s inhibition of STAT1 signaling play in vivo? 
 We also don’t know exactly what role the ability of Toxoplasma strains to inhibit IFN-γ-
induced transcription plays in vivo. Mice deficient in IFN-γ, the IFN-γ receptor, STAT1, and 
IRF1 are acutely susceptible to Toxoplasma infection (Khan et al., 1996; Lieberman et al., 2004; 
Scharton-Kersten et al., 1996; Suzuki et al., 1988; Yap and Sher, 1999). However, mice deficient 
in single downstream IRG effectors, Igtp (Irgm3) (Taylor et al., 2000) or LRG-47 (Irgm1) 
(Collazo et al., 2001) are as susceptible as IFN-γ deficient mice in the acute phase. If the IRGs 
are responsible for the majority of IFN-γ induced killing of Toxoplasma, why do Toxoplasma 
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strains that carry active copies of ROP18 and ROP5, which directly inhibit IRG activity, also 
have an effector to inhibit the expression of these and other IFN-γ induced genes? For one thing, 
not all animals possess such a diversity of IRG effectors, but the IFN-γ response might still be 
important for host resistance to Toxoplasma in these species. When the Toxoplasma STAT1 
inhibitor is identified, it will be interesting to determine the phenotype in mice of a parasite that 
is deficient in this inhibitor but still expresses ROP18 and ROP5. There are several reasons why 
all of these effectors might also be required in mice. A specific and limited number of copies of 
ROP18 and ROP5 protein are directly injected into the host cell upon infection and since ROP5 
directly interacts with the IRGs and is hypothesized to act as a scaffold, keeping IRGs in their 
monomeric form (Fleckenstein et al., 2012; Niedelman et al., 2012), perhaps it can only inhibit a 
limited number of IRG proteins. The STAT1 inhibitor might then be required to keep the 
expression of these proteins limited. ROP18 and ROP5 might also be most important in cases 
where Toxoplasma infects a cell that has already been exposed to IFN-γ and already upregulated 
the IRGs. It is possible as well that, at least during the acute phase of infection, these factors act 
redundantly.  
 The STAT1 inhibitor also might play a much larger role in survival of Toxoplasma 
during the chronic phase of infection. While the IRGs are the main effector mechanism against 
Toxoplasma infection during the acute stage of infection, in the chronic phase they appear to play 
a more limited role in mouse survival, while STAT1 is still critical (Collazo et al., 2002). To 
establish and maintain a chronic infection, Toxoplasma must evade the adaptive immune 
response, which is largely driven by the presentation of antigen to T cells on MHC molecules, 
and by inhibiting STAT1 activity Toxoplasma also inhibits MHC molecule expression. 
Toxoplasma also inhibits other IFN-γ induced mechanisms such as iNOS and NO production that 
are most important during the chronic phase of infection (Scharton-Kersten et al., 1997; Seabra 
et al., 2002). However, all of our studies and the studies of others have focused on the ability of 
Toxoplasma tachyzoites to inhibit IFN-γ signaling. It would be interesting to determine whether 
Toxoplasma bradyzoites, which are predominant during chronic infections, can also inhibit 
STAT1-mediated gene expression. 
 As with GRA15, we also don’t know whether the presence of this STAT1 inhibitor is 
more or less important in different cell types in vivo. IRGs are expressed by and can kill 
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Toxoplasma in a variety of cell types, including macrophages (Butcher et al., 2005b), fibroblasts 
(Niedelman et al., 2012), and astrocytes (Halonen et al., 2001), and expression in both 
hematopoietic and non-hematopoietic compartments is required for mouse resistance (Collazo et 
al., 2002). In contrast, other IFN-γ induced effector mechanisms are more restricted in the cells 
types in which they are expressed. MHC class II molecule expression is restricted to professional 
antigen presenting cells, including macrophages, dendritic cells, and B cells, and iNOS 
expression is only required in hematopoietic cells to help control Toxoplasma infections (Yap 
and Sher, 1999).  
 This STAT1 inhibitor may also be more or less important in hosts other than the mouse. 
In humans, for example, the IFN-γ response is not as important for control of Toxoplasma 
infection as in mice. For one thing, humans do not have many of the IFN-γ induced effector 
mechanisms that control parasite growth in the mouse. Humans lack both the diverse 
complement of IRGs that mice have (Hunn et al., 2011), and the strong induction of nitric oxide 
by macrophages upon IFN-γ treatment (Schneemann and Schoeden, 2006; Schneemann et al., 
1993). It is therefore not surprising that human patients that carry mutations in the IFN-γ receptor 
are not susceptible to Toxoplasmosis, whereas they are more susceptible to infections of 
Salmonella (Janssen et al., 2002). 
 
What happens after STAT1 D+A binding? 
 The mechanism by which Toxoplasma inhibits STAT1 transcriptional activity remains 
unknown. However, we have narrowed down where in the activation pathway a Toxoplasma 
effector acts. Toxoplasma infection does not inhibit STAT1 DNA binding at promoter target 
sequences in host cells (Chap. 4 Fig. 2A), it must act downstream of this step. However, it is not 
very well described in the literature what steps after STAT1 binding are required for productive 
gene transcription. Therefore it is very difficult to test further specific steps of activation to see if 
Toxoplasma infection inhibits them. For example, how does STAT1 recruit general transcription 
factors and RNA polymerase II? Could Toxoplasma prevent the recruitment of RNA polymerase 
II by STAT1, or are there primary response genes, such as IRF1, whose expression Toxoplasma 
inhibits, that already have RNA polymerase II basally bound to their promoters? It is probably 
worthwhile testing the binding of RNA polymerase II to the promoters of both primary and 
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secondary IFN-γ response genes in uninfected and infected cells, both in unstimulated and IFN-γ 
stimulated conditions. While Toxoplasma does not require histone deacetylase activity to inhibit 
STAT1 signaling, we could also test whether Toxoplasma infection dysregulates specific histone 
methylation marks that are associated with active genes, such as H3K4me3 at transcription start 
sites and H3K36me3 in gene bodies towards 3’ ends (Barski et al., 2007).  
 One hypothesis for how Toxoplasma inhibits STAT1-mediated transcription is by 
preventing the association of STAT1 with necessary co-activators. For example, it has been 
proposed that Toxoplasma inhibits the recruitment of the chromatin remodeler BRG-1 to STAT1 
target genes such as MHC class II genes and CIITA (Lang et al., 2012). However, chromatin 
remodeling, and BRG-1 specifically, is not necessary at every IFN-γ induced locus, including at 
the IRF1 promoter (Wang et al., 2011). In general this seems to be the case for all of the co-
activators that have been shown to bind to STAT1 and enhance IFN-γ-induced gene expression, 
including CBP/p300 (Zhang et al., 1996), MCM5 (Zhang et al., 1998), Nmi (Zhu et al., 1999), 
and BRCA1 (Ouchi et al., 2000). It is unknown whether these factors 1) are actually required for 
STAT1 activity, they do not just augment STAT1 activity, 2) are expressed and active in all IFN-
γ responsive cell types, and 3) act to increase STAT1-mediated transcription of all target genes, 
not just a select few. To be a co-activator that Toxoplasma could modulate to inhibit STAT1 
transcriptional activity, all of these criteria must be met, as Toxoplasma infection can inhibit 
STAT1 activity directly, regardless of the locus, as shown by our experiments with stable 
STAT1 reporter cell lines (Chap. 3 Fig. 5), and infection can inhibit IFN-γ induced gene 
expression in multiple disparate cell types, including human embryonic kidney cells (Chap. 3 
Fig. 5), human fibroblasts (Chap. 3 Fig. 1), and mouse macrophages (Chap. 3 Fig. 6). It is more 
likely that Toxoplasma directly prevents the association of STAT1 with more general factors, 
either RNA polymerase II or the Mediator complex. However, recently, the CDK8 module of the 
Mediator complex was shown to be responsible for the serine phosphorylation of STAT1 
(Bancerek et al., 2013), which is not inhibited by Toxoplasma infection (Chap. 3 Fig. 3), 
suggesting that its recruitment is not inhibited. 
 One experiment that might provide a clue to both the mechanism of STAT1 
transactivation and the inhibition of STAT1 activity by Toxoplasma is the treatment of a STAT1 
reporter cell line with MG132, a proteasome inhibitor (Chap. 4 Fig. 6). Treatment with this 
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inhibitor alone, in the absence of infection, potently inhibits IFN-γ induced STAT1 mediated 
transcription. While cells can undergo apoptosis after extended treatment with this drug and this 
could be a possible explanation for a decrease in gene expression, the proteasome has also been 
implicated in transcriptional activation by several transcription factors (Geng et al., 2012; 
Lipford et al., 2005). One model that explains this dependence is that each time a transcription 
factor binds to its cognate sequence in the DNA, it can recruit one round of general transcription 
factors and RNA polymerase II. Then it is somehow “used up” and must be removed from the 
DNA and be degraded before another round of transcription factor can bind and initiate another 
round of transcription. If this model is correct, it seems clear that Toxoplasma infection blocks 
this recycling (Fig. 2).  
 
Figure 2. Model of STAT1 recycling and inhibition by Toxoplasma. STAT1 binds to target sequences in the 
DNA (1), recruiting general transcription machinery and RNA polymerase II (2). STAT1 must then be degraded by 
the proteasome (3), so that a new round of STAT1 can bind to initiate a new round of transcription (4). I hypothesize 
that a Toxoplasma effector inhibits this proteasome-mediated removal of STAT1 from the DNA and degradation. 
 
 Multiple lines of evidence point to the fact that STAT1 is actually more bound to DNA 
after infection plus IFN-γ treatment than after IFN-γ treatment alone. First, we observe higher 
levels of IFN-γ-induced tyrosine phosphorylated STAT1 in the nucleus after infection (Chap. 3 
Fig. 2). Second, in my STAT1 ChIP experiments, not only did Toxoplasma infection not inhibit 
IFN-γ induced STAT1 binding, it actually increased IFN-γ induced STAT1 binding at three loci 
(IRF1, SOCS3, and ICAM1), even when the infecting strain lacked ROP16 and therefore did not 
induce STAT1 binding with infection alone (Chap. 4 Fig. 2A). Third, in nuclear and chromatin 
isolations from uninfected and infected cells stimulated with IFN-γ, we observed this same 
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phenomenon: the amount STAT1 found in the chromatin fraction by Western blot was greatly 
increased by infection combined with IFN-γ compared to IFN-γ alone (Chap. 4 Fig. 2B, C). 
Mass spectrometry results from STAT1 IPs from these fractions gave the same result, the 
percentage of total STAT1 peptides that were found in the chromatin fraction was greater upon 
infection plus IFN-γ treatment compared to IFN-γ treatment alone (Chap. 4 Fig. 2D). Another 
group has observed more IFN-γ induced STAT1 binding to DNA after Toxoplasma infection in 
an EMSA assay as well (Schneider et al., 2013). All of these lines of evidence suggest that 
infection plus IFN-γ induces a more stable STAT1-DNA interaction than IFN-γ alone, and 
supports the hypothesis that Toxoplasma is somehow inhibiting STAT1’s disassociation with the 
DNA. It will be very interesting to test if STAT1 is ubiquitinated upon IFN-γ treatment and if 
Toxoplasma modulates this ubiquitination. Other experiments could directly measure whether 
STAT1 recycling is occurring, and whether multiple rounds of STAT1 binding and RNA 
polymerase II recruitment are occurring. Additionally, all of my experiments have always been 
done with continuous IFN-γ stimulation, but if Toxoplasma is blocking STAT1’s dissociation 
from DNA, differences in STAT1 bound to DNA might be even more pronounced in cells that 
are only exposed to a pulse of IFN-γ.  
 In this model of proteasome-dependent recycling of transcriptional activators, these 
activators must be somehow marked as “used” to signal for their degradation (Geng et al., 2012). 
This signal is often a phosphorylation event, and many transcription factors have residues that 
are phosphorylated within their transactivation domains (TADs), and their TADs partially 
overlap with a degron sequence (Salghetti et al., 2000). One of these factors that is known to 
have an overlapping TAD and degron is the STAT family member, STAT5. I therefore think that 
if STAT1 is being recycled, the mark that is most likely to signal for STAT1’s degradation is its 
serine phosphorylation at residue 727 within its TAD. This phosphorylation can only occur when 
STAT1 is associated with DNA (Sadzak et al., 2008), and as mentioned previously, it can be 
phosphorylated by the CDK8 protein within the Mediator complex (Bancerek et al., 2013). 
However, CDK8 is present in a distinct module of the Mediator complex, and the CDK8 
complex has been reported to change the conformation of the Mediator complex, preventing its 
association with RNA polymerase II (Elmlund et al., 2006). In my model, however, these two 
reports do not necessarily conflict. The CDK8 module could bind only after RNA polymerase II 
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has been recruited and is elongating along and transcribing the DNA, at which point CDK8 
would mark STAT1 for degradation. 
 The phosphorylation of this serine residue has long been implicated in the full 
transcriptional activation of STAT1 target genes, as STAT1 S727A mutants induce decreased 
gene expression upon IFN-γ treatment (Varinou et al., 2003). It has been hypothesized that the 
serine phosphorylation is required for STAT1 to recruit co-activators and/or RNA polymerase II, 
however, how this would occur is still unknown. It could be that by allowing STAT1 to more 
efficiently recycle off of the DNA, the serine phosphorylation would achieve the same result—
greater association of STAT1 with co-activators and RNA polymerase II—as new rounds of 
STAT1 would be able to re-establish these interactions for new rounds of transcription. If this 
STAT1 recycling is occurring, Toxoplasma infection is blocking STAT1 recycling, and the 
serine phosphorylation of STAT1 is a signal for degradation, we can then ask how Toxoplasma is 
blocking this recycling. Infection does not block STAT1 serine phosphorylation (Chap. 3 Fig. 3), 
but perhaps it blocks STAT1 ubiquitination, association of STAT1 with a ubiquitin E3 ligase, or 
association of STAT1 with some other degradation factor. It would be interesting to test what 
happens to STAT1 serine phosphorylation after only a pulse of IFN-γ. If this model is correct, I 
would hypothesize that in uninfected cells this phosphorylation would decrease over time, as 
STAT1 is degraded off of the DNA, but that in infected cells, it would remain indefinitely as 
STAT1 is kept on the DNA and not degraded.  
 
Does eospora caninum modulate the IF+-γ response? 
 eospora caninum, a parasite species also in the phylum Apicomplexa and therefore 
related to Toxoplasma, does not inhibit the expression of IRF1 in host cells after IFN-γ treatment 
(Kim et al., 2007a) (Appendix 3 Fig. 1A). However, results from experiments with eospora in 
the STAT1 reporter cell lines that I made have been hard to interpret. Infection of these lines 
with eospora at a lower MOI does not seem to inhibit the expression of IFN-γ-induced 
luciferase, giving similar results to the IRF1 IF experiments. In contrast, at these lower MOIs 
Toxoplasma can inhibit STAT1 activity in these lines to some extent. However at much higher 
MOIs, sometimes I have seen inhibition of these reporters by eospora. It is unclear, however, 
how much cell death and cell lysis is occurring in these experiments, as these would also 
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decrease luciferase expression. Ideally, these experiments would be repeated with multiple MOIs 
of eospora and with cell viability or cell death assays done in parallel. One hypothesis that 
could explain possible differences between IRF1 IF results and STAT1 reporter results is that 
eospora activates IRF1 through some other transcription factor, such as NF-κB, just as 
Toxoplasma type II strains do (Chap. 3 Fig. 1). However, in unstimulated cells, I do not observe 
such IRF1 activation (Appendix 3 Fig. 1A), and eospora infection does not activate our NF-κB 
reporter cell line (Appendix 3 Fig. 2) or NF-κB p65 nuclear translocation (Herman et al., 2007). 
Additionally, in a co-infection with the type I Toxoplasma RH strain and eospora, RH still 
potently inhibits IFN-γ-stimulated IRF1 expression, again suggesting that all of this expression is 
induced by STAT1 and that eospora does not induce IRF1 through some other transcription 
factor (Appendix 3 Fig. 1B). Therefore, the most likely explanation is that eospora does not 
inhibit STAT1 activity and that any inhibition I have observed in the STAT1 reporter cell lines is 
due to cell lysis or death or the presence of anti-inflammatory cytokines in my eospora parasite 
preparations that are also transferred into the well and have an inhibitory effect on STAT1-
mediated expression at high concentrations. Therefore, in thinking about screens and selections 
for the Toxoplasma effector that inhibits STAT1 activity, we could complement eospora with 
Toxoplasma genes instead of mutagenizing Toxoplasma itself. This could be done with either of 
the Toxoplasma cosmid libraries that are available (http://toxomap.wustl.edu/cosmid.html), or by 
testing possible candidate genes. 
 
What is the Toxoplasma STAT1 inhibitor? 
 Our data indicates that the Toxoplasma effector(s) responsible for inhibiting IFN-γ-
stimulated gene expression is not secreted into the host cell upon infection, as parasites treated 
with cytochalasin D or mycalolide B, which attach to host cells and secrete their rhoptry contents 
but do not invade, cannot inhibit this response. We therefore have three main hypotheses for the 
identity of this effector: 1) a protein that is secreted upon invasion but needs to be activated 
somehow on the outside of a parasitophorous vacuole (PV), 2) a small molecule or metabolite 
that diffuses or is transported into the host cell through the parasitophorous vacuole membrane 
(PVM), or 3) a protein that Toxoplasma secretes into the host cell post-invasion across the PVM. 
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 To investigate this first possibility, I pre-infected cells with eospora, which doesn’t 
inhibit IFN-γ induced IRF1 expression but forms a PV very similar to Toxoplasma, and then 
added Toxoplasma parasites pre-treated with mycalolide B. In this scenario, we expect that any 
proteins secreted by Toxoplasma into the host cell that normally traffic back to the outside of the 
PV and associate with the PVM will associate with the eospora PVM. However, this 
hypothesis should be tested in the future by staining these eospora PVs for a Toxoplasma 
protein such as ROP2 that is known to be secreted into the host cell and then traffic back to the 
outside of the PV (Reese and Boothroyd, 2009; Sinai and Joiner, 2001). I then stimulated these 
eospora-infected, Toxoplasma-injected cells with IFN-γ. In preliminary results, in both HFFs 
stained for IRF1 expression and in a STAT1 reporter cell line, I did not observe any inhibition of 
IFN-γ induced gene expression in these conditions, suggesting that the Toxoplasma effector is 
not a protein that is secreted upon infection that requires the presence of a PV for its activity. 
However, it is also possible that there are unknown fundamental differences in the composition 
of eospora and Toxoplasma PVMs. 
 One reason why we think that the Toxoplasma effector could be a small molecule or 
metabolite is the relatively recent finding that STAT1 activity can be controlled by nuclear 
receptors (Lee et al., 2009; Li et al., 2011). Nuclear receptors regulate transcription and are 
activated by a variety of small molecule ligands, the most well characterized of which are 
steroids, through binding of these ligands to a specific receptor domain (Glass and Saijo, 2010). 
These receptors often interact at promoters with other transcription factors or co-repressor and 
co-activator complexes (Glass and Saijo, 2010). STAT1 activity can be inhibited by ligands for 
LXR, RXR, and PPAR nuclear receptors, through the modulation of STAT1 phosphorylation, 
STAT1 DNA binding, or the recruitment of SUMO E3 ligase complexes to STAT1 (Lee et al., 
2009; Li et al., 2011). It is still unclear though whether these pathways are present in all cells or 
only in inflammatory cells, such as macrophages and astrocytes. I did some preliminary 
experiments in HFFs, and found that several LXR agonists did not inhibit IRF1 expression after 
treatment with 100 U/ml of IFN-γ, the concentration of IFN-γ that I generally use in all of my 
assays. However, in one experiment with only 10 U/ml of IFN-γ and a high concentration of 
LXR ligand, quantitation of IRF1 in the nucleus did suggest that STAT1 activity was at least 
somewhat inhibited. Another reason that this hypothesis is appealing is that depending on its size 
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and structure, the activating ligand from Toxoplasma might be able to passively diffuse through 
the PVM. It might also be transported into the host cell through a pore complex. Recent work in 
our lab has discovered a Toxoplasma protein, GRA17, that seems to comprise at least part of a 
pore in the PVM that allows small molecules to get into the PV from the host cell (Dan Gold, 
submitted). However, a Toxoplasma strain that is deficient in this gene still inhibits IFN-γ 
induced IRF1 expression, making the possibility that the Toxoplasma effector is a secreted small 
molecule slightly less likely (Appendix 4 Fig. 3).  
 Currently, I believe that the best hypothesis we have for the identity of this Toxoplasma 
effector is that it is a protein that is secreted into the host cell post-invasion, most likely from the 
dense granules. Recently, a dense granule protein, GRA16, was shown to accumulate in the host 
nucleus with increasing intensity over time post-invasion (Bougdour et al., 2013), and a PEXEL 
secretion motif known from malaria parasites was shown to also be present in Toxoplasma 
proteins (Hsiao et al., 2013). The main problem with this hypothesis is that I observe strong 
inhibition of IFN-γ induced IRF1 expression quite early after infection, after less than three 
hours (Chap. 3 Fig. 1), whereas nuclear accumulation of GRA16 does not peak until 15-24 hours 
after infection. GRA15, another protein that contains a PEXEL motif and that we suspect is 
secreted into the host cell via this mechanism, requires four hours of infection to induce 
observable levels of NF-κB p65 nuclear translocation (Chap. 2 Fig. S4). While in an infection 
time course the average inhibition of IFN-γ induced IRF1 nuclear protein does increase over time 
(Fig. 3), these infections were not synchronized and I believe this increase in inhibition over time 
is at least partially due to some percentage of parasites infecting host cells after IFN-γ was added 
in the earlier time points. As early as two hours and five minutes after infection, ~1/3 of infected 
cells have the same level of inhibition as the maximal average inhibition seen at 26 hours after 
infection (Fig. 3), suggesting that the amount of effector in the host cell at this early time point is 
sufficient to fully inhibit STAT1 activity. It could be either that only a small amount of the 
protein secreted into the host cell is enough to inhibit STAT1 activity or that this inhibitor is very 
highly expressed and a lot of it is secreted into the host cell during only two hours of infection. 
Depending on how confident we are in this hypothesis, that the Toxoplasma effector is a secreted 
dense granule protein, we can easily form a list of candidate genes using two main criteria: 1) 
high and non-variable mRNA expression, since while rhoptry proteins are only secreted into the 
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host cell upon invasion and their expression is synchronized with the Toxoplasma cell cycle, 
dense granule proteins are continuously secreted and therefore continuously expressed, and 2) 
contains a PEXEL motif, signaling for secretion of the protein into the host cell post-invasion. 
With the available Toxoplasma cosmid libraries, it would be relatively easy to express cosmids 
containing these genes in eospora, which does not inhibit IFN-γ induced IRF1 expression, and 
screen for this dominant inhibition phenotype. However, preliminary results suggest that 
eospora does not secrete proteins into the host cell post-invasion; in one experiment, cells 
infected with eospora expressing a transgenic copy of GRA16 did not accumulate GRA16 in 
their nuclei. We would therefore need to first define the composition of this protein translocation 
machinery and express it in eospora. It is possible that expression of this Toxoplasma effector 
alone in mammalian cells would inhibit STAT1 activity, as transient expression of GRA15 in 
HeLa cells activates NF-κB p65 nuclear translocation. It could be possible then to clone the 
coding regions of these candidate genes in mammalian expression vectors, directly transfect 
them into human or mouse cells, and measure their ability to inhibit IFN-γ-induced gene 
expression. 
 
Figure 3. Toxoplasma can inhibit IF+-γ-induced IRF1 expression as early as two hours and five minutes after 
infection. HFFs on coverslips were infected with RH Toxoplasma parasites for the indicated lengths of time and 
subsequently stimulated with 100 U/ml IFN-γ for two hours. Cells were then fixed, permeabilized, and stained for 
IRF1. The intensity of IRF1 in the nuclei of host cells was quantified and is plotted. Each dot represents one cell. 
Red bars represent average IRF1 levels and error bars represent standard deviation. 
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Unbiased methods to determine the mechanism of inhibition and/or the Toxoplasma 
effector 
 Exactly how STAT1 initiates transcription of downstream target genes is unknown, and 
while I hypothesize that Toxoplasma inhibits the activity of STAT1 by preventing it’s recycling 
on and off of DNA, this is still purely speculation, and there are no reports in the literature that 
describe this STAT1 recycling even in uninfected cells. Whatever the mechanism of inhibition 
is, it is likely to directly inhibit STAT1 activity, but determining how an unknown Toxoplasma 
effector inhibits STAT1 activity is virtually impossible when the mechanism of transactivational 
activity of STAT1 is poorly described. Therefore, in future studies, we would like to pursue more 
unbiased methods to discover both host cell mechanisms that regulate STAT1 activity and 
Toxoplasma effectors that are necessary for the inhibition of STAT1 activity. 
 
Immunoprecipitation and mass spectrometry 
 One method that I have been undertaking is the immunoprecipitation of STAT1 and mass 
spectrometry of co-immunoprecipitating proteins. With this method I can compare what proteins 
are pulled down with STAT1 in both uninfected and infected cells and in unstimulated and IFN-γ 
stimulated conditions. Ideally, we would detect either Toxoplasma or host cell proteins that 
specifically associate with STAT1 in certain conditions. For example, we might find a co-
activator that specifically interacts with STAT1 in uninfected cells but that is depleted in infected 
cells. Alternatively, there could be a negative inhibitory repressor that specifically interacts with 
STAT1 in infected cells. 
 Initially, I tried immunoprecipitating STAT1 from whole cell extracts. While this was 
successful in terms of pulling down STAT1, I was never able to detect reported STAT1 
interactors, such as p300/CBP or BRG-1, by Western blot, and there was still a lot of STAT1 
remaining in flow through samples, indicating that there is a high level of STAT1 expressed in 
cells. Because of this, I think that by IP-ing total STAT1 from a whole cell extract, I was pulling 
down mostly cytoplasmic STAT1. But to look for STAT1 interactors that affect it’s activity on 
the DNA, I am most interested in the DNA-bound fraction of STAT1. I tried one IP using an 
antibody against the tyrosine phosphorylated form of STAT1, instead of total STAT1, which 
should specifically be in the nucleus, but this antibody is raised against a short peptide of STAT1 
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containing the phospho-tyrosine residue and if an important factor is interacting with this region 
of STAT1, that complex might not be pulled down as the region binding to the antibody would 
be blocked. Additionally, STAT1 proteins associate with each other into homodimers by binding 
via their phosphorylated tyrosines and SH2 domains, so it is also unclear whether this antibody 
can even IP STAT1 homodimers, although it does recognize the dimerized form of STAT1 by 
native PAGE (Chap. 4 Fig. 1) and nuclear STAT1 by IF (Chap. 3 Fig. 2). 
 Therefore, I decided to use a protocol that includes a cell fractionation procedure prior to 
STAT1 immunoprecipitation to specifically isolate nuclear fractions. I used the Qiagen 
Qproteome Nuclear Protein Kit, which isolates very clean cytoplasmic, nuclear extract, and 
chromatin fractions, based on Western blottings for GAPDH, STAT1, and histone H3. However, 
the buffers that are used to isolate each of these fractions are very different, so after isolation I 
diluted all of the fractions in the same buffer to try to make IPs from each of these fractions have 
a similar efficiency. I was able to IP STAT1 from these different fractions successfully, in a 
pattern that would be expected in unstimulated, IFN-γ stimulated, and infected cells. However, 
mass spectrometry of these fractions from three different experiments has not resulted in any 
promising leads. This could be due to a variety of reasons, but I believe that the most important 
reason is the high salt concentration used in the chromatin and nuclear extract fractionations. 
Although the makeup of these extraction buffers is proprietary, Qiagen’s technical assistance 
told me that the sodium chloride concentrations in these buffers is 1000 mM and 350 mM, 
respectively. It is therefore likely that in these fractions the isolation procedure disrupts many 
STAT1 interactions that we would like to detect. 
 In the future, I do think this line of experimentation is worth pursuing, although with 
changes in the experimental procedures. I do think that it is very important to specifically isolate 
a nuclear fraction, and even if possible the fraction of STAT1 specifically bound to DNA. 
Perhaps the best way to do this without losing specific interacting proteins is to fix the cells prior 
to isolation. I did try one IP experiment where I IP-ed STAT1 using the same protocol that I used 
in the ChIP assays (fixing the cells with formaldehyde, doing a dirty nuclear preparation, and 
sonicating prior to the IP), but then boiling the entire IP-ed material in SDS buffer instead of 
purifying the DNA. However, I concluded that this nuclear preparation is in fact quite dirty and I 
was still getting a lot of cytoplasmic protein contamination. While for the ChIP assay, in which 
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you are only interested in the DNA, this doesn’t matter, it does matter for our purposes. The best 
protocol would include a fixation step, a much cleaner nuclear isolation, and either sonication or 
an enzymatic treatment to cut the DNA to allow the specific IP of DNA-bound STAT1. 
 One consideration that we might need to think about further is what controls to include. 
Initially, I thought that having all of the IPs from the different fractions would be a great internal 
control. A protein that modulates STAT1 activity is likely to be found in the nuclear fractions, 
while contaminating proteins that are pulled down by the antibody or beads aspecifically might 
be found in all of the fractions. However, I did some controls with random IgG antibodies, and it 
seemed that most proteins, including STAT1, were also pulled down by these antibodies, perhaps 
because STAT1 and many of our other hits are so abundant. It may be worthwhile to use 
STAT1-deficient host cells, such as the U3A mutant and the parental line 2FTGH (McKendry et 
al., 1991; Pellegrini et al., 1989), to identify specific STAT1 interactors. We also need to decide 
what strain of Toxoplasma to infect the cells with prior to IFN-γ stimulation and STAT1 IP. The 
Toxoplasma effector ROP16 can induce the phosphorylation (Chap. 3 Fig. 2), nuclear 
translocation (Chap. 3 Fig. 2), and DNA binding (Chap. 4 Fig. 2) of STAT1 in the absence of 
IFN-γ treatment, but this STAT1 is not transcriptionally active (Chap. 3 Fig. 3). In some ways 
this is an appealing condition in which to IP STAT1, because many more proteins might be 
induced by IFN-γ to bind at STAT1-regulated loci, including secondary transcription factors 
such as IRF1, but Toxoplasma can apparently inhibit ROP16-induced STAT1 activity in the 
absence of all of these proteins. However, it does not allow for a good control to subtract out 
Toxoplasma proteins that bind aspecifically to the antibody or the beads from the infected, 
unstimulated nuclear fractions. Therefore it might be best to do side by side infections with both 
an RH strain and an RH ∆rop16 strain to get the most information. We should also probably 
investigate further exactly where the Toxoplasma PV and its contents end up during the cell 
fractionation procedure, as this could affect exactly what Toxoplasma proteins are aspecifically 
pulled down from the different fractions. This could be determined by Western blot of the 
different fractions for different Toxoplasma proteins that have a known localization, for example 
Toxoplasma nuclear, mitochondrial, rhoptry, and dense granule proteins.  
 Another avenue worth pursuing, and which might be more simple and more promising, is 
to perform mass spectrometry on STAT1 containing complexes that are pulled down by GAS 
171 
 
oligonucleotides. This would automatically select for interactors that specifically bind to STAT1 
on DNA. Additionally, in two recent studies, an aberrant complex, of a greater molecular weight 
but still containing STAT1, has been observed in an EMSA assay binding to such 
oligonucleotides (Lang et al., 2012; Schneider et al., 2013). While we do not observe this 
complex in a native PAGE (Chap. 4 Fig. 1), it is possible it can only form while bound to DNA. 
It would be very interesting to specifically do mass spectrometry on these complexes.  
 
Using FACS for a genetic screen 
 An unbiased method that could directly discover Toxoplasma genes that are necessary for 
this inhibition is a screen for a Toxoplasma mutant that can not inhibit IFN-γ-induced STAT1 
activity. This could be done using the luciferase reporters that we have or IRF1 IF experiments to 
do a full screen, however, these assays would require a lot of time and effort. For one thing, we 
would not be able to directly screen a whole population of mutants, but instead would need to 
clone a mutated population, into either 96- or 384-well plates. The luciferase assay would be 
more high-throughput but would require some way to account for differences in parasite growth 
and viability, because the cloned parasites would have to be replica-plated into the reporter cells, 
and we would not be able to be sure that the infecting MOI was the same across all of the clones. 
The IRF1 IF assay could get around this MOI dependence, as only one infecting parasite is 
capable of inhibiting IFN-γ-induced IRF1 expression, and infected and uninfected cells can be 
individually visualized, however the assay is not high-throughput and would require a lot of 
time. 
 The ideal method to perform such a screen would utilize an assay such as FACS that 
could sort through a whole population of mutant Toxoplasma parasites in a high-throughput way 
and specifically sort out those that cannot inhibit IFN-γ-induced gene expression (Fig. 3). In 
order to then grow and validate any mutants, these cells cannot be fixed and permeabilized to 
stain for an intracellular protein such as IRF1. Instead, sorting must be based on a natively 
fluorescent reporter or the expression of extracellular proteins that can be bound in their native 
form by fluorescently conjugated antibodies.  
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Figure 3. A FACS-based genetic screen. In an ideal screen, IFN-γ stimulation induces the expression of either a 
fluorescent reporter (red) or extracellularly exposed membrane proteins to which good antibodies exist. A wild-type 
Toxoplasma parasite should then potently inhibit the upregulation of these proteins. We could then screen for 
parasites within a mutant pool that do not inhibit the expression of these proteins. 
 
 Unfortunately, generating a STAT1 reporter line that strongly induces the expression of a 
fluorescent reporter has not been trivial. The original reporters that I made, both a “STAT1” and 
“GAS” reporter, made from pGreenFire (pGF) lentiviral vectors purchased from System 
Biosciences (see Materials and Methods, Chap. 3, 4), drive the expression of one open reading 
frame, which consists of a destabilized version of GFP (dscGFP) and luciferase. These 
polypeptides are separated by a T2A self-cleaving peptide, such that both proteins will be 
produced separately from one transcript. However, while I can detect luciferase expression in 
these cell lines (Chap. 3 Fig. 4, Chap. 4 Fig. S2), I was never able to detect a significant increase 
in GFP expression that could be easily used to separate responding versus non-responding cells 
by flow cytometry (Appendix 1 Fig. 1). The induction of even luciferase in these cell lines is also 
relatively low (3-6 fold), and I think that this level is just not high enough to see induction of a 
destabilized version of GFP. Our HEK293 NF-κB reporter cell line, made using the same pGF 
vector backbone, in which dscGFP induction is robust, has levels of luciferase induction of 
greater than 1000-fold after TNF-α stimulation and between 200- and 400-fold after infection 
with a type II strain of Toxoplasma which activates NF-κB through GRA15. Additionally, 
contact with System Biosciences technical assistance indicated that several of the reporter 
vectors they produce do not induce significant levels of GFP, likely due to weak induction in 
general. Replacing this destabilized GFP and luciferase cassette with a copy of a more robust 
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fluorescent protein, tdTomato, did not result in better fluorescent reporter induction (Appendix 1 
Fig. 2). Additionally, sorting specific cells within the population for “high-responders” did not 
work, indicating that differences in how the cells responded were stochastic and not intrinsic to 
the cell due to more viral integrations or integration of the vector into more highly expressed 
regions of the genome. 
 In an effort to design a reporter vector that responds more robustly to IFN-γ stimulation, I 
cloned into these vectors regions of the IRF1 enhancer/promoter, with the idea that having a 
more complete sequence where not only STAT1, but also IRF1 itself and histone 
acetyltransferases such as CBP/p300 can bind would increase transcriptional output. I used 
ChIP-seq data from the ENCODE project to pick three different regions of the IRF1 promoter 
where all of these factors have been found to bind upon IFN-γ stimulation, but that are short 
enough to fit in the pGF1 lentiviral vector (< 3000 bp). However, I have not been able to detect 
GFP or Tomato induction in these lines either. 
 An alternative method to a fluorescent reporter is to sort cells based on the expression of 
IFN-γ-induced extracellular proteins with fluorescently conjugated antibodies. The problem with 
this method is that IFN-γ-induced proteins can also be controlled by other transcription factors, 
and different IFN-γ-induced loci may require different co-activators or chromatin remodeling 
factors. Therefore this method would work best with a panel of IFN-γ-induced genes, such that 
we could select for mutant parasites that do not inhibit the expression of any of these proteins. To 
this end, I choose three genes that were well expressed upon IFN-γ stimulation in RAW264.7 
murine macrophage cells in previous microarray experiments (Chap. 3 Fig. 6), were not induced 
by infection with a RH ∆rop16 strain, and for which there exists commercially available 
fluorescently conjugated antibodies. We then measured the expression of these proteins upon 
IFN-γ stimulation and the inhibition of the expression of these proteins in Toxoplasma pre-
infected cells by flow cytometry (Appendix 2). Unfortunately, however, two of these proteins do 
not seem to be induced highly enough by IFN-γ treatment in every single cell to be able to use 
them in such a screen. Some cells that are infected with a parasite mutant in this effector will not 
express these proteins by chance and would therefore be false-negatives, and we would not select 
for them and lose them from our population. Additionally, the infected and uninfected cell 
populations after IFN-γ treatment also have some overlap, and we might have to set the cut-off 
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for lack of inhibition so low that we would also still sort a large number false-positives—
parasites that can still inhibit this response. 
  
How does Toxoplasma continuously secrete dense granule proteins across the PVM into the 
host cell post-invasion? 
 If the Toxoplasma effector that is responsible for STAT1 inhibition is indeed secreted 
into the host cell post-invasion, then any Toxoplasma strain that is mutant in this secretion 
mechanism would also be mutant in terms of inhibiting IFN-γ. Additionally, we believe that 
GRA15 also uses this secretion mechanism, and therefore another logical follow-up to this 
research is to find the identity of this pore/secretion mechanism. We hypothesize that a 
Toxoplasma parasite which has components of this pore mutated will not be able to inhibit 
STAT1 activity or to activate NF-κB. Therefore, we could use our robustly expressing GFP NF-
κB reporter (Chap. 2 Fig. 2) to perform a FACS screen of a mutant pool of parasites that express 
GRA15II to select for parasites that do not activate NF-κB. Parasites that are mutant for the 
secretion mechanism will not be able to secrete very much GRA15 into the host cell and should 
not activate the reporter. Theoretically we could also recover mutants in the GRA15 gene, 
however we have RH GRA15II transgenic clones that carry multiple copies of the gene, making 
this scenario less likely. It would be very interesting to study the virulence of a parasite that lacks 
this proposed protein secretion mechanism. It is still unknown how many proteins are secreted 
by this pathway and their relevance in vivo.  
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Appendix 1. Construction of additional STAT1 reporter cell lines 
Emily E. Rosowski, Kirk D.C. Jensen, and Jeroen P.J. Saeij 
Massachusetts Institute of Technology, Department of Biology, Cambridge, MA 
KDCJ assisted in all FACS analysis and sorting. 
 
Results 
 Previously I have described the construction of three IFN-responsive cell lines (GAS, 
STAT1, and ISRE) in HEK293 cells from lentiviral vectors purchased from System Biosciences 
(Chapters 3 and 4, Materials and Methods). These cell lines consistently and specifically activate 
expression of luciferase upon IFN stimulation (Chap. 3 Fig. 4, Chap. 4 Fig. S2). These lines 
should also express GFP in these conditions, as the transcriptional response elements in these 
vectors drive the expression of one transcript which codes for a destabilized version of GFP, a 
T2A self-cleaving peptide, and luciferase all in one polypeptide. However, by FACS analysis, 
while some induction of GFP can be measured in some of these cell lines after IFN-γ treatment, 
this induction is not high enough to be able to easily distinguish responding versus non-
responding cells in a FACS-based screen (Fig. 1). 
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Figure 1. Flow cytometry of GFP expression in IF+-responsive HEK reporters. HEK293 pGF1-CMV, STAT1, 
GAS, and ISRE lines. This experiment was done twice, with different clones, with similar results. A. Gating of cells 
based on side and forward scatter. B. GFP levels in parental HEK cells and positive control CMV-GFP. C. GFP 
levels in unstimulated (red) and IFN-γ stimulated (blue) GAS, ISRE, and STAT1 reporter clones. 
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 In an effort to make a cell line that induces higher levels of a fluorescent reporter in 
response to IFN-γ stimulation, I replaced the dscGFP-T2A-luciferase coding region in a GAS 
pGF1 vector with a copy of tdTomato. After transduction and selection of a HEK293 cells with 
this construct, I stimulated the population with IFN-γ. While a CMV-Tomato vector strongly 
expressed Tomato fluorescent reporter in comparison to the parental HEK293 line (Fig. 2A), we 
could not detect significant Tomato expression by eye in the microscope or by flow cytometry 
(Fig. 2B). We therefore tried sequentially sorting cells from this population that both responded 
to IFN-γ stimulation with high levels of Tomato expression and that did not express Tomato in a 
basal unstimulated state (Fig. 2C). The idea was that perhaps some cells had integrated multiple 
copies of the lentiviral vector or had inserted the construct into more or less “silent” regions of 
chromatin and that we could sort specifically for these cells. However, re-analysis of these sorted 
populations showed that the distribution of Tomato expression through the population was 
virtually identical to that of an unsorted population, indicating that differences in Tomato 
expression are not due to differences in integration site or number but instead to stochasticity in 
Tomato expression (data not shown). Additionally, treatment of these populations with 
increasing concentration of drug did not result in selection of higher responders with more copies 
of the lentiviral vector (data not shown).  
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Figure 2. Sorting of HEK GAS-Tomato population for high responders. A. tdTomato levels in a mixed sample 
of the HEK parental line and HEK cells expressing tdTomato under the control of a CMV promoter. B. tdTomato 
levels in populations of unstimulated (red) and IFN-γ stimulated (blue) GAS-tdTomato cells. C. “High responders” 
were sorted from the IFN-γ stimulated sample (blue) and “low expressors” were sorted from the unstimulated 
sample (red). 
 
 Next, I decided to use a more complete promoter instead of four tandem STAT1 binding 
sites to drive the expression of the reporter, with the idea that perhaps STAT1 by itself is not a 
strong enough inducer but at a complete promoter, other factors such as histone 
acetyltransferases and secondary transcription factors such as IRF1, would also be able to bind 
and help induce a higher level of expression. I chose regions of the IRF1 promoter at which 
STAT1, IRF1, and/or p300 have been found to bind, using data available online from the 
ENCODE project (http://genome.ucsc.edu/ENCODE), amplified them, and inserted them into 
both pGF1 vectors driving the dual expression of luciferase and GFP or the expression of 
tdTomato. I then infected HEK293 cells with virus containing these lentiviral vectors and 
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selected for transduced cells. However, treatment of this population of cells also did not result in 
visible induction of either GFP or Tomato expression by eye in the microscope. 
 
Materials and Methods 
Construction of pGF1-eo-GAS-Tomato 
 The tdTomato coding region was amplified by PCR from ptub-tdTomato-CAT (received  
from Mariane from UMass), incorporating BamHI and PacI restriction sites (italicized in 
primers) at the 5’ and 3’ ends of the amplicon, respectively, with the following primers: 
tdTomato_F_BamHI_2: 5’-caccggatccgacatccaccaaacggtgtt-3’, tdTomato_R_PacI_2: 5’-
ccttaattaagatccctccgaaaagagagg-3’, and cloned into pENTR/D-TOPO (Invitrogen). pGF1-Neo-
GAS, STAT1, ISRE, and CMV vectors (System Biosciences) were digested with BamHI and 
PacI to cut out the dscGFP-T2A-luciferase cassette, and BamHI-tdTomato-PacI was ligated into 
the cut vector. 
 
Construction of pGF1-eo Gateway compatible vectors 
 pGF1-Neo-mCMV, pGF1-Neo-GAS, and pGF1-Neo-GAS-tdTomato were digested with 
SpeI which cuts once in these vectors, just before the mCMV sequence. After isopropanol 
precipitation, vectors were then blunted with T4 DNA polymerase, and the Gateway cassette C.1 
insert (Invitrogen) was ligated into the vector, to make pGF1-Neo-mCMV-att, pGF1-Neo-GAS-
att, and pGF1-Neo-GAS-att-tdTomato. Vectors were digested and sequenced to check that the 
cassette had ligated in the correct direction. 
 
Construction of pGF1-eo-IRF1promoter vectors 
 Regions of the IRF1 promoter were amplified by PCR from HFF genomic DNA, with 
primers listed in Table 1 (complementary regions to genome shown in uppercase), and cloned 
into pENTR/D-TOPO (Invitrogen). These constructs were then recombined into pGF1-Neo-
GAS-att and pGF1-Neo-GAS-att-tdTomato by LR recombination with LR clonase II Plus 
(Invitrogen). 
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Table 1. Primers for amplifying IRF1 promoter constructs. 
  
187 
 
Appendix 2. FACS analysis of IF+-γ-induced protein expression in RAW264.7 murine 
macrophages. 
Emily E. Rosowski, Kirk D.C. Jensen and Jeroen P.J. Saeij 
Massachusetts Institute of Technology, Department of Biology, Cambridge, MA 
KDCJ assisted in all FACS analysis and sorting. 
 
Results 
 Another method by which to analyze IFN-γ-induced gene expression by FACS in unfixed 
cells is to use antibodies that recognize cell surface proteins. Using previous microarray data 
(Chap. 3 Fig. 6) (Rosowski and Saeij, 2012), I chose three proteins that were highly induced by 
IFN-γ in RAW264.7 murine macrophages, were also significantly inhibited by prior infection 
with an RH ∆rop16 strain, are expressed on the cell surface, and have good commercially 
available fluorescent conjugated antibodies designed for FACS analysis. These proteins are 
ICAM1, B7-H1, and MHC class II. 
 I then pre-infected RAW264.7 murine macrophages with GFP-expressing RH ∆rop16 
parasites at an MOI < 1, stimulated with murine IFN-γ, and stained for these proteins (Fig. 1). 
One of these proteins, ICAM1, was already basally expressed at a high level in uninfected cells, 
although voltage settings might be able to be changed to separate the expression in uninfected 
and infected cells better. The expression of another of these proteins, MHC class II proteins, was 
only induced in a subset (~30%) of cells. B7-H1 was induced well by IFN-γ. The IFN-γ induced 
expression of all of these proteins was inhibited on a population level by Toxoplasma infection, 
however, in each case there were also individual infected cells which expressed normal levels of 
the proteins. 
 Similar results were also obtained in infected, IFN-γ-stimulated B6 BMDMs. 
 
 
 Figure 1. FACS analysis of IF+-induced expression in RAW
based on forward and side scatter, PI staining, and presence of GFP labeled parasite. 
H1, and MHC class II proteins in unstimulated and IFN
(red) within the sample are both shown.
 
Materials and Methods 
Antibodies 
The following antibodies were used to stain cells
clone M5/114.15.2 (eBioscience)
Pharmingen); and anti-mouse CD274 (B7
 
Cell infection, isolation, and staining
8x105/well RAW264.7 murine macrophages were plated in 12
infection. Cells were infected with RH 
188 
264.7 murine macrophages. A.
B. Expression of ICAM1, B7
-γ stimulated cells. Uninfected cells (blue) and infected cells 
 
: anti-mouse MHC Class II (I-A/I
; anti-mouse CD54 (ICAM-1) APC, clone 3E2 (
-H1) PE, clone MIH5 (BD Pharmingen
 
-well plates, 18 hours before 
∆rop16 gfp luc 1A2 parasites thoroughly washed in PBS 
 
 Gating strategy 
-
-E) eFluor450, 
BD 
). 
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at an intended MOI = 0.5 for 3.5 hours, and subsequently stimulated with 100 U/ml murine IFN-
γ. After 18 hours of stimulation, cells were scraped from plates, collected and washed in cold 
PBS, and strained over a 70 µm filter. Cells were blocked in FACS buffer (2% FBS) containing 
10% normal hamster serum and 1% Fc block. Antibodies were then incubated with cells in the 
same FACS buffer at a dilution of 1:100 for 25 minutes and excess antibody was washed off 
prior to flow cytometry analysis. 
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Appendix 3. Effect of eospora caninum on host IF+-γ/STAT1 and +F-κB pathways 
Emily E. Rosowski and Jeroen P.J. Saeij 
Massachusetts Institute of Technology, Department of Biology, Cambridge, MA 
 
Results 
 eospora caninum is another Apicomplexan species related to Toxoplasma gondii which 
has a very similar life cycle to Toxoplasma. eospora can also infect human cells in tissue 
culture, however, unlike Toxoplasma, eospora was reported to not inhibit the expression of 
IRF1 after IFN-γ treatment (Kim et al., 2007a). In our search for the Toxoplasma effector 
responsible for this inhibition, we thought that knowing more about eospora’s ability, or lack 
of ability, to inhibit this response could give us more information. For example, comparative 
genetic analyses might show whether Toxoplasma candidate genes are also present in eospora. 
 To investigate the ability of eospora to inhibit IFN-γ induced IRF1 expression in host 
cells further, I pre-infected HFFs on coverslips with eospora or Toxoplasma RH(I) strain 
parasites and subsequently stimulated the cells with IFN-γ. I then fixed the cells and stained for 
IRF1 protein expression. This experiment confirmed previously published results, that infection 
with eospora does not inhibit host cell expression of IRF1 in response to IFN-γ, while cells 
infected with RH(I) Toxoplasma parasites had much lower levels of IRF1 in their nuclei (Fig. 
1A).  
 However, Pru parasites, a type II strain of Toxoplasma, can inhibit the IFN-γ induced 
expression of IRF1 but also activate IRF1 expression via activation of another transcription 
factor, NF-κB (Chap. 3 Fig. 1). While eospora infection alone, in unstimulated cells, does not 
result in IRF1 expression (Fig. 1A), I also wanted to be sure that eospora does not also activate 
NF-κB family transcription factors. eospora has been reported to not induce NF-κB p65 
nuclear translocation (Herman et al., 2007), but to check eospora’s ability to induce NF-κB-
meditated gene expression through other NF-κB family members, I infected a stable HEK293 
NF-κB reporter cell line, which expresses luciferase upon NF-κB activation (Chap. 2 Materials 
and Methods), with either eospora parasites or Pru(II) Toxoplasma parasites (Fig. 2). TNF-α 
stimulated and uninfected, unstimulated controls were also included. However, I did not detect 
any significant luciferase activity induction upon eospora infection, while TNF-α induced 
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luciferase activity > 1000-fold over uninfected, unstimulated cells and Pru(I) infection induced 
luciferase activity 200-400 fold over controls, with increasing activation by higher MOIs (Fig. 
2). 
 It therefore seems that eospora is not inducing IRF1 expression via NF-κB activation, 
but what about other transcription factors? In a co-infection of RH(I) Toxoplasma parasites and 
eospora, the presence of even one RH vacuole potently inhibited IFN-γ stimulated IRF1 
expression (Fig. 1B). Since RH is only known to inhibit STAT1-mediated transcription, this 
suggests that all of the IRF1 expressed is through STAT1 and that eospora is not inducing 
IRF1 through some other transcription factor (Fig. 1B). 
 
 
Figure 1. eospora does not inhibit IF+-γ-induced IRF1 expression. HFFs were infected with eospora or RH 
(A) or eospora and RH in a co-infection (B). Cells were then stimulated, or not, with IFN-γ, fixed, and stained for 
IRF1 (red) and with Hoechst dye (blue). RH parasites express GFP (green). IRF1 IFA after eospora infection has 
been repeated more than 3 times with similar results. eospora + RH co-infection plus IFN-γ has been done twice 
with similar results. 
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Figure 2. eospora does not activate +F-κB mediated gene expression. A HEK293 NF-κB luciferase reporter 
cell line was infected with Pru(II) Toxoplasma parasites or eospora parasites at two different MOIs, or treated with 
TNF-α. Cells were then lysed and luciferase activity was measured. This experiment has been performed twice with 
no detectable NF-κB activation by eospora infection. 
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Appendix 4. Toxoplasma genes that are dispensable for inhibition of IF+-γ induced IRF1 
expression 
 
Emily E. Rosowski, Diana Lu, Stephanie Lin, Dan A. Gold, Ana Camejo, and Jeroen P.J. Saeij 
Massachusetts Institute of Technology, Department of Biology, Cambridge, MA 
DL, SL, and DAG constructed the ROP47 knockout, DAG constructed the GRA17 knockout, 
and AC constructed the tgd057 knockout. 
 
Results 
 One approach that we have taken to try to identify any Toxoplasma effectors that might 
inhibit IFN-γ-induced, STAT1 mediated transcription is to test any Toxoplasma gene knockouts 
that are made in the lab and seem like they could plausibly affect this response. Previously, I 
have reported that two effectors, ROP16 and GRA15, are dispensable for inhibition of luciferase 
expression in a STAT1 reporter cell line (Chap. 3 Fig. 5). The South American strain BOF does 
not express the ROP5 pseudokinase (Mariane Melo, in preparation), but it still inhibits IRF1 
expression to the same level as an RH strain which expresses high levels of ROP5, indicating 
that ROP5 is not necessary for this inhibition (Fig. 1). We also tested parasites deficient in GRA2 
(Fig. 2), ROP47 (Fig. 2), GRA17 (Fig. 3), or tgd057 (Fig. 4). All of these knockout strains were 
able to inhibit IFN-γ induced IRF1 expression as well as a wild-type RH strain. 
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Figure 1. BOF inhibits IF+-γ-induced IRF1 expression. HFFs were infected with either RH or BOF Toxoplasma 
parasites, subsequently stimulated with IFN-γ, fixed, and stained for IRF1. Nuclear levels of IRF1 were quantitated 
in at least ten cells in each condition and average induction of IRF1 expression was normalized to the UI, US 
sample. Error bars represent standard deviation. This experiment has been done twice with similar results. 
 
 
Figure 2. RH strains deficient in GRA2 or ROP47 inhibit IF+-γ-induced IRF1 expression. HFFs were infected 
with Toxoplasma strains, subsequently stimulated with IFN-γ, fixed, and stained for IRF1 (red) and with Hoechst 
dye (blue). 
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Figure 3. An RH strain deficient in GRA17 inhibits IF+-γ-induced IRF1 expression. HFFs were infected with 
Toxoplasma parasites, subsequently stimulated with IFN-γ, fixed, and stained for IRF1 (green), pSTAT1 (red), and 
with Hoechst dye (blue). Scale bar represents 20µm. 
 
 
Figure 4. An RH strain deficient in tgd057 inhibits IF+-γ-induced IRF1 expression. HFFs were infected with 
Toxoplasma parasites, subsequently stimulated with IFN-γ, fixed, and stained for IRF1 (red), SAG1 (green), and 
with Hoechst dye (blue). 
 
 
